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 Canine mammary gland tumours (CMGTs) are a major cause of illness and premature 
death in female dogs, especially in countries like Sri Lanka where early de-sexing is not a 
routine veterinary practice. Therefore, there is a need for prognostic markers which can 
better predict the behaviour of a CMGT. In human breast cancers (HBCs), some markers of 
tumour-associated inflammation (TAI) have been shown to better predict prognosis than 
many conventional prognostic markers. This thesis investigated whether TAI prognostic 
markers adopted from human breast cancers are similarly prognostic for CMGTs. 
 
The prognostic markers investigated in this thesis included tumour stromal mast cell 
density determined by toluidine blue staining, gene expression of chemokines: CCL5, 
CXCL12, CXCL10, and chemokine receptors: CXCR3, CXCR4, CXCR7, CCR4, CCR9  and gene 
expression and immunostaining of two immune checkpoint molecules: programme death 
ligand-1 (PD-L1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4) . Similar to HBCs, all 
markers except CXCL10 and CCR4 were prognostic of the disease outcome determined by 
disease-specific survival times of the dogs with mammary neoplasms. Of them, stromal 
mast cell density, CCL5 gene expression and PD-L1 immunostaining were prognostic 
independent of tumour size, tumour histological grade, and lympho-vascular invasion 
observed in histological sections. In conclusion, this thesis identified that similar to HBCs, 
TAI related prognostic markers are useful to better predict the behaviour of CMGTs while 
stromal mast cell density has the potential to be adopted for routine laboratory prognostic 
determination.   
 
In addition to identification of prognostic markers, surveys of CMGTs in Sri Lanka and New 
Zealand conducted for sample collection gathered large amounts of information that 
allowed a comparison of CMGTs between the two countries. These studies allowed a 
determination of the characteristics of dogs with CMGTs, as well as allowing histological 
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CMGTs   Canine mammary gland tumours 
OHE   Ovariohysterectomy 
BRCA1   Breast cancer associated gene 1 
BRCA2   Breast cancer associated gene 2 
DFI   Disease-free interval 
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TME   Tumour microenvironment 
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VTH   Veterinary teaching hospital 
VPC   Veterinary practice Colombo 
α-SMA   α-smooth muscle actin 
BCS   Body condition score 
NZ   New Zealand 
MGD   Mammary gland disease 
FFPE   Formalin-fixed paraffin-embedded 
HE   Haematoxylin and eosin 
MCD   Mast cell density 
MST   Mean survival time 
cDNA   Complementary DNA 
NCBI   National centre for biotechnology information 
RT-PCR   Real-time polymerase chain reaction 
CV   Coefficient of variance 
Ct   Cycle threshold 
SDS-PAGE  Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
PVDF   Polyvinylidene difluoride 
TBS   Tris-buffered saline 
NFDM   Non-fat dry milk 
TBST   Tris-buffered saline with 0.1% tween 20 
HPRT   Hypoxanthine-guanine phosphorybosyltransferase 





HRP   Horse-radish peroxidase 















































Table of contents 
Chapter 1 : Literature review .............................................................................................................. 1 
1.1 Introduction to tumour-associated inflammation (TAI) related prognostic markers in canine 
mammary gland tumours ............................................................................................................... 1 
1.2 Morphology of the canine mammary gland............................................................................. 3 
1.3 Development of canine mammary gland tumours in dogs ...................................................... 4 
1.4 Risk factors for canine mammary gland tumours .................................................................... 5 
1.4.1 Age ..................................................................................................................................... 5 
1.4.2 Prolonged exposure to reproductive hormones ............................................................... 6 
1.4.3 Breed ................................................................................................................................. 6 
1.4.4 Diet and obesity ................................................................................................................ 7 
1.5 Histological classification and grading of CMGTs ..................................................................... 7 
1.5.1 Histological classification of CMGTs .................................................................................. 7 
1.5.2 Histological grading of CMGTs ........................................................................................ 10 
1.6 Treatments for CMGTs ........................................................................................................... 12 
1.7 Prognostic factors of CMGTs .................................................................................................. 13 
1.7.1 Clinical prognostic factors ............................................................................................... 14 
1.7.1.1. Age ........................................................................................................................... 14 
1.7.1.2. Lymph node metastasis ........................................................................................... 14 
1.7.1.3 Tumour staging ......................................................................................................... 15 
1.7.2 Reproductive status related prognostic factors .............................................................. 17 
1.7.3 Tumour related prognostic factors ................................................................................. 17 
1.7.4 Histological prognostic factors ........................................................................................ 18 
1.7.4.1 Histological sub-type ................................................................................................ 18 
1.7.4.2 Histological grade ..................................................................................................... 20 
1.7.5 Molecular prognostic markers ........................................................................................ 21 
1.7.5.1 Steroid hormone receptors: progesterone receptor (PR) and oestrogen-receptor-
alpha (ERα) ........................................................................................................................... 21 
1.7.5.2 Markers of cell proliferation: Ki-67 and proliferating cell nuclear antigen (PCNA) . 22 
1.7.5.3 Tumour suppressor genes: p53 ................................................................................ 23 
1.7.5.4 Oncogenes: human epidermal growth factor receptor-2 HER-2 ............................. 23 
1.7.5.5 Cyclooxygenase-2 (COX-2) ........................................................................................ 24 





1.9 Tumour microenvironment (TME) and tumour associated inflammation (TAI) .................... 25 
1.9.1 Prognostic significance of immune cell infiltration in cancers ........................................ 26 
1.9.2 Prognostic significance of chemokines and chemokine receptors in cancer .................. 28 
1.9.3 Prognostic significance of immune checkpoints and chemokine receptors in cancer ... 32 
1.9.3.1 Programme death ligand-1 (PD-L1) .......................................................................... 32 
1.9.3.2 Cytotoxic T-lymphocyte antigen-4 (CTLA-4) ............................................................. 34 
1.10 Summary .............................................................................................................................. 35 
1.11 Bibliography.......................................................................................................................... 37 
Chapter 2 : Clinicopathological features of mammary gland  tumours in dogs in Sri Lanka ............. 46 
2.1 Introduction ............................................................................................................................ 46 
2.2 Material and methods ............................................................................................................ 47 
2.2.1 Sample collection ............................................................................................................ 47 
2.2.2 Histopathology and tumour classification....................................................................... 48 
2.2.3 Statistical analysis ............................................................................................................ 49 
2.3 Results .................................................................................................................................... 49 
2.3.1 Clinical characterization of dogs with mammary gland tumours ................................... 49 
2.3.2 Gross pathological characterization of canine mammary gland tumours ...................... 51 
2.3.3 Histological classification of mammary gland tumours .................................................. 54 
2.4 Discussion ............................................................................................................................... 58 
2.5 Bibliography ............................................................................................................................ 64 
Chapter 3 : Mammary gland disease in dogs in New Zealand .......................................................... 66 
3.1 Introduction ............................................................................................................................ 66 
3.2 Material and methods ............................................................................................................ 67 
2.2.1. Data collection and categorization ................................................................................. 67 
3.2.2 Statistical analyses ........................................................................................................... 68 
3.3 Results .................................................................................................................................... 68 
3.3.1 Selected cases ................................................................................................................. 68 
3.3.2 Types of mammary gland lesions .................................................................................... 69 
3.3.3 Age, reproductive status, and breed of dogs with mammary gland diseases ................ 70 
3.3.4 Size of the mammary gland lesions ................................................................................. 71 
3.4 Discussion ............................................................................................................................... 74 
3.5 Bibliography ............................................................................................................................ 79 





4.1 Introduction ............................................................................................................................ 81 
4.2 Material and methods ............................................................................................................ 82 
4.2.1 Case selection and assessment of survival times ............................................................ 82 
4.2.2 Histology and mast cell quantification ............................................................................ 83 
4.2.3 Statistical analysis ............................................................................................................ 85 
4.3 Results .................................................................................................................................... 86 
4.3.1. Selected cases ................................................................................................................ 86 
4.3.2 Tumour size, histological sub-type, and grade ................................................................ 86 
4.3.3 Mast cell distribution ...................................................................................................... 88 
4.3.4 Cut-off Analysis ................................................................................................................ 91 
4.3.5 Risk of tumour metastasis ............................................................................................... 91 
4.3.6 Survival time analysis ...................................................................................................... 93 
4.4 Discussion ............................................................................................................................... 96 
4.5 Bibliography .......................................................................................................................... 101 
Chapter 5 : Prognostic significance of chemokines and chemokine receptors in canine mammary 
gland tumours................................................................................................................................. 104 
5.1 Introduction .......................................................................................................................... 104 
5.2 Material and methods .......................................................................................................... 105 
5.2.1 Case selection and assessment of survival times .......................................................... 105 
5.2.2 Histological classification and grading .......................................................................... 106 
5.2.2 RNA extraction .............................................................................................................. 106 
5.2.3 RT-PCR ........................................................................................................................... 107 
5.2.4 Relative quantification of the chemokine and chemokine receptor gene expression in 
mammary tumour samples .................................................................................................... 110 
5.2.5 Statistical analysis .......................................................................................................... 110 
5.3 Results .................................................................................................................................. 111 
5.3.1 Selected cases ............................................................................................................... 111 
5.3.2 Tumour size, histological sub-types and grades............................................................ 111 
5.3.3 Risk of tumour metastasis ............................................................................................. 111 
5.3.4 Assay validation of CXCR7 and reference gene stability ............................................... 114 
5.3.5 Relative gene expression of chemokines CCL5, CXCL12 and CXCL10 in CMGTs ........... 114 
5.3.6 Gene expression of chemokine receptors: CXCR3, CXCR4, CXCR7, CCR4 and CCR9 in 
CMGTs .................................................................................................................................... 115 





5.3.8 Gene expression in benign CMGTs ................................................................................ 120 
5.4 Discussion ............................................................................................................................. 120 
5.5. Bibliography ......................................................................................................................... 125 
Chapter 6 : Prognostic significance of immune checkpoints PD-L1 and CTLA-4 in canine mammary 
gland tumours................................................................................................................................. 128 
6.1 Introduction .......................................................................................................................... 128 
6.2 Material and methods .......................................................................................................... 130 
6.2.1 Case selection and assessment of survival times .......................................................... 130 
6.2.2 Histological classification and grading .......................................................................... 130 
6.2.3 Immunohistochemistry ................................................................................................. 130 
6.2.3.1 Anti-PD-L1 and anti-CTLA-4 antibody validation .................................................... 130 
6.2.3.2 Immunohistochemistry .......................................................................................... 133 
6.2.3.3. Quantification of immunostaining ........................................................................ 134 
6.2.4 Real time PCR (RT-PCR) for PD-L1 and CTLA-4 genes .................................................... 135 
6.2.5 Statistical analysis .......................................................................................................... 137 
6.3 Results .................................................................................................................................. 138 
6.3.1 Selected cases ............................................................................................................... 138 
6.3.2 Tumour size and histological classification ................................................................... 138 
6.3.3 Disease outcome of the selected cases......................................................................... 138 
6.3.4 SDS-PAGE and immunoblotting ..................................................................................... 138 
6.3.5 Immunohistochemistry ................................................................................................. 142 
6.3.6 PD-L1 and CTLA-4 RT-PCR assay validation ................................................................... 148 
6.3.6 Relative quantification of PD-L1 and CTLA-4 gene expression in canine mammary gland 
tumours .................................................................................................................................. 148 
6.3.7 Cut-off analysis for PD-L1 and CTLA-4 immunostaining scores. ................................... 149 
6.3.8 Correlation between PD-L1 or CTLA-4 immunostaining scores and the survival times of 
the dogs with malignant mammary gland tumours and prognostic ability of PD-L1 and CTLA-4 
immunostaining scores on survival times. ............................................................................. 150 
6.3.9 PD-L1 and CTLA-4 immunostaining scores and gene expression in benign mammary 
gland tumours. ....................................................................................................................... 151 
6.3.10 Immunostaining of tumour infiltrating immune cells for PD-L1 and CTLA-4 in malignant 
canine mammary gland tumours. .......................................................................................... 153 
6.4 Discussion ............................................................................................................................. 153 
6.5 Bibliography .......................................................................................................................... 159 





7.1 Bibliography .......................................................................................................................... 173 







































List of Tables 
Table 1.1 Histological classification of CMGTs ................................................................................... 9 
Table 1.2 Scoring and grading system for simple carcinomas. ........................................................ 11 
Table 1.3 Canine mammary gland tumour staging .......................................................................... 16 
Table 1.4 Chemokines and chemokine receptors associated with disease outcome of human 
breast cancers and their expression in canine mammary gland tumours. ...................................... 31 
Table 2.1 Reproductive status of the dogs with mammary gland tumours ..................................... 51 
Table 2.2 Distribution of mammary gland tumours. ........................................................................ 53 
Table 2.3 Size of canine mammary gland tumours. ......................................................................... 54 
Table 2.4 Histological classification of canine mammary gland tumours ........................................ 57 
Table 3.1 Canine mammary gland biopsies submitted to IDEXX laboratories, NZ from 2012-2016.
 .......................................................................................................................................................... 72 
Table 3.2 Histological sub-types of neoplastic mammary gland lesions .......................................... 73 
Table 4.1 Histological classification of canine mammary gland tumours. ....................................... 88 
Table 4.2 Peripheral and stromal MC densities in various categories of mammary gland tumours 
and non-neoplastic mammary tissue. .............................................................................................. 90 
Table 4.3 Survival times of dogs with mammary gland tumours. .................................................... 95 
Table 5.1 Primer sequences of the chemokines and chemokine receptors used in this study ..... 109 
Table 5.2 Clinical characteristics of the patients and gross and histological characteristics of the 
neoplasms included in the malignant-metastatic, malignant non-metastatic and benign canine 
mammary gland tumour categories ............................................................................................... 113 
Table 5.3 Gene expression analysis for chemokine receptors. ...................................................... 117 
Table 5.4 Hierarchical multivariate analysis. .................................................................................. 118 
Table 6.1 Primers used for PD-L1 and CTLA-4 RT-PCR assays. ....................................................... 136 









List of Figures 
Figure 4.1 Grade II simple mammary carcinomas. ........................................................................... 89 
Figure 4.2 Clustered Boxplot of stromal and peripheral mast cell densities in different canine 
mammary gland tumour categories. ................................................................................................ 90 
Figure 5.1 Kaplan-Meier survival curves of the dogs. .................................................................... 119 
Figure 6.1 SDS-PAGE gel and corresponding immunoblot with anti-PD-L1 antibodies. ................ 141 
Figure 6.2 PD-L1 Immunostaining (primary antibody dilution 1:100). .......................................... 144 
Figure 6.3 CTLA-4 immunostaining (primary antibody dilution 1:50). ........................................... 145 
Figure 6.4 Canine mammary gland tumours with PD-L1 immunostaining (primary antibody dilution 
1:100). ............................................................................................................................................ 146 
Figure 6.5 Canine mammary gland tumours with CTLA-4 immunostaining (primary antibody 
dilution 1:50). ................................................................................................................................. 147 
Figure 6.6 Boxplots of PD-L1 immunostaining in “malignant-metastatic”, “malignant non-
metastatic” and benign canine mammary gland tumours............................................................. 152 
Figure 6.7 Boxplots of CTLA-4 immunostaining in “malignant-metastatic”, “malignant non-










1.1 Introduction to tumour-associated inflammation (TAI) related prognostic 
markers in canine mammary gland tumours 
Mammary gland tumours are the most common neoplasm among intact female dogs and 
remain a major cause of illness and premature death in dogs around the world where early 
de-sexing is not routinely advocated and performed.125 Most studies suggest, 40 – 50% of 
canine mammary gland tumours (CMGTs) are malignant.54,2,13,125 The percentage of dogs 
that develop tumour metastases and subsequently die within two years due to mammary 
neoplasms ranges from 20 to 44%.138,54,115,20 Many clinical and tumour related prognostic 
factors such as tumour size, histological classification, and grade have been proposed to 
predict the behaviour of CMGTs and some of them are routinely used by veterinary 
pathologists and clinicians to provide prognostic information.88,104 However, while these 
techniques provide some information regarding the likely neoplasm behaviour, it is 
currently difficult to predict which CMGTs will metastasise.149 This uncertainty is a limiting 
factor for implementing new therapeutics for CMGTs.137 Therefore, there is a need to 




Tumours not only consist of tumour cells but also include a tumour stroma which consists 
of connective tissues, blood-lymph network, and tumour infiltrating immune cells.157 These 
stromal components are collectively known as the tumour microenvironment.157 Many 
recent human cancer studies suggest the cross-talk between tumour cells and the tumour 
microenvironment is crucial in determining tumour behaviour, especially the metastatic 
potential.157,120 Tumour associated inflammation is the mediator of this cross-talk and its 





including human breast carcinomas. Many morphological, clinical, and molecular 
similarities between CMGTs and human breast cancers have been identified.112 In view of 
these similarities, the main aim of this thesis was to determine whether some of the 
tumour-associated inflammation related markers which were shown to be prognostic in 
human breast cancer can be used to better predict the disease outcome of CMGTs. 
 
 
Although mammary neoplasms are reported in dogs in many countries across the world, 
the incidence of mammary neoplasia is higher in countries where early spaying of female 
dogs is not a routine practice.37,12 Therefore, these countries would particularly benefit 
from the novel prognostic markers expected to be identified in this thesis. Sri Lanka is a 
South Asian country where spaying of female dogs at an early age is not a common 
practice.33 In Sri Lanka, mammary neoplasia is a common cause of disease and mortality of 
female dogs.33 Thus, it was initially planned that mammary tumours obtained from dogs in 
Sri Lanka would be used to identify novel prognostic markers. However, due to the limited 
post-surgical follow-up data from these dogs, it was necessary to identify outcome-known 
mammary neoplasms from dogs in New Zealand. During this data collection process, it was 
recognised that no previous studies have investigated the canine mammary neoplasms 
present in dogs either in Sri Lanka or New Zealand. Therefore, another aim of this thesis 
was to describe the clinicopathological features of CMGTs of dogs in Sri Lanka and New 
Zealand and determine whether any of the clinical features could be useful for clinicians to 
predict the histological malignant or benign status of these neoplasms. 
 
 
This chapter will introduce CMGTs, review currently available prognostic markers for 
CMGTs and compare the clinical and molecular characteristics of CMGTs with human 
breast cancers. The literature on cross-talk between tumour cells and the tumour 
microenvironment will then be discussed and currently available prognostic markers of 
tumour-associated inflammation will be reviewed with an emphasis on markers of this 
category that have been previously studied for use in human breast cancers or CMGTs. The 





include three different types of markers: tumour infiltrating immune cells, chemokines and 
chemokine receptors, and immune checkpoint molecules. 
 
 
1.2 Morphology of the canine mammary gland 
Dogs have five pairs of mammary glands located bilateral to the ventral abdominal 
midline.40 A mammary gland is a circumscribed area of mammary gland tissue which opens 
into a teat.40 According to their anatomical location, mammary glands are identified as 
thoracic, abdominal, or inguinal. The thoracic mammary glands are the most cranial and 
include cranial and caudal thoracic mammary glands. Caudal to these are the cranial and 
caudal abdominal mammary glands while the most caudal pair is the inguinal mammary 
glands.40,135 The mammary glands are modified sweat glands. The secretory tissue of the 
mammary gland is composed of lobes, with each containing several lobules. Each lobule is 
composed of small secretory units called alveoli. The interlobular ducts originate from the 
alveoli and open into an interlobular lactiferous duct, which opens into a larger channel 
called the lactiferous sinus. The lactiferous sinus continues into the teat sinus. The papillary 
duct (teat canal) leads to the teat opening. In the dog, 8-12 papillary ducts per teat open 
onto the teat surface.40,9 The stromal tissue of a mammary gland contains nerves, blood, 
and lymphatic vessels and, in juvenile animals, an abundant amount of adipose tissue.9,134 
 
Microscopically, the alveolar epithelium varies between simple cuboidal and columnar 
depending on the secretory activity at the time.134 The characteristic star-shaped 
myopeithelial cells are found between the alveolar basal laminar and the epithelial lining. 
The contractile nature of the myoepithelial cells facilitates the ejection of milk. The lining 
epithelium of the ducts varies with the size of the duct. The intra-lobular and small inter-
lobular secretory ducts are lined by a simple cuboidal epithelium. The larger ducts and 
sinuses are lined by a double layer of cuboidal to columnar epithelium. The papillary ducts 






The canine mammary glands are supplied by multiple arteries, which frequently 
anastomose.134 Consequently, a single mammary gland will receive blood through several 
different arteries. The cranial and caudal thoracic mammary glands are mainly supplied by 
the cranial superficial epigastric artery. The cranial abdominal mammary glands are also 
supplied by the cranial superficial epigastric artery whereas the caudal abdominal 
mammary glands and inguinal mammary glands are mainly supplied by branches of the 
caudal superficial epigastric artery.134 The venous outflow from the mammary gland  is 
similar to the arterial supply except that more extensive anastomosis is seen with the 
craniocaudal veins compared to the arteries.134 In regards to lymphatic drainage, the 
thoracic mammary glands are drained by the axillary lymph nodes, while the abdominal 
mammary glands drain into the inguinal lymph nodes. The inguinal mammary glands are 
drained by inguinal lymph nodes. Lymph vessels also form ipsilateral and contralateral 
anastomoses.107 Interestingly, the venous drainage pattern is often shown to be altered in 
neoplastic mammary glands with neoplastic glands typically forming more extensive 
anastomoses than non-neoplastic glands.107,103 
 
 
1.3 Development of canine mammary gland tumours in dogs 
The canine mammary gland undergoes extensive proliferation, differentiation, and 
remodelling throughout the entire reproductive life of female dogs.127 Each oestrus cycle 
includes waves of epithelial and mesenchymal proliferation, ductal branching and 
alveologenesis which are followed by intense regressive changes.140,84 These activities are 
coordinated and controlled by oestrogen and progesterone hormone concentrations.12 
However, the continuous cellular changes mediated by reproductive hormones predispose 
the mammary glands to neoplasia. Therefore, mammary gland tumours are the most 
common neoplasm among intact female dogs.12 Ovariohysterectomy (OHE) performed at 
an early age minimizes the prolonged exposure of mammary tissues to reproductive 
hormones and thereby reduces the risk of mammary neoplasia.12 Specifically, the risk of 
mammary neoplasia is only 0.5% when OHE is performed before the first oestrus while the 





the incidence of CMGTs is decreasing in regions of the world where OHE is routinely 
performed at an early age.2,3,125 However, in many developing countries, including Sri 
Lanka, where spaying of female dogs at an early age is not a common practice, mammary 
gland tumours are still the most common tumour among female dogs and one of the 
major causes of female dog mortality.125,3 
 
 
1.4 Risk factors for canine mammary gland tumours 
A risk factor is a character, condition, behaviour or any other factor that increases the 
likelihood of developing a disease. 81 Advanced age, prolonged exposure to reproductive 
hormones and breed are generally considered as risk factors for CMGTs.34,13,140 To a lesser 
extent, frequent feeding of red meat and obesity may also contribute to the risk of 




Mammary gland tumours typically occur in middle-aged or older dogs and are rare in dogs 
less than 5-years-old.129,44 The average age of onset is 7-8 years while the incidence 
decreases after 10 years old55,13 However, the age of peak incidence of CMGTs has been 
found to vary among breeds. In general, shorter-lived breeds such as Rottweiler and Saint 
Bernard typically develop mammary gland tumours earlier in their life, compared to breeds 
that live longer, such as Maltese terrier and Beagle.13 Two previous studies have shown 
that age at diagnosis of malignant CMGTs is significantly higher than  age at diagnosis of 
benign CMGTs.153,138 However, advanced age at diagnosis was not found to have a 







1.4.2 Prolonged exposure to reproductive hormones 
 As previously stated, prolonged exposure to reproductive hormones is considered a risk 
factor for CMGTs.12 Early OHE prevents prolonged exposure to reproductive hormones and 
consequently reduces the risk of mammary neoplasia.13 Frequent occurrence of 
pseudopregnancy, a physical state where all the signs and symptoms of pregnancy are 
exhibited except presence of a fetus, and low parity are two conditions which have been 
suggested to promote prolonged exposure of mammary tissues to endogenous 
reproductive hormones.18,129,150 Of these conditions, pseudopregnancy has been identified 
as a risk factor for CMGTs by one previous study.130 However, the significance of low parity 
as a risk factor for CMGT development has not yet been confirmed. Exposure of mammary 
glands to synthetic reproductive hormone preparations have also been shown to increase 
the risk of mammary neoplasia in dogs.143 The studies which have investigated the effects 
of dose, duration and type of exogeneous reproductive hormones on the risk of developing 
CMGTs have concluded that progestins alone mainly increase the risk of benign tumours, 




In general, mammary gland tumours are more common in smaller breeds.159 The small 
breeds reported to have an increased risk include poodle, chihuahua, dachshund, Yorkshire 
terrier, Maltese terrier, and cocker spaniel.159  However, some large breeds such as 
German shepherd, pointer, doberman, and boxer are also reported to have an increased 
risk of developing mammary neoplasia.90,55,35 In addition, purebred dogs are more 
commonly affected than crossbred dogs. The familial or inherited germ line mutations 
observed in the canine analogues of human breast cancer 1 (BRCA1) and human breast 
cancer 2 (BRCA2) genes, have been proposed as contributory factors for reported breed 
predisposition to CMGTs.119 Germline mutations in both BRCA1 and BRCA2 were found to 
associate with a significantly high risk of mammary neoplasia in English springer spaniels 






1.4.4 Diet and obesity 
A large case control study conducted in the United States of America (USA) in 1991 
suggested that obesity at the time of puberty, and a diet high in red meat increases the risk 
of mammary neoplasia development in dogs.136 The connection between obesity and 
increased risk of mammary neoplasia has been explained by two theories.136,1 According to 
the first theory, obese dogs have low levels of sex hormone-binding serum globulin which 
consequently increases free oestrogen in circulation, promoting neoplasia. The other 
theory suggests that adipose tissues are a source of oestrogen as they possess enzymes 
necessary for conversion of androgens to oestrogen. Therefore, obese female dogs are 




 1.5 Histological classification and grading of CMGTs 
 
1.5.1 Histological classification of CMGTs 
Canine mammary gland tumours are a highly heterogeneous group of neoplasms.51 The 
marked histological diversity observed in mammary gland tumours prompted human and 
veterinary pathologists to develop histological classification systems to categorise them in a 
more meaningful way. Subsequently, it was identified that some histological patterns are 
consistently associated with distinct clinical presentations or disease outcomes. Therefore, 
histological tumour sub-types are used for prognostic determination in human breast 
cancers and canine mammary gland tumours. 
 
Two initial classification systems for CMGTs were published in 197456 and 199989 and a 
revised system was published in 2011.51 According to the 2011 classification proposed by 
Goldschmidt and colleagues, neoplastic, dysplastic or hyperplastic conditions in the canine 
mammary gland are subdivided into eight basic categories including malignant epithelial 





malignant mixed tumours, benign tumours, hyperplasia and dysplasia, tumours of the 


























Table 1.1 Histological classification of CMGTs 
Source: Goldschmidt et al. (2011) 
Malignant neoplasms Benign neoplasms 
1. Malignant epithelial neoplasms 5. Benign neoplasms 
Simple carcinomas Adenoma-simple 
Carcinoma-in-situ Intraductal papillary adenoma 
Tubular Ductal adenoma 
Tubulopapillary  Fibroadenoma 
Cystic papillary Myoepithelioma 
Cribriform    Complex adenoma 
Carcinoma-micropapillary invasive Benign mixed tumour 
Carcinoma- solid  
Comedo carcinoma 6. Hyperplasia/dysplasia 
Carcinoma-anaplastic  
Ductal carcinoma 7. Neoplasia of the nipple 
Intra-ductal papillary carcinoma  
Carcinoma-arising from in a complex 
adenoma/mixed tumour 8. Hyperplasia/dysplasia of the nipple 
Carcinoma-complex type  
Carcinoma and malignant myoepithelioma  
Carcinoma-mixed type  
2. Malignant epithelial neoplasms - Special types  
Squamous cell carcinoma  
Adenosquamous carcinoma  
Mucinous carcinoma  
Lipid rich carcinoma  
Spindle cell carcinoma  
     Malignant myoepithelioma  
     Squamous cell carcinoma-spindle cell variant  
    Carcinoma -spindle cell variant  
      Inflammatory carcinoma  





Other sarcomas  








The different histological classification systems used to classify CMGTs in various studies 
makes it difficult to compare the results between studies. However, in general, epithelial 
mammary neoplasms were more frequently reported than mesenchymal neoplasms. The 
most frequently reported malignant epithelial mammary neoplasm is simple carcinoma 
while simple carcinoma sub-types including tubular carcinoma, tubulopapillary carcinoma 
and solid carcinoma were reported more frequently than other sub-types. 125,149,54,117,41 In 
contrast to simple carcinomas, special types of malignant epithelial neoplasms were 
infrequently reported.51 Inflammatory carcinoma is a rare, fast growing, special type of 
epithelial mammary neoplasm which requires clinical findings in addition to histology for 
proper characterisation.141 Characteristic clinical presentation of inflammatory carcinoma 
in dogs include generalised oedema, erythema, and pain in the neoplastic glands. The 
histological features of canine inflammatory mammary carcinoma include a high-grade 
carcinoma, often a tubular or solid type, with dermal lymphatic invasion.141,67 Mixed 




1.5.2 Histological grading of CMGTs 
Histological grade is a numerical assessment of the degree of cellular differentiation and 
proliferation of a neoplasm, which is suggested to reflect the aggressiveness of its clinical 
behaviour. In general, human breast cancers and CMGT grading systems include three 
grades.38 Grade I tumours closely resemble the normal mammary gland in terms of cellular 
morphology, organisation pattern and proliferative activity. In contrast, the tissue 
architecture, cellular morphology and proliferation rate of grade II and grade III tumours 
are markedly different from normal mammary gland.38 Usually, the clinical behaviour of a 
grade I tumour is less aggressive compared to a grade III tumour with grade II tumours 
typically showing clinical behaviour intermediate between low and high grade tumours. 
Therefore, histological grade is used to predict the disease outcome in human breast 






Currently, veterinary pathologists use a modified method developed from the Elston and 
Ellis grading method (1991) for human breast cancers widely known as the “Nottingham 
histological grade” to grade CMGTs.38 In this method histological features of, tubule 
formation, nuclear pleomorphism and mitotic counts are assessed and scored on a scale 
from 1 to 3 (Table 1.2). Although the Elston and Ellis method is still used for grading 
CMGTs, it is not considered as an ideal method for grading several CMGT sub-types, 
particularly, mixed mammary carcinoma and complex carcinoma.38 This is due to some 
basic histological dissimilarities between human breast cancers and CMGTs.  Most breast 
cancers contain only a neoplastic epithelial cell component whereas CMGTs may include 
epithelial, myoepithelial and mesenchymal components. Further, neoplastic cells in a 
human breast cancer mostly exhibit a uniform proliferation pattern whereas in CMGTs, 
multiple patterns of neoplastic epithelial cell proliferation are often observed in a single 
tumour. In addition, unlike in human breast cancers, myoepithelial proliferation is a main 
feature of some of the common CMGT sub-types including complex carcinoma and 
malignant myoepithelioma.51 Finally, dogs frequently develop mixed carcinomas which  
include a benign mesenchymal component usually present in the form of bone, cartilage or 
adipose tissue.51 The Elston and Ellis method does not provide specific guidelines to grade 
carcinomas with multiple epithelial proliferation patterns, significant myoepithelial 
proliferation or neoplastic mesenchymal components. 
 
 
Table 1.2 Scoring and grading system for simple carcinomas.  





Mitoses per 10 
HPFs 
1 point > 75% Absent < 9 
2 points 10 -75% Moderate 9 - 17 
3 points < 10% Marked > 17 
Sums of scores 3 -5 6 -7 8 -9 







The recent CMGT grading method proposed by Pena et al. (2013), which is again a 
modified method of the Elston and Ellis method, addresses some of these shortcomings 
and better caters for grading complex and mixed carcinomas.104 According to the Pena 
method, in heterogeneous carcinomas, tubular scoring is assessed in the most 
representative malignant area. In complex and mixed tumours, the percentage of tubule 
formation is scored considering only epithelial areas, and nuclear pleomorphism is 
evaluated in all the malignant components. 
 
 
1.6 Treatments for CMGTs 
Surgical excision is the most widely used method of treatment for CMGTs.140,137 The extent 
of the surgical procedure varies from simple lumpectomy to staged bilateral mastectomies 
depending on the tumour characteristics and goals of treatment. For example, the goal of 
surgery for small, solitary neoplasms with less invasive behaviour is to excise them with 
clean margins by simple lumpectomy. In contrast, veterinary surgeons practice bilateral 
mastectomy when dogs have multiple neoplasms or neoplasms that are large or invasive to 
excise the current tumour or tumours with clean margins while preventing development of 
new tumours in future.137,140   Surgical excision is curative for all benign tumours and some 
malignant CMGTs. However, 40%–50% of dogs that undergo surgical excision of malignant 
tumours experience post- surgical tumour recurrence and metastasis.138 Post-surgical 
adjuvant therapy may be useful in these patients to prevent tumour recurrence and 
metastasis. The adjuvant therapies used for CMGTs include chemotherapy, cyclooxygenase 
(COX) inhibitors, desmopressin, anti-hormonal agents and immunotherapy with 
monoclonal antibodies.66 Chemotherapy is the most used adjuvant therapy and commonly 
used chemotherapeutic agents include 5-Fluorouracil, Cyclophosphamide, Gemcitabine 
and Doxorubicin.66,8 However, chemotherapy, has not shown to be particularly effective in 
reducing the rate of tumour metastasis in malignant CMGTs. Other adjuvant treatment 
modalities have been rarely used and therefore the efficacy of them is uncertain.66 





neoplasms should receive adjuvant therapy and which are unlikely to metastasise and 
therefore are unlikely to benefit from additional treatments.140 
 
  
1.7 Prognostic factors of CMGTs 
Prognostic factors are clinical, pathological or molecular measures that are used to predict 
the behaviour of neoplasms and the subsequent disease outcome.47 Prognostic factors 
range from simple measures such as the diameter of a tumour to more complex indicators 
like molecular markers of cell division.47 Disease-free interval (DFI) and overall survival (OS) 
are two commonly used determinants of disease outcome.47 Disease-free interval is the 
length of time between the primary treatment and the first sign of recurrence.47 Overall 
survival is the time from the first diagnosis of neoplasia to death from any cause, or to the 
end of the follow-up period.47 Univariate analysis and multivariate analysis are two 
statistical analytical methods commonly used to determine the effect of prognostic factors 
on the disease outcome. A univariate analysis determines the effect of a single prognostic 
factor towards disease outcome.79 In contrast, a multivariate analysis considers the effect 
of multiple prognostic factors at the same time.79 Therefore multivariate analysis facilitates 
the recognition of influence of other prognostic factors, towards the prognostic factor of 
interest.79 If the disease outcome determined by a prognostic factor is not significantly 
affected by other prognostic factors, it is considered an independent prognostic factor.79 
Consequently, an independent prognostic factor can determine the disease outcome 
reliably, even in the absence of information regarding other prognostic factors.79 This 
makes independent prognostic factors particularly useful in clinical medicine.79 A range of 
clinical, pathological and molecular prognostic factors with varying prognostic capacity 
have been described for CMGTs. However only a few have been identified to be 







1.7.1 Clinical prognostic factors 
1.7.1.1. Age 
Whether it is possible to use the age of a dog to determine the disease outcome of CMGTs 
is currently uncertain. Advanced age of the dog was reported to be associated with a 
shorter DFI and OS in five studies.57,106,2,16,95 Of these, only two studies identified age as an 
independent prognostic factor by multivariate analysis.2,95 However, several other studies 
have reported that age does not influence DFI or OS. 108,155,25,31 One reason for this 
observed variability may be that the age composition of the canine populations used, 
varied between studies. In addition, most of the studies have not clearly documented 
whether they used the age at diagnosis of mammary neoplasia or the age when the dog 
owner has first noticed the mammary tumours. This could be another reason for the 
apparent discrepancy observed between results. 
 
 
1.7.1.2. Lymph node metastasis 
Initial metastasis of CMGTs occurs through the lymphatic system. However, contradictory 
findings have been reported on lymph node metastasis and disease outcome of CMGTs. 
Four studies have reported that, lymph node metastasis was associate with poor disease 
outcome in dogs, using univariate analysis.155,95,25,2 However, two studies which have used 
multivariate analysis, failed to demonstrate any relationship between lymph node 
metastasis and DFI or OS in dogs with CMGTs.31,88,126 All these studies used cytology to 
determine lymphatic metastasis. However, cytology is not considered to be a highly 
sensitive method to detect tumour cells in lymph nodes as cytological examination only 
include a small area of a lymph node which may not include metastatic cells.128 This might 
be one possible reason for the observed difference in results between studies. When 
cancer metastasis occurs via the lymphatic system, the lymph node or group of lymph 
nodes that the cancer cells first reaches are “sentinel” lymph nodes.76 In human breast 
cancers, sentinel lymph nodes are well recognized.76 Dogs have five pairs of mammary 
glands and the lymphatic drainage is more complex than in humans. Therefore, the 
knowledge about sentinel lymph nodes is limited in dogs and currently there is no 





detect tumour metastasis. Most studies which have evaluated the prognostic significance 
of lymph node metastasis have not documented which lymph nodes were evaluated 
suggesting another possible reason for the observed difference in results between studies. 
In addition, micrometastases in lymph nodes are difficult to recognise using light 
microscopy and immunohistochemistry (IHC) or more sophisticated methods including 
positron emission tomography (PET) scanning which are not readily available for dogs may 
be required to identify these. Therefore, results between studies may also vary according 
to the methods used to identify tumour cells present in lymph nodes. 
 
 
1.7.1.3 Tumour staging  
A staging system for canine mammary tumours was first developed by Owen and 
colleagues in 1980 based on the staging system used for human breast cancer.100 This 
staging system considers three components: tumour size (T), lymph node status (N), and 
distant metastasis (M) when determining the clinical stage of a mammary neoplasm (Table 
1.3).100 A simplified version of this system was later proposed by Rutteman et al. in 2001.140 
Many studies have shown that both systems provide consistent prognostic information 
regarding DFI and OS in dogs with mammary tumours. 159,57,25,3 In addition to providing 
prognostic information, tumour staging is an important determinant when making 

















Table 1.3 Canine mammary gland tumour staging  
 Source: Owen et al. (1980) 
 
Stage Size Regional metastasis Distant metastasis 
Stage I T1 N0 M0 
Stage II T2 N0 M0 
Stage III T3 N0 M0 
Stage IV Any size N1 M0 
Stage V Any size N0 or N1 M1 
Key: T1: ≤ tumour diameter 3 cm; T2: tumour diameter: 3—5 cm; T3: tumour diameter ≥ 5 
cm; N0: without lymph node metastasis; N1: metastasis in lymph node present; M0: 
absence of distant metastases; M1: presence of distant metastases. 
 
 
Canine mammary gland tumours include a range of neoplasms of various histological sub-
types and grades with highly variable biological behaviour.139 Some recent studies suggest 
that, although the current CMGT staging system provides a useful anatomical assessment 
of the extent of tumour spread within the body, it is not able to capture the biological and 
histological diversity within each stage which may lead to inaccurate prognostication for 
individual patients.139,26 For example, it is possible for two tumours in the same stage not 
have the same disease outcome if one tumour is a low-grade tumour while the other is a 
high-grade tumour. Similarly, two tumours of  the same stage may not have the same 
prognosis if one tumour belongs to a histological sub-type such as mixed mammary 
carcinoma which is less likely to metastasise while the other is a simple carcinoma which is 
more likely to metastasise.139  In addition, other biological factors, including hormone 
receptor expression or cellular proliferation indices may also vary within each stage and 
influence prognosis.139 Therefore, the currently available clinical staging systems need 
updating to include prognostic factors which may capture more of the biological behaviour 






1.7.2 Reproductive status related prognostic factors 
The prognostic significance of several reproductive status variables has been analysed in 
many studies. Whether these factors can be used as reliable prognostic indicators is 
uncertain due to contrasting results observed in different studies. Dogs with short oestrous 
cycles and a low number of oestrous cycles were reported to have shorter OS and DFI for 
CMGTs by univariate analysis.18 However, the prognostic significance of these factors was 
lost on multivariate analysis in another study.104 Ovariohysterectomy during mammary 
tumour excision was shown to be predictive of longer OS and DFI in univariate analysis by 
some authors.155 while the same variable was shown not to affect either OS or DFI in 
several other studies. 130,57,37 Other reproductive variables including, number of 
pregnancies, age at first full term pregnancy and pseudopregnancy, have been analysed for 
their prognostic significance by many authors. However, none of these factors were shown 
to affect the post-surgical DFI or OS in dogs with mammary gland tumours. 31,37,57,129 
 
 
1.7.3 Tumour related prognostic factors 
Tumour related factors including the tumour size, number of malignant tumours in a single 
animal at the time of presentation, surface ulceration, fixation to the underlying tissues 
and tumour growth rate have been evaluated in many prognostic analysis studies.57,25 Of 
these, tumour size is the most widely evaluated tumour- related prognostic factor.42,57 
According to the findings of several studies, the larger the tumour size the shorter the DFI 
and OS. However, many of these studies evaluated the prognostic significance by 
univariate analysis only. 42,48,88,155,3 When the prognostic significance was evaluated by 
multivariate analysis in three studies, tumour size was found to be prognostic only in 
one.57,25,108  Therefore, the ability of tumour size to reliably predict the outcome of CMGTs 
is still uncertain. This uncertainty is further complicated by the marked differences 
observed in the methods used by various authors to classify the tumours into “large”, 
“medium” and “small” categories.  The most widely used method of classification is the 
separation of tumours as T1 (0—3 cm), T2 (3—5 cm) and T3 (> 5 cm) according to the 





> 3 cm diameter tumours and < 3 cm diameter while Misdrope et al. (1976) used 4 size-
categories: > 15 cm, > 10—15 cm, > 5—10 cm, > 0—5 cm. 108,88 
  
Rapid and invasive growth, ulceration of the skin, fixation to underlying tissues, location of 
the tumour, and the presence of additional mammary tumours have also been assessed 
for the prognostic significance by univariate and multivariate analyses. 42,57,126,159,3 Of these, 
ulceration of the skin overlying the tumour and rapid and invasive growth rate have been 
associated with shorter DFI and OS in dogs with mammary gland tumours.42,126 Moreover, 
the study by Pena et al. (1998) found a significant association between tumour ulceration 
and metastasis.106 However, the prognostic significance of surface ulceration was identified 
only by univariate analysis. 
 
 
1.7.4 Histological prognostic factors 
1.7.4.1 Histological sub-type 
The prognostic value of histological tumour sub-types in CMGTs is inconclusive for several 
reasons. Firstly, there are studies which describe contrasting disease outcomes for the 
same histological sub-type. 115,116,65 For example, in one study, OS of dogs with simple 
tubular carcinoma was reported to be considerably shorter that the OS of dogs with 
complex carcinoma. However, in another study, the same group of researchers reported 
that OS of dogs with simple tubular carcinoma was not significantly different from OS of 
dogs with complex carcinoma.115,116 The authors of this study attributed this discrepancy to 
the presence of a higher proportion of grade I simple tubular carcinomas in the latter study 
compared to the first. Grade I carcinomas usually have a better prognosis compared to 
grade II or III carcinomas. However, the results of these two studies indicate that 
histological tumour sub-type may not provide reliable prognostic information when it is 
used as the only prognostic indicator.  
 
Secondly, although there are many histological sub-types of CMGTs described under 
different classifications, the prognostic significance is only well reported for a few sub-





either limited prognostic information is available or the prognostic significance is unknown. 
This is mostly due to the low prevalence of some histological sub-types such as 
carcinosarcoma, myoepithelial sarcoma, mucinous carcinoma, lipid rich carcinoma 
compared to others making meaningful studies and data collection difficult.115,22 
Consequently, many prognostic studies contain few or none of the less common CMGT 
sub-types. In fact, one of the largest prognostic studies conducted by Hellmen et al. 
(1993)57, included only one uncommon sub-type, namely malignant myoepithelioma. The 
prognostic significance of malignant myoepithelioma was not analysed in this study due to 
the low number of cases recruited. Similarly, only six uncommon sub-types were included 
in the largest of the four studies evaluating the prognostic significance of tumour sub-types 
described in the 2011 Goldschmidt classification. In that study, the prognostic significance 
of two of the uncommon sub-types, including, lipid-rich carcinoma and micropapillary 
invasive carcinoma, were not evaluated due to inadequate numbers of cases.115,116,62,104 
Some researchers have attempted to form broad categories of mammary tumours, by 
collating several sub-types sharing common features together. In one such study 
conducted by Misdrope et al. (1976)88, all CMGTs included were considered in three broad 
categories: simple carcinoma, complex carcinoma and sarcoma. In this study, dogs in the 
sarcoma category had the shortest OS while dogs with complex carcinomas had the 
longest OS. However, prognostic information revealed by this study was general and 
therefore has a limited prognostic value. 
 
In addition to the prior mentioned ambiguities of the prognostic significance of histological 
classification of CMGTs,  currently there is no consensus on which histological sub-type 
classification system best predicts the disease outcome of CMGTs.23 So far, only a single 
study has compared the prognostic ability of different classification systems.20 Further, rare 
types of CMGTs, such as mammary carcinoma with sebaceous differentiation, lobular 
carcinomas, and pleomorphic lobular carcinomas which were not discussed in the 
Misdorpe classification or Goldschmidt classification are published in veterinary 
literature.23 Prognostic determination of these sub-types is challenging, and it is highly 
unlikely to achieve satisfactory prognostic guidelines for these rare tumour entities without 






1.7.4.2 Histological grade 
Although tumour grade is considered as one of the best prognostic indicators for human 
breast cancers, the utility of tumour grade as a prognostic factor for canine MGTs is not 
well established. 104 Two studies have evaluated the prognostic significance of the Elston 
and Ellis method when used to grade CMGTs. In the first study conducted by Misdrop et al. 
(1976), the grade I category had a significantly lower percentage of tumour related deaths 
compared to grade III category.88 However, percentage tumour related deaths in the grade 
II category was not significantly different either from grade I or grade III categories. In this 
study, most of the tumours categorised as grade I or grade III tumours were simple 
carcinomas while the neoplasms categorised as grade II included the least number of 
simple carcinomas. The authors of this study attributed this weak distinction between 
grade II category and other categories in terms of percentage tumour related deaths to the 
lower proportion of simple carcinomas included in the grade II category. Further, based on 
this assumption, it was suggested that grading of canine mammary neoplasms using Elston 
and Ellis method has a prognostic utility when it is used to grade simple carcinomas while it 
is least useful with other histological sub-types. The other study by Karayannopoulou et al. 
(2005) mostly included simple carcinomas in all grade I, grade II and grade III categories.65 
In this study, survival intervals were significantly shorter in dogs diagnosed with grade III 
tumours than the dogs diagnosed with either grade I or grade II tumours. The dogs with 
mammary gland tumours categorised as grade I had the longest average survival time. 
However, in the grade II category, nearly 50% of the dogs were dead at the end of the 2-
year follow-up period suggesting that dogs with grade II tumours were equally likely to live 
as to die making this grade poorly prognostic of disease outcome for malignant CMGTs.65  
 
More recently Peña  et al. (2013) modified the original Elston and Ellis method for grading 
CMGTs.104 This canine-adopted Pena method caters for grading complex and mixed 
carcinoma in addition to simple carcinomas. However, several studies have revealed that, 
even using this updated method, there is no significant difference in the disease outcome 
for dogs with grade II mammary neoplasms when compared to grade I neoplasms.115,80 In 
these studies, both grade I and grade II tumours behaved similarly with prolonged overall 
survival, infrequent local recurrence and distant metastasis. Therefore, in this modified 





Many studies reported satisfactorily low inter- and intra-observer variability of Elston and 
Ellis method when it is used to grade human breast cancers. Therefore, currently tumour 
grade determined by Elston and Ellis method is recommended to use in prognostic 
determination for human breast cancers.114 However, no studies have determined the 
inter- and intra-observer variability of Elston and Ellis grading method when it is used to 
grade CMGTs. Two studies have reported a considerably higher degree of inter-observer 
variability in the grading method proposed by Peña et al (2013).104 Except for these two 
studies, no other studies have evaluated the CMGT grading methods regarding inter and 
intra-observer variability. Therefore, considering the shortcomings and insufficient 
validation information on currently available grading methods, the definite utility of 
tumour grade as a prognostic factor for CMGTs is currently uncertain. 
 
 
1.7.5 Molecular prognostic markers 
A molecular marker for cancer is a molecular entity (DNA, RNA, or protein) which can be 
isolated from biological materials to obtain a quantitative measurement of biological 
homeostasis in cancer-affected cells, tissues, or an organism.121 In human breast cancers, 
the prognostic potential of molecular markers has been extensively studied.124 Many 
molecular markers, particularly, steroid hormone receptors, cell proliferation markers, 
tumour suppressor genes and oncogenes and enzymes such as cycloxgenase-2 (COX-2) 
have been identified as reliable prognostic factors for breast cancers. However, in 
veterinary medicine, only a few studies have been conducted to evaluate the prognostic 
potential of these molecular markers and they are not currently routinely used to 
determine prognosis for CMGTs.106,161,31 
 
 
1.7.5.1 Steroid hormone receptors: progesterone receptor (PR) and oestrogen-receptor-
alpha (ERα) 
In the last decade, the utility of steroid hormone receptors as prognostic factors for human 
breast cancers has been investigated in-depth. Progesterone receptor (PR) and oestrogen-





cancers. Patients with ERα-positive breast cancers have been shown to have a better 
response to hormonal therapy and therefore these neoplasms have a better prognosis 
than patients with ERα-negative breast cancers.109 Expression of PR was detected more 
frequently in well-differentiated breast carcinomas than in poorly differentiated ones and 
tumours with higher number of PR receptors were reported to respond better to 
tamoxifen therapy.10 Studies evaluating the prognostic significance of ERα and PR 
expression in canine MGTs are limited and include one retrospective study24 and two 
prospective studies.95,31 The findings of these studies are inconclusive. In one prospective 
study, increased immunostaining for ER or PR receptors in malignant CMGTs was 
associated with a better prognosis. However, a similar association was not observed in the 
other prospective study. The increased presence of PR was associated with an increased 
OS in the retrospective study.24 The value of ER and PR immunostaining as a predictive 
marker of favourable response to hormone therapy has been evaluated in one study of 
CMGTs. In this study, the presence of ER or PR receptors on the neoplastic cells did not 
have any impact on the response of neoplasm to hormone therapy.53  
  
 
1.7.5.2 Markers of cell proliferation: Ki-67 and proliferating cell nuclear antigen (PCNA) 
Uncontrolled cellular proliferation is a key feature of cancer development and progression. 
The nuclear proliferation marker Ki-67 is one of the most researched molecular biomarkers 
for prognostic determination in human breast cancers and many studies have suggested 
that Ki-67 immunostaining can be effectively used to predict prognosis in breast 
cancers.30,63,97 Despite the studies showing prognostic significance of Ki-67 in human 
cancers, the American Society of Clinical Oncology does not recommend its use in clinical 
practice due to the lack of uniformity in laboratory techniques and analysis.110 Few canine 
studies have investigated the presence of Ki-67 in mammary gland tumours. In these 
studies, presence of high Ki-67 immunostaining was positively correlated with the 
development of metastasis as well as shorter DFI and OS.106,126 However, these studies 
have included relatively low numbers of samples. In addition, levels of Ki-67 in older dogs 
were shown to be lower than in younger dogs, probably because cell proliferation in 
general is slower at older age.106 Further, in contrast to human breast cancer studies, no 





immunostaining in CMGTs and cut-offs relevant to clinical decision making have not been 
determined for CMGTs. Therefore, the utility of Ki-67 for prognostic determination in 
CMGTs is currently uncertain and more studies with a large number of samples are 
necessary for confirmation.  
 
Proliferating cell nuclear antigen (PCNA) is another marker of cell proliferation used as a 
prognostic factor in human breast cancers. However, in contrast to human breast cancers, 
PCNA immunostaining was not associated with tumour metastasis, recurrence or DFI in 
dogs with mammary neoplasms.106  
 
 
1.7.5.3 Tumour suppressor genes: p53 
The gene p53 codes for a protein that regulates the cell cycle and therefore functions as a 
tumour suppressor gene. Mutations in p53 gene lead to uncontrolled cellular proliferation 
ultimately causing cancer.164  Regarding  the prognostic significance of p53, mutations in 
the p53 gene have been shown to be associated with a significantly shorter DFI and OS in 
human breast cancer patients.164 However, p53 expression has been shown to vary 
between different sub-types of human breast cancers.102  Additionally, some studies have 
demonstrated that increased p53 expression correlates with longer DFI and OS of breast 
cancer patients. Therefore, currently the prognostic utility of p53 in human breast cancers 
is unclear. A limited number of studies have investigated the prognostic significance of p53 
expression in canine mammary neoplasms with contrasting results.36,94 Therefore, similar 




1.7.5.4 Oncogenes: human epidermal growth factor receptor-2 HER-2 
An oncogene is defined as a gene that encodes a protein that is capable of transforming 
cells in culture or has the potential to cause cancer.28 Human epidermal growth factor 
receptor-2 (HER-2) is a cell surface protein encoded by HER-2 gene oncogene. It is used as 
a prognostic marker in human breast cancers. Patients with HER-2-positive breast cancers 





The prognostic function of HER-2 in CMGTs is uncertain as some studies have 
demonstrated that HER-2-positive malignant CMGTs have a worse prognosis, while other 
studies found that dogs with HER-2-positive neoplasms actually had a better prognosis 
than dogs with HER-2 negative tumours.105  
 
 
1.7.5.5 Cyclooxygenase-2 (COX-2) 
Cyclooxygenase-2 or COX-2 is an enzyme that in humans is encoded by the Prostaglandin-
endoperoxide synthase 2 (PTGS2) gene. Recent studies have investigated the presence of 
cyclooxygenase-2 (COX-2), an enzyme involved in inflammation, as a prognostic marker in 
human breast cancers as well as in CMGTs. In human breast cancers, increased 
immunostaining for COX-2 was associated with a poor prognosis.118 A limited number of 
studies have similarly investigated the prognostic significance of COX-2 in CMGTs. In one 
study, increased COX-2 immunostaining was significantly associated with reduced tumour 
differentiation, suggesting that neoplasms with increased COX-2 may have a poorer 
prognosis.86,71  This was supported by another study that  observed increased 
immunostaining of COX-2 was associated with  lymph node metastasis at the time of 
surgery, development of distant metastasis during the follow-up, and shorter DFI and 
OS.111,71 However, as these observations were only tested by univariate analysis, it is 
currently unknown whether that COX-2 can be used as an independent prognostic factor in 
CMGTs. In summary, the prognostic significance of many molecular markers tested so far 
for CMGTs is either inconclusive or show conflicting results.   
 
 
1.8 Canine mammary gland tumours and human breast cancers  
In recent decades, many studies have compared mammary neoplasia of humans and dogs 
and identified many clinical and molecular similarities between them.112 The clinical 
similarities include spontaneous occurrence of tumours, hormonal aetiology, and age of 
onset.  Both women and intact female dogs develop spontaneous mammary neoplasms 
that are thought to be influenced by reproductive hormones.112,14 When adjusted for the 





(after 40 years) is approximately the same as dogs (after 6 years) with the peak incidence 
of the disease is also comparable between the two species.126 The clinical course of 
mammary tumours also similar but not identical in dogs and humans. In dogs, 
approximately 50% of the mammary neoplasms are malignant while 20-50% of malignant 
neoplasms metastasising to regional lymph nodes and lungs. Bone metastasis is 
infrequent. Approximately 50%-70% of human breast lesions are benign neoplasms.52,99 
Nearly 20% of women with breast cancers develop metastasis to lymph nodes and lung 
with frequent bone metastasis.122 In both species, a larger tumour size, presence of 
lymph node metastases and advanced clinical stage are linked with a worse prognosis.112  
 
Despite these similarities, CMGTs are histologically more variable than human breast 
cancers. The most common histological type of mammary neoplasm in women is invasive 
ductal carcinoma while other histological sub-types are less frequent.112 In contrast, 
CMGTs may originate from different types of tissues in the mammary gland including 
epithelial or mesenchymal tissues and the most common histological sub-types include 
simple carcinoma and mixed mammary tumours. Many recent studies have compared 
CMGTs and human breast cancers on a molecular level and these studies have identified 
similarities regarding steroid receptors, proliferation markers, epidermal growth factor, 
p53 suppressor gene mutations, metalloproteinases, and cyclooxygenases, among many 
others.112 Based on these clinical and molecular similarities it has been suggested that 
canine mammary tumours are a valid model to study human breast cancer. 
  
 
1.9 Tumour microenvironment (TME) and tumour associated inflammation 
(TAI) 
Recent research in the field of cancer biology has suggested that while genetic alterations 
in tumour cells are essential for tumour development, the cancer stroma also plays a 
critical role in tumour progression and metastasis.5 Cancer stroma is the tissue surrounding 
the tumour cells in a tumour which is composed of many cellular and non-cellular 
components collectively known as the tumour microenvironment (TME).5 In addition to the 





polysaccharides, the TME includes many cellular components including immune-
inflammatory cells, fibroblasts, myofibroblasts, neuroendocrine cells, adipose cells, and the 
blood and lymphatic vascular networks.5 Inflammation is the main process which maintains 
and regulates the crosstalk between the TME and the tumour cells. Within the TME, 
inflammation influences every aspect of tumour development and progression, as well as 
response to therapy.123 In fact, inflammatory components within the TME, termed as 
tumour associated inflammation (TAI),  can promote an anti-tumour immune response or 
support tumour progression and metastasis.123 The key features of TAI include leukocyte 
infiltration in response to cytokines or chemokines, angiogenesis and tissue 
remodeling.5,156 Given the importance of TAI, recent cancer studies have been aimed at 
identifying the key inflammatory mediators in the TME which can better predict the 
tumour behaviour. Additionally, a better understanding of TAI could also be important for 
cancer treatment as the TAI response can be modified by novel therapeutics, potentially 
changing the biological behaviour of cancers, to achieve a better disease outcome. 
Interestingly, some reports have concluded that prognostic markers related to TAI are in 
fact better predictors of patient survival than other conventional prognostic factors that 
are currently used for various human cancer types.21,5  In human medicine, currently there 
are three key research areas which are focused on identifying TAI related prognostic 
markers and therapeutic targets. These include immune cell infiltration of tumours152, 
chemokines and their receptor expression by tumour cells165, and aberrant expression of 
immune checkpoint molecules by tumour cells.156  
 
 
1.9.1 Prognostic significance of immune cell infiltration in cancers 
The three components: quantity, functionality, and the localisation of immune cells within 
the TME are collectively identified as the “immune contexture” of a cancer.45,11 Many 
human studies have extensively investigated the immune contexture of different types of 
cancers and revealed that it can have a significant impact on cancer recurrence, metastasis 
and patient survival. For example, in colorectal cancers the presence of a high number of 
memory T-cells in the invasive front and within the centre of the neoplasm correlated with 





an increased number of intra-epithelial T-lymphocytes was associated with longer OS times 
of the patients.60 Increased infiltration of tumour stroma by CD8+ lymphocytes was 
associated with longer OS times in patients with non-small cell lung cancers.50 In 
hepatocellular carcinoma, increased intra-tumoural and peri-tumoural infiltration of 
FOXP3+ regulatory T-cells was associated with shorter DFIs and OS times of the 
patients.11,50 Some of these studies have compared the prognosis suggested by the 
immune cell infiltration with other conventional prognostic factors including tumour size, 
tumour grade and clinical stage of the tumour and found that immune cell infiltration 
often better predicts disease outcome than conventional prognostic indicators. In human 
breast cancer, the presence of various types of tumour infiltrating immune cells including 
macrophages142, T-cells162,132,70 and mast cells113 have been correlated with the disease 
outcome of the patients. 
 
 
Prognostic significance of mast cell number and distribution in cancers 
Mast cells are an important innate immune cell type frequently found in the inflammatory 
cell infiltrates of many cancers.83,32 Mast cell-derived mediators can either be pro-
tumourigenic, causing tumour progression and metastasis, or anti-tumourigenic limiting 
tumour growth.86 The tumour promoting functions of mast cells are attributed to different 
types of angiogenic factors, proteases and growth factors secreted by them.32,83,98 These 
pro-tumourigenic mediators secreted by mast cells promote tumour progression, either by 
direct effect on tumour cells, or indirect influence on TME. Regarding the indirect effect of 
mast cells on TME, the pro-tumourigenic mediators secreted by mast cells can alter the 
TME in favour of tumour growth and metastasis by enhancing tumour angiogenesis and 
remodelling of tumour matrix.98 The anti-tumour effects of mast cells are mostly attributed 
to the TNF-α, IL-4 and IL-9 that they secrete. These cytokines stimulate the immune system 
enhancing tumour cell destruction, limiting the growth of neoplasms. 
  
The degree of mast cell infiltration is shown to be predictive of disease outcome in some 
human cancers.83,152 The majority of reports have correlated increased mast cell infiltration 
with a unfavourable prognosis, 82,91,145 although a few studies have associated mast cell 





measured the overall mast cell density irrespective of their location. Some recent studies 
have suggested that presence of mast cells at different locations within a tumour may have 
distinct roles in tumour progression in cancers. Further, these studies have proposed that 
rather than the overall mast cell density, mast cell density in different tumour locations to 
be better prognostic indicators for some human cancers.7 One such large study on invasive 
breast cancers showed that patients with higher stromal mast cell density had better 
disease outcomes including longer OS and DFI than patients with lower stromal mast cell 
density.113 In addition to the prognostic utility of mast cells in breast cancers the potential 
of using them as therapeutic targets has also been considered. Experimental studies 
carried out with murine models suggested that mast cells could be used as potential 
therapeutic targets for breast cancers. These studies indicated that compounds which 
promote controlled release of anti-tumourigenic mediators from mast cells may enhance 
anti-tumour immunity.98 
 
Limited numbers of studies have explored mast cells in CMGTs and the role of mast cells in 
prognosis of CMGTs is currently not well known. One study reported a positive correlation 
between mast cell density and micro-vessel density in malignant mammary tumours 
suggesting a contribution of mast cells towards tumour angiogenesis.72 Im et al. (2011)61 
demonstrated similar findings and further suggested that increased amount of the enzyme 
tryptase produced by mast cells may have promoted tumour angiogenesis.61 Although 
these studies provide some useful clues about the role of mast cells in CMGTs, none of 
these studies investigated the prognostic significance of mast cell distribution in CMGTs 
using retrospective or perspective survival analysis studies. Therefore, it may be useful to 
investigate the prognostic potential of tumour infiltrating mast cells in CMGTs. 
 
 
1.9.2 Prognostic significance of chemokines and chemokine receptors in cancer 
Chemokines are low molecular weight signalling proteins that are produced by innate 
immune cells such as eosinophils, neutrophils, macrophages, dendritic cells, and natural 
killer cells. Chemokines function to regulate the trafficking and positioning of the cells of 





located on the surfaces of many inflammatory cells and some tissue cells.96 All chemokines 
contain the amino acid cysteine in them. According to the spacing pattern of the first two 
cysteines in their sequence, there are four structural sub-types of chemokine; C, CC, CXC 
and CX3C.165 Functionally, chemokines are categorised either as homeostatic or 
inflammatory.165,92 Homeostatic chemokines are constitutively produced by certain 
inflammatory and tissue cell types and  assist the host immune system in recognising 
transformed cells. In contrast, inflammatory chemokines are induced by inflammatory 
stimuli to attract neutrophils and eosinophils from the circulation to the site of infection or 
injury.92,165 
 
To date, nearly 50 chemokines have been identified. Twenty chemokine receptors, which 
are expressed mainly by leukocytes, have been identified along with four atypical 
chemokine receptors which are expressed by non-leukocyte cell types, including 
erythrocytes, and vascular endothelial cells.101 Of the 24 chemokine receptors, six are 
known to bind to a single chemokine while other receptors have affinity to multiple 
chemokines.165 Some tumour cells were also shown to aberrantly express chemokines and 
chemokine receptors on their cell surfaces. More than half of the chemokine receptors 
have been known to be important in tumour biology, especially tumour growth and 
metastasis.165 The recognition of the role of chemokines in tumour biology suggested that 
chemokine receptors could be potential therapeutic targets for the treatments of some 
cancers.96,92  
 
In human breast cancer, intra-tumoural chemokine expression has been found to influence 
tumour growth, angiogenesis and distant metastasis.50 Studies of human breast cancer 
have suggested that expression of chemokines and chemokine receptors may be useful to 
predict the behaviour of neoplasms, especially the development of distant metastasis.4,92  
Chemokine receptors, including CXCR2, CXCR3, CXCR4, CXCR7, CCR4 and CCR9 were shown 
to influence cancer cell survival and proliferation, tumour angiogenesis, and development 
of resistance to conventional and targeted therapies in human breast cancers.96,165 Further, 
targeting chemokines and chemokine receptors using monoclonal antibodies developed 
against them has been reported to show promise as therapy.4 In dogs, little research has 





the details of four chemokine receptors and four chemokines identified as useful 
prognostic indicators in human breast cancers and the research findings investigating the 
same receptor and ligands in CMGTs. In summary, the prognostic significance of the 
chemokines studied in human breast cancers show variable prognostic significance in 







Table 1.4 Chemokines and chemokine receptors associated with disease outcome of human breast cancers and their expression in canine mammary gland tumours. 
Chemokine 
receptor/ligand 
Known physiological function Prognostic significance in human breast cancer Expression/prognostic significance in canine mammary gland tumours  
CXCR4 Regulate lymphopoiesis, myelopoiesis, 
and T-cell migration   
Increased gene expression or immunostaining 
correlates with increased metastatic potential.,4,150  
Increased gene expression in malignant neoplasms compared to normal 
mammary gland.68 
  
CXCR7 Scavenging of CXCR4 and CXCL11 
receptors 
Increased gene expression of CXCR7 correlates with a 
poor prognosis and co-expression of CXCR4 and CXCR7 
genes correlates with reduced metastasis. 4,85 
Increased gene expression in malignant neoplasms compared to normal 
mammary gland.68  
CXCL12 Regulate haematopoiesis, T-lymphocyte 
migration and angiogenesis 
Increased gene expression or immunostaining 
correlates with metastasis.87,46  
Lower gene expression in tumour stromal cells of mammary carcinoma than 
stroma of adjacent non-neoplastic mammary gland tissues.39 
CXCR3 Regulate T-lymphocyte trafficking and 
function 
Increased gene expression or immunostaining 
correlates with distant metastasis.75,163 
Increased gene expression in metastatic mammary neoplasms than non-
metastatic neoplasms, benign neoplasms, and non-neoplastic mammary gland.19 
CCR4 Regulate T-lymphocyte and dendritic cell 
migration and lymphopoiesis 
Increased gene expression or immunostaining 
correlates with increased LN metastasis.74 
Not studied in canine MGTs. 
CCR9 Regulate T-lymphocyte homing to gut Increased immunostaining correlates with increased 
tumour invasion and metastasis. 4,64 
Not studied in canine MGTs. 
CXCL10 Regulate T-lymphocyte migration and 
involve with adaptive immune responses 
Increased gene expression correlates with poor 
prognosis.92,93 
Increased gene expression in malignant tumours compared to adjacent non-
neoplastic mammary gland.68,69 
CCL5 Regulate T-lymphocyte and monocyte 
migration and innate and adaptive 
immune responses 
Increased gene expression correlates with distant 
metastasis.,4,153,158 
Significantly higher gene expression in simple adenoma and tubulopapillary 








1.9.3 Prognostic significance of immune checkpoints and chemokine receptors in 
cancer 
The host immune system continuously monitors the body to detect and destroy infected or 
neoplastic cells via a process known as immunological surveillance.156 However,  
immunosurveillance may lead to uncontrolled immune responses which may cause severe 
damage to the host tissues.162 To prevent this, the magnitude of the host immune 
response is regulated by a balance between co-stimulatory and co-inhibitory signals.162 The 
co-stimulatory signals promote the host immune response while co-inhibitory signals 
suppress the host immune response. These signals, which are generated through receptor-
ligand interactions, are collectively referred to as immune checkpoints.156 The immune 
checkpoint receptors are usually located on the surfaces of immune and inflammatory cells 
and the ligands are produced by either inflammatory and immune cells or certain types of 
tissue cells. The co-inhibitory immune checkpoints are important in tumour biology, as 
tumour cells exploit these to evade the host immune response. Programmed death ligand 
1 (PD-L1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4) are two such co-inhibitory 




1.9.3.1 Programme death ligand-1 (PD-L1) 
Usually, PD-L1 is present on the surface of macrophages, and the corresponding receptor, 
PD-1, is present on activated CD8+ T-cells.156 These cells are the main mediators of 
immune-mediated cytotoxic cell lysis.  The interactions between PD-L1 and PD-1 prevent 
indiscriminate destruction of normal tissue cells by CD8+ T-cells during immune mediated 
cytotoxic cell lysis. Inflammatory cytokines present in TME induce aberrant PD-L1 
expression on tumour cells. The co-inhibitory signal generated by the interaction between 
PD-1 expressed on activated CD8 + T-cells and PD-L1 produced by tumour cells, suppresses 
the host anti-tumour immune response by inhibiting CD8 + cytotoxic T-cell mediated 






In many studies of human cancers, PD-L1 was shown to be more frequently present on 
cells from malignant neoplasms than cells from benign tumours.156,162 Based on this 
finding, the prognostic utility of PD-L1 in human cancers has been extensively investigated 
during the past few years. A recent meta-analysis of previously published studies showed a 
strong association between increased immunostaining for PD-L1 protein in cancer cells and 
shorter DFI and OS.156 Another meta-analysis of five previously published studies on the 
presence of PD-L1 in breast cancers suggested that PD-L1 immunostaining is a promising 
biomarker for predicting the biological behaviour of human breast cancers.162  
 
In addition to its role as a potential prognostic marker in human cancers, some studies 
have suggested that PD-1 and PD-L1 can be manipulated to achieve therapeutic benefits.58 
Monoclonal antibodies developed against PD-1 or PD-L1 proteins can block the receptor-
ligand interaction in vitro or in vivo, restoring the host immune response against cancer 
cells in humans and dogs.17 Currently, commercial preparations of anti-PD-1 and anti-PD-L1 
monoclonal antibodies are available for therapeutic usage.17 They are currently used as 
adjuvant immunotherapies in human patients with various types of cancers including 
breast carcinomas.17 
 
Immune checkpoints are infrequently studied in dogs and there are currently only a few 
preliminary studies of PD-L1 gene expression and immunostaining in canine cancers. Two 
studies have identified the presence of PD-L1 in several canine cancers using 
immunohistochemistry.77,133 According to these studies, PD-L1 is frequently detectible in 
melanoma, mammary gland tumours, mast cell tumour, prostate cancers and lymphoma, 
but less frequently present in different types of sarcomas including osteosarcoma, 
fibrosarcoma and haemangiosarcoma.77,133 Of the two studies, all tumours included in one 
study were malignant tumours133 while the other study included both malignant and 
benign tumuors.77 The number of cases included from each tumour type as well as from 
benign and malignant categories were low in both studies. Therefore, differences in PD-L1 
immunostaining among various tumour types and between benign and malignant tumours 
were not analysed. Moreover, none of these studies have evaluated the prognostic utility 






One recent study has investigated the therapeutic potential of PD-L1 blockade in dogs 
using monoclonal antibodies developed against canine PD-L1 protein.78 This study included 
an in vitro assay and a pilot clinical study. The in vitro assay investigated the 
immunomodulatory effects of recombinant anti-PD-L1 monoclonal antibody using a canine 
tumour cell line.78 In this assay, PD-L1 blockade was shown to significantly enhance 
cytokine production by tumour cells. In the pilot clinical study, seven dogs with oral 
melanomas and two dogs with undifferentiated sarcomas were treated with recombinant 
anti-PD-L1 monoclonal antibody. At the end of the treatment period subsequent tumour 
regression was observed in single cases from each tumour type.78  
 
Given the prognostic and therapeutic efficacy of PD-L1 immune checkpoint in human 
breast cancer, it may equally be useful as a prognostic marker and therapeutic target in 
canine mammary neoplasms. However, the prognostic utility of PD-L1 or the therapeutic 
potential of PD-L1 blockade in canine MGTs have not yet been evaluated. 
 
 
1.9.3.2 Cytotoxic T-lymphocyte antigen-4 (CTLA-4) 
Cytotoxic T-lymphocyte antigen-4 (CTLA-4) is a member of the immunoglobulin 
superfamily present on activated T-cells. Unlike PD-L1, CTLA-4 is usually present in 
intracellular vesicles and is only transiently present on the surface of activated T-cells. T-
cells costimulatory protein-28 (CD28) is homologous to CTLA-4, and both molecules bind to 
CD80 and CD86 ligands present on antigen-presenting cells including macrophages and 
dendritic cells.59 Cytotoxic T-lymphocyte antigen-4  binds with CD80 and CD86 with greater 
affinity than CD28 which enables it to outcompete CD28. Upon binding with the ligand, 
CTLA-4 transmits an inhibitory signal to T-cells. Additionally, CTLA-4 is also found in 
regulatory T- cells and contributes to their inhibitory function. There are two isoforms of 
human CTLA-4: a membrane-bound receptor isoform with both extracellular and 
intracellular domains and a secreted, soluble isoform, which only has the extracellular 
domain for ligand-binding.59 These two isoforms reduce T-lymphocyte activation to 
maintain self-immune tolerance and homeostasis. Similar to human CTLA-4, canine CTLA-4 






In human medicine CTLA-4 has been shown to be expressed on some tumour cells in 
different types of cancers including melanoma, neuroblastoma, oesophageal carcinoma, 
lung cancer and human breast cancer. Despite the well-known immunosuppressive role of 
CTLA-4, the association between the presence of CTLA-4 and disease outcome is unclear, 
possibly due to the limited number of studies investigating this association.160,131 While one 
study reported CTLA-4 immunostaining in human breast cancers to predict prognosis 
independent of other conventional prognostic factors including age, clinical stage, tumour 
histological grade, presence of tumour emboli, ER, PR or HER-2 status and Ki-67 immune 
staining160, these findings were inconsistent with other similar studies. In veterinary 
medicine only a few studies have investigated CTLA-4 gene expression in canine 
neoplasms. One study comparing CTLA-4 gene expression in peripheral blood lymphocytes 
between dogs with histiocytic sarcoma, other neoplasms, and healthy dogs, reported that 
CTLA-4 expression was significantly higher in the peripheral blood lymphocytes of dogs 
with histiocytic sarcoma than in the other two groups.147  Another study showed that CTLA-
4 gene expression is prognostically important in canine high-grade B cell lymphomas.146 No 
previous studies have investigated the presence of CTLA-4 either by gene expression or 





Mammary gland tumours are common in female dogs and a significant cause of disease 
and mortality, especially in countries where early spaying is not a routine practice. Risk 
factors for CMGT development include old age, prolonged exposure to reproductive 
hormones, breed, and obesity. Canine mammary gland tumours represent a group of 
highly heterogeneous neoplasms with variable biological behaviours. Approximately half of 
CMGTs are histologically classified as malignant and approximately 50% of the malignant 
neoplasms progress to develop distant metastasis. Many clinical, histological, and 
molecular prognostic markers are currently available to predict the behaviour of CMGTs. 
Of these prognostic markers, tumour size, tumour histological classification, and tumour 





of a CMGT. However, current prognostic determination methods based on histological 
features of the neoplasms including tumour histological classification and tumour grade 
are subject to marked inter and intra-observer variation. In addition, tumour staging which 
is considered as one of the best methods for prognostic determination has been shown 
not to accurately predict the biological behaviour of CMGTs. Further, some molecular 
methods have been suggested for prognostic determination in CMGTs, but none have 
been thoroughly investigated.  
 
The main modality of treatment for CMGTs is surgical tumour excision and adjuvant 
therapies are infrequently included in CMGT treatment protocols. This is partly due to an 
inability to accurately identify which tumours would benefit from adjuvant therapy as well 
as the poor efficacy of currently available adjuvant therapies. Therefore, there is a need for 
more accurate prognostic markers to accurately determine the prognosis of CMGTs. 
Tumour associated inflammation in the tumour microenvironment influences the 
behaviour of many human cancers including human breast cancers. Some of the features 
of TAI were shown to predict the prognosis of human breast cancers more accurately than 
conventional prognostic markers. These features include tumour-infiltrating immune cells, 
chemokines and chemokine receptors, and immune checkpoint molecules present on 
tumour cells. Considering the similarities of clinical and molecular features of CMGTs and 
human breast cancers, these prognostic markers may similarly be prognostic for CMGTs.  
 
The following chapters of this thesis will present research aimed at identifying 
inflammation-related prognostic markers for CMGTs. Chapter 2 and Chapter 3 will include 
the surveys carried out in Sri Lanka and New Zealand to identify the clinical and 
pathological features of mammary neoplasms in dogs in these two countries. Chapter 4, 
Chapter 5, and Chapter 6 will discuss the research work carried out to determine the 
prognostic significance of inflammation-related prognostic markers adopted from human 
breast cancers. The prognostic markers investigated in CMGTs include mast cell 
distribution - Chapter 4; chemokines and chemokine receptor expression by tumour cells - 
Chapter 5; and aberrant immune checkpoint expression by tumour cells - Chapter 6.  
Chapter 7 will provide a general discussion and directions for future research. 
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Chapter 2 : Clinicopathological features of mammary gland   





Prolonged exposure to female reproductive hormones promotes mammary 
carcinogenesis.30 Consequently, mammary gland tumours are the most common neoplasm 
among intact dogs.2,12 Ovariohysterectomy (OHE), which is the surgical removal of the 
ovaries in companion animals colloquially known as spaying performed at an early age 
minimises the prolonged exposure of mammary tissues to reproductive hormones, and 
thereby reduces the risk of mammary neoplasia.17,32  As a result, the incidence of canine 
mammary gland tumours (CMGTs) is decreasing in the regions of the world where OHE is 
routinely performed at an early age.29 Sri Lanka is a South Asian country where spaying of 
dogs at an early age is not a common practice.6 Dog spaying in Sri Lanka is mostly 
conducted during mass de-sexing programs that are generally done on an opportunistic 
basis.6 Therefore, most of the dogs in Sri Lanka are either intact or have been spayed at an 
older age, which predisposes them to mammary neoplasia. In fact, mammary gland 
tumours are one of the most common neoplasms of dogs in Sri Lanka and are an important 
cause of mortality in this population. 
 
Given the importance of canine mammary neoplasia in Sri Lanka, it is necessary to improve 
the diagnostic, prognostic, and therapeutic aspects of CMGTs. In this thesis, tumour-
associated Inflammation related prognostic markers were investigated to see whether 
these could be useful for veterinary pathologists and clinicians to better predict pronosis in 
dogs with mammary neoplasms. To achieve this, samples were collected as part of a one-
year prospective survey conducted at two veterinary practices in Sri Lanka. Unfortunately, 
due to the inability to obtain follow-up data for some patients, CMGT cases obtained from 
Sri Lanka could not be used for prognostic analysis. However, the collected information 
was still valuable as no previous study has investigated mammary neoplasms in dogs in Sri 





clinicopathological features of mammary neoplasms in female dogs in Sri Lanka. It was 
expected that these features could be a useful guide for Sri Lankan veterinary pathologists 
and clinicians to inform and possibly modify their current approaches to more accurately 
diagnose and effectively treat mammary neoplasms in dogs.  
 
A knowledge of possible risk factors for CMGTs is important to help develop effective 
strategies to minimise the incidence of these neoplasms. Previous studies have suggested 
that dogs older than 7 years, small-sized dogs, obese dogs, and dogs that were spayed later 
in life but still nulliparous, are at increased risk of developing mammary gland 
tumours.3,7,23,10 However, the relative impact of these risk factors appears to be variable 
within different regions of the world. Therefore, as a second objective, patient profile 
including age, breed, body condition score, reproductive status, and parity of the dogs 
included in the survey was analysed to identify possible risk factors for mammary neoplasia 
in dogs in Sri Lanka. 
 
 
2.2 Material and methods 
2.2.1 Sample collection 
Samples for the present study were obtained from the Veterinary Teaching Hospital (VTH), 
Faculty of Veterinary Medicine and Animal Science, University of Peradeniya, and a private 
veterinary practice in Colombo (VPC), Sri Lanka. All dogs that presented to these clinics 
between June 2016 and June 2017, with one or more spontaneous mammary gland 
tumours that were treated by surgical excision, were included in the study. The primary 
clinicians that saw these cases kindly provided the patient records and the surgically 
excised mammary tumours collected in 10% neutral buffered formalin. Full owner consent 
was obtained before sample collection. 
 
The following information was determined from the patient records: primary complaint, 
breed, age, body condition score, age at neutering, parity, general clinical exam findings, 
and information regarding any prior investigations related to the presenting mammary 





tumours were classified as T1 (≤ 3 cm in greatest dimension), T2 (tumour > 3 cm but ≤ 5 
cm in greatest diameter), or T3 (tumour > 5 cm in greatest diameter), following the World 
Health Organization guidelines as applied by Sorenmo et al. (2009).29 Other gross 
pathological features of the tumours including adherence of tumour mass to the 
underlying tissues and ulcerations of the skin overlying the tumour, were also extracted 
from the patient records. 
 
 
2.2.2 Histopathology and tumour classification 
The formalin-fixed mammary gland tumours received from the primary clinicians were 
further processed in the histopathology laboratory of the VTH. Briefly, tumours were 
dehydrated in a gradient of alcohol, embedded in wax, processed into thin sections (3 µm), 
stained with haematoxylin and eosin, and examined microscopically. When multiple 
tumours were present in a single dog, only the tumour with the greatest diameter was 
considered for histological examination. Immunohistochemistry for α-smooth muscle actin 
(SMA) was performed to evaluate a myoepithelial origin of the neoplastic cells using an 
anti-α-SMA antibody (Sigma-Aldrich, St. Louis, MO, USA), following the standard protocols 
using vascular smooth muscles as the positive control and cardiac muscle as the negative 
control. Mammary tumour classification was performed according to the definitions in the 
2011 classification proposed by Goldschmidt and colleagues.14 Histological malignancy of 
the tumours was determined following the criteria described in the 2011 Goldschmidt 
classification: tumour type, nuclear and cellular pleomorphism, mitotic index, presence of 
randomly distributed areas of necrosis within the neoplasm, peri-tumoural and lymphatic 
invasion, and the presence of intra-tumoural inflammatory cell infiltration.14 All carcinomas 
except inflammatory carcinomas were graded according to the guidelines provided by 
Pena et al. (2013).19 Briefly, tubule formation, nuclear pleomorphism, and mitotic counts 
were considered and rated on a scale from 1 to 3. The scores for each category were 
added together and the total scores were used to determine the histological grades for 
each tumour. In heterogeneous carcinomas, tubular scoring was assessed in the most 





formation was scored considering only epithelial areas, and nuclear pleomorphism was 
evaluated in all the malignant components. 
 
 
2.2.3 Statistical analysis 
Chi-squared test was performed to determine whether the malignant mammary tumours 
were equally distributed among the thoracic, abdominal and inguinal mammary glands. 
Chi-squared test was followed by the Marascuillo process to identify the glands which had 
a significantly different proportion of malignant mammary tumours compared to the other 
glands. For this, the number of malignant mammary gland tumours in each anatomical 
location was compared with the mammary gland tumours in other locations in a pair-wise 
manner using a calculated absolute and critical value for each pair. The difference was 
considered significant if the calculated absolute value was greater than the critical value. 
The same statistical methods were used to investigate differences in the distribution of 
malignant mammary neoplasms among T1, T2 and T3 tumour size categories. Single 
proportion test was used to compare the malignant tumour proportions in the right and 
left inguinal mammary glands, respectively. All statistical tests were performed using add-
on for Excel/XLSTAT software (Version 2017.4) (Addinsoft, New York, NY, USA). Differences 





2.3.1 Clinical characterization of dogs with mammary gland tumours 
Seventy-four dogs with mammary gland tumours were included in the study. Thirty-six 
(48.6%) of them were from Veterinary Teaching Hospital (VTH), Peradeniya, and 38 (51.4%) 
were from the veterinary practice in Colombo (VPC). 
 
Out of the 74 dogs included in the study, 41 (55.4%) dogs were presented primarily seeking 





previously diagnosed as benign mammary neoplasms by cytology. In addition to the 
mammary neoplasm, reduced appetite and lethargy were secondary complaints in 10 
(13.5%) and 17 (23.0%) dogs, respectively. In 33 (44.6%) dogs, mammary neoplasia was 
detected during a clinical examination when the dog was presented for an unrelated 
complaint. These dogs were presented for veterinary care primarily due to reduced 
appetite (n = 19, 25.7%) or lethargy (n = 14, 18.9%). Interestingly, the owners of 9 (12.1%) 
of the dogs admitted that even though they had noticed the mammary masses in their 
dogs prior to the clinical exams, they did not seek veterinary care specifically regarding 
them, assuming that the masses were harmless.  
 
During clinical examination of the 74 dogs, lymphadenopathy was identified in 40 (54.1%) 
dogs. According to the clinical records, lymphadenopathy was detected in inguinal lymph 
nodes alone in 10 (13.5%) dogs, while both inguinal and popliteal lymph nodes were 
concurrently enlarged in 15 (20.3%) dogs. The affected lymph nodes were not specified in 
15 (20.3%) dogs. Cytological examination of fine needle aspirates from the enlarged lymph 
nodes was performed in only 4 dogs and none of the aspirates were reported to contain 
neoplastic cells. Further, concurrent with lymphadenopathy, dyspnoea or pyrexia was 
detected during clinical examination in 16 (21.6%) and 14 (18.9%) dogs, respectively. 
Lateral thoracic radiographs had been taken in six dogs and evidence suggestive of 
pulmonary tumour metastasis was observed in 3 dogs. Weight loss was recorded in 7 out 
of the 30 dogs for which previous weight records were available. Two dogs were diagnosed 
with pyometra in addition to mammary neoplasia. Overall, 54 dogs, which accounted for 
approximately 75% of the group, were systemically ill at the time of presentation. 
 
Thirty nine of the 74 dogs presented were crossbred dogs which represented 
approximately half of the group (50%). German shepherd was the most common pure dog 
breed (n = 21, 28.4%), followed by dachshund (n = 2, 2.7%). Single cases of following 
breeds were also observed: Boxer, Fox Terrier, Japanese Spitz, Pomeranian, Tibetan 
Terrier, Cocker Spaniel, English Springer Spaniel, Pekingese, Doberman, Dalmatian, Great 






The overall mean and median ages of dogs with MGTs were 8.0 (SD 2.4) years and 8.0 
years, respectively. The age of the dogs with MGTs was further analysed separately in 4 
categories, namely: 0–4 years, 5–8 years, 9–12 years and ≥ 13 years. The most frequently 
represented age category was 5–8 years, which included 41 (55.4%) dogs. There were 26 
(35.1%) dogs in the 9–12 years category. The categories 0–4 years and ≥13 years, which 
included the youngest and oldest dogs, were less frequently represented as there were 
only 4 (5.4%) and 3 (4.0%) dogs in those categories, respectively. The mean age of the dogs 
with benign and malignant MGTs were 6.7 (SD 1.66) years and 7.9 (SD 2.15) years, 
respectively. There was no significant difference between the age of the dogs with benign 
tumours and malignant tumours. 
 
Primary clinicians had used the 1–5 body condition scoring system (BCS) described by 
Eastland-Jones et al. (2014).11 Accordingly, the body condition of the majority of dogs was 
BCS 3 with 42 (56.8%) dogs in this category. BCS 2 and BCS 4 categories included 15 
(20.6%) and 13 (17.6%) dogs respectively, while the BCS 5 group was the least represented 
group of all (n = 4, 5.4%). Reproductive status of the dogs with MGTs is summarized in 




Table 2.1 Reproductive status of the dogs with mammary gland tumours  
Reproductive status # of cases % 
Intact 46 62.2 
OHE: ≤ 3 years 8 10.8 
OHE: 4 - 6 years 12 16.2 
OHE: ≥ 7 years 6 8.1 




2.3.2 Gross pathological characterisation of canine mammary gland tumours 
Tumours were detected in a single mammary gland in 53 (71.6%) dogs, while 21 (28.3%) 





among the mammary glands is summarised in Table 2.2. Inguinal mammary glands were 
most often affected: 46 (62.1%) dogs had tumours in these glands. Surprisingly, a 
significantly higher (p < 0.001) number of dogs had tumours in the left inguinal gland (n = 
42, 56.8%) than the right (n = 4, 5.4%). No such significance was detected in mammary 
gland tumours in the thoracic or abdominal mammary glands. Nine dogs with inguinal 
mammary tumours had another mammary tumour in a different location, while four dogs 







Table 2.2 Distribution of mammary gland tumours. 
For malignant neoplasms, different superscripts (a, b) between different tumour locations indicate 
significant differences. Critical and absolute values: Thoracic—Abdominal (0.13, 0.04), Thoracic—







The size of the mammary gland tumours is summarized in Table 2.3. Overall, 31 dogs had 
T2 tumours, 25 had T3 tumours, and 18 had T1 tumours. Dogs which were primarily 
presented for mammary neoplasia had either T2 (n = 18) or T3 (n = 25) tumours, but none 
had T1 tumours. The MGTs which were incidentally detected in a clinical exam of a dog 
that was presented for unrelated complaints were either T1 (n = 18) or T2 (n = 15). 
 
The size of the mammary gland tumours is summarised in Table 2.3. Overall, 31 dogs had 
T2 tumours, 25 had T3 tumours, and 18 had T1 tumours. Dogs which were primarily 
presented for mammary neoplasia had either T2 (n = 18) or T3 (n = 25) tumours, but none 
had T1 tumours. The MGTs which were incidentally detected in a clinical exam of a dog 











Location Benign Malignant Total 
Thoracic 5 (55.6%) 9 (13.8%)a 14 (18.9%) 
Abdominal 2 (22.2%) 12 (18.4%)b 14 (18.9%) 
Inguinal 2 (22.2%) 44 (67.7%)b 46 (62.2%) 





Table 2.3 Size of canine mammary gland tumours.  
For malignant neoplasms, different superscripts (a, b) between different tumour size categories 
indicate significant differences. Critical and absolute values: T1–T2 (0.18, 0.32), T1–T3 (0.17, 0.22), 
T2–T3 (0.2, 0.1). 
 





Ulceration of the skin overlying the tumour was observed in 20 (27.0%) dogs, while 15 
(20.3%) tumours were fixed to the underlying tissues. 
 
 
2.3.3 Histological classification of mammary gland tumours 
Sixty-five (87.8%) of the tumours examined histologically were classified as malignant, 
while 9 (12.2%) were classified as benign. All mammary gland tumours histologically 
identified as malignant included at least three cellular or nuclear criteria of malignancy. 
Histological evidence of peri-tumoural (n = 6) and lymphatic (n = 4) invasion was identified 
in 10 malignant tumours, while randomly distributed areas of necrosis within the neoplasm 
were observed in 16 malignant tumours. 
 
Using the histologic classification of malignant mammary gland tumours, tumours were 
identified in three categories: carcinomas, carcinomas-special types, and sarcomas (Table 
2.4). There were 9 sub-types of carcinomas, 6 sub-types of special carcinomas and 3 sub-
types of sarcomas. Of the carcinoma sub-types, simple carcinoma (n = 13, 17.6%) and 
mixed-type carcinoma (n = 10, 10.8%), were the most frequent sub-types in the carcinoma 
group. Thirteen simple carcinomas included 5 tubular carcinomas, 7 tubulo-papillary 
carcinomas, and 1 cribriform carcinoma. In addition, single cases of ductal carcinoma, 
 Benign Malignant Total 
T1 8 (88.8%)   10 (15.4%)a 18 (24.3%) 
T2 1 (11.1%) 30 (47.7%)b 31 (41.9%) 
T3 0 (0%) 25 (38.5%)b 25 (33.8%) 





anaplastic carcinoma, and carcinoma-spindle cell variant were identified in the carcinoma 
group.  
Adenosquamous carcinoma (n = 8, 10.5%) was the most frequent special type carcinoma, 
while hemangiosarcoma (n = 2, 2.7%) was the most frequent type of sarcoma. Simple 
adenoma (n = 3, 4.0%) was the most frequent benign MGT sub-type, while single cases of 
fibroadenoma and mixed benign tumour sub-types were observed. Immunostaining using 
antibodies against smooth muscle actin (α-SMA) was present in 3 MGTs interpreted to be 
complex carcinomas and in 1 neoplasm that was classified as a malignant myoepithelioma. 
The absence of immunostaining was used to support a classification of mammary gland 
fibrosarcoma in one case. 
 
Intra-tumoural inflammatory cell infiltrates were observed in 21 malignant tumours; 
moderate intra-tumoural cell infiltration was identified in 11 tumours, and it was low and 
marked in 6 and 4 tumours respectively. Sixty carcinomas were graded. Of the sixty, 24 
were classified as grade I, 19 were grade II, and 17 were grade III carcinomas. 
 
All the dogs that were presented primarily due to mammary neoplasia had neoplasms that 
were classified as malignant, and all the benign tumours included in this study had been 
detected incidentally during clinical examination. No clinical features allowed definitive 
determination between malignant and benign neoplasms. However, ability to associate 
malignancy with a clinical feature in this study was impaired by the small number of dogs 
with dogs with benign mammary neoplasms. In all the dogs with multiple mammary 
tumours, the tumours with the greatest diameters were malignant. In addition, all the 
tumours with surface skin ulcerations, and those which were fixed to the underlying 
tissues, were malignant. 
 
The tumour location was predictive of malignancy with a significantly higher proportion of 
malignant mammary gland tumours developing in the inguinal mammary glands than in 





proportions of malignant T2 or T3 tumours were significantly higher compared to the 
proportion of malignant T1 tumours (Table 2.3). Thus, T2 or T3 tumours were more likely 
to be malignant than T1 tumours. However, there was no significant difference between 
the proportions of malignant T2 and T3 tumours. This indicates that the further 
differentiation of large mammary tumours in to T2 or T3 categories does not provide any 

















Table 2.4 Histological classification of canine mammary gland tumours  
Malignant tumours  # of cases % 
Carcinoma  45  
Carcinoma: simple  13 17.5 
Carcinoma: mixed  10 13.5 
Carcinoma: solid  6 8.1 
Intra-ductal papillary carcinoma  5 6.8 
Comedocarcinoma  5 6.7 
Carcinoma: complex  3 4.1 
Ductal carcinoma  1 1.3 
Carcinoma: anaplastic  1 1.3 
Carcinoma in situ  1 1.3 
    
Carcinoma special types  16  
Adenosquamous carcinoma  8 10.8 
Squamous cell carcinoma  3 4.1 
Lipid-rich carcinoma  2 2.7 
Carcinoma: spindle cell variant  1 1.3 
Inflammatory carcinoma  1 1.3 
Malignant myoepithelioma  1 1.3 
    
Sarcoma  4  
Haemangiosarcoma  2 2.7 
Fibrosarcoma  1 1.3 
Osteosarcoma  1 1.3 
    
Benign tumours  9  
Complex adenoma  5 6.7 
Simple adenoma  3 4.0 









The present study reports a systematic evaluation of the clinicopathological features of 
mammary gland tumours in 74 Sri Lankan dogs. In these dogs, 88% of the mammary 
tumours were histologically classified as malignant. This proportion of  is higher than the 
40–50% of CMGTs reported to be malignant in studies conducted in United States of 
America (USA),1 Canada,18 Japan,35 and Mexico.23 However, the proportion of malignant 
tumours observed in Sri Lankan dogs was similar to the rates reported from India (83%) 
and Brazil (86%).9,34 The reasons for the higher proportion of malignant mammary tumours 
in dogs in Sri Lanka, Brazil and India are unknown. It is possible that the malignant 
mammary tumours were overrepresented in these countries as a consequence of frequent 
exposure of the dogs to carcinogens which may not be present in countries such as the 
USA, Canada, Japan and Mexico. However, it is also possible that malignant mammary 
neoplasms were over-represented in the developing countries because of under detection 
of benign mammary gland tumours. Benign CMGTs are often incidental clinical exam 
findings, rather than the primary concerns of the dog owners.21 The incidental detection of 
benign CMGTs during a clinical examination may be less likely to occur in developing 
countries because dog owners in these countries may seek veterinary care less frequently 
compared to owners in more developed countries. It appears likely that owners may not 
seek veterinary advice unless they observe a rapidly growing ulcerated mammary gland 
mass and such masses are  more likely to be malignant tumours.22 This is supported by the 
observation in the present study that all dogs that presented for a mammary gland mass 
had malignant tumours, while all the benign tumours observed in this study were from 
dogs that had presented to the veterinarian for reasons other than the mammary 
neoplasia. The high percentage of CMGTs that were malignant at the time of presentation 
in Sri Lanka suggests that veterinarians should be aware of this disease and consider 
mammary neoplasia as a serious health problem among Sri Lankan dogs. In this study, 
when there were multiple mammary tumours in a single dog, only the tumour with the 
greatest diameter was considered for histological analysis due to the financial limitations. 
The preferential examination of the largest neoplasm could also have contributed to the 






Nine malignant CMGTs included in the present study had been previously diagnosed as 
benign, using cytology. This discrepancy could be either due to the limited capability of 
cytology to differentiate benign from malignant tumours1 or possible benign to malignant 
transformation which had occurred during the time between the initial diagnosis and the 
second examination.22,31 This observation suggests that pathologists should be cautious 
when classifying a mammary gland tumour as benign solely on cytology. Additionally, it 
suggests that benign tumours should be carefully monitored for evidence of progression to 
a malignant neoplasm. It is noteworthy that nine dog owners who had observed the 
CMGTs in their dogs had not considered them as conditions requiring veterinary care. This 
indicates that some Sri Lankan dog owners may not to be sufficiently aware of the adverse 
consequences of CMGTs and emphasises the necessity of improving awareness on 
mammary neoplasms among the Sri Lankan dog owners. 
 
A majority of affected dogs in the present study were 5–8 years old, and the mean age at 
the diagnosis of mammary neoplasia was 8.0 (SD 2.47) years. The mean age reported from 
Sri Lanka is comparatively lower than the age of diagnosis of mammary neoplasia in dogs 
reported from Sweden (9.33 years),16 Slovenia (10 years),4 Turkey (10.3 years),28 Canada 
(11 years),18 Brazil (11.6 years and 12 years),8,13 Mexico (9–12 years)23 and Czech Republic 
(13 years).36 However, the reported ages of diagnosis of mammary neoplasia in three 
studies from India, Bhutan and Malaysia were 7–9 years,15 8.4 years,5 and 8.6 years22 
respectively. It is interesting to note that dogs from Asia have been reported to develop 
MGTs at an earlier age than dogs from North America, South America, and Europe. 
Whether this reflects exposure to an external carcinogen, or a genetic predisposition in 
dogs in Asian counties is unknown. Other possible factors include different feeding 
practices, spaying practices, and immunisation protocols followed in Asian countries 
compared to those of North American, South American and European countries.25 
Alternatively, it is possible that dogs in the Asian countries do not live long and the earlier 







In the present study, the majority of dogs with CMGTs were crossbred dogs. Generally, 
crossbred dogs are considered to be comparatively less predisposed to mammary gland 
tumours compared to pure breeds.36 In Sri Lanka, crossbred dogs are reportedly the most 
common pet dog breed.15 Thus, the predominance of them in the present study is most 
likely a reflection of their commonality, rather than a true breed predisposition. Similarly, 
the over-representation of German shepherds in the present study might also be due to 
their high popularity in Sri Lanka and may not necessarily indicate a breed predisposition. 
The minimal representation of Labradors in this study is noteworthy, considering the 
reportedly high popularity of this breed among Sri Lankan dog owners.25 
 
An interesting feature regarding the reproductive histories of the dogs in the present study 
was that over half of the dogs were nulliparous. A recent study conducted in Switzerland in 
2018 suggested that nulliparous dogs are at a significantly higher risk for developing 
mammary tumours compared to multiparous dogs.33 The elevated risk was attributed to 
the higher frequency of pseudopregnancy and oestrus in nulliparous dogs than 
multiparous dogs. As both pseudopregnancy and oestrus increase the production of 
female reproductive hormones, the mammary gland tissues of nulliparous dogs may be 
exposed to greater amounts of female reproductive hormones than the mammary gland 
tissues of multiparous dogs.33 While the results of the present study suggest that 
nulliparous dogs in Sri Lanka may similarly be at higher risk for CMGTs, it has to be noted 
that the proportion of dogs in the studied populations that are nulliparous is unknown. 
Therefore, it is possible that the high proportion of dogs with CMGTs that were nulliparous 
in the study was simply due to the high proportion of dogs in Sri Lanka that are nulliparous.  
 
Most of the dogs in the present study had an ideal body condition score (BCS 3). Obesity at 
1 year of age and in the year prior to diagnosis of mammary gland neoplasia is significantly 
associated with a higher risk of CMGTs.1 In contrast, we found only 5 obese dogs in our 
study. While this may suggest obesity does not predispose to CMGTs, this cannot be 






The proportion of dogs with multiple mammary tumours in this study (27.6%) was higher 
than the proportions of dogs reported in the majority of previous studies, which are mainly 
of dogs from Western countries.15,26 An exception was a Malaysian study in which 29.2% of 
dogs were reported to have multiple CMGTs.22 The occurrence of multiple mammary gland 
tumours is well recognised in dogs and is believed to be due to the concurrent exposure of 
all mammary glands in a single animal to circulating reproductive hormones.31 The 
resulting tumours are more likely to be at the same stage of development and are more 
frequently benign than malignant.31 However, benign to malignant transformation may 
occur in some tumours over time, resulting a combination of malignant and benign 
tumours in the same animal.31 
 
In the present study, the majority of CMGTs were detected in the inguinal mammary 
glands. This distribution is consistent with the findings of many previous studies.27,28,4 The 
frequent involvement of the inguinal glands is attributed to their abundant tissue mass and 
prolonged secretory activity, compared to other glands.22 However, unlike in previous 
studies, our results show significantly higher involvement of the left inguinal gland 
compared to the right. As both left and right inguinal glands have been previously reported 
to be affected at equal rates,22,23 the marked left gland involvement observed in the 
present study is difficult to explain. In addition to a significantly greater number of CMGTs 
in the inguinal mammary glands, the tumours that did occur in this location were 
malignant. This has not been described in previous studies, and the reason for a higher 
proportion of malignant inguinal CMGTs in the present study is unknown. 
 
The results of the present study suggest that tumours which have a diameter > 3 cm are 
more likely to be malignant. This is consistent with the findings of previous studies. A 
retrospective study conducted by Philibert and colleagues (2003)20 showed that dogs with 
tumours > 3 cm in diameter have decreased overall survival compared to the dogs with 
tumours < 3 cm in diameter. In another study, tumour size of > 3 cm diameter was 
correlated with several factors indicating poor prognosis, such as loss of hormone 





the malignancy of a mammary tumour, and histological examination is essential for 
confirmation. In the present study, all the tumours with surface skin ulceration, and 
tumours which were fixed to the underlying tissues, were malignant, indicating that these 
features could also be predictive of malignancy. Previous studies also indicate that 
malignant mammary gland tumours which are usually large in size are more likely to 
develop ulceration, due to more frequent contact with rough surfaces compared to small 
sized benign tumours.22 Since malignant neoplasms invade or infiltrate surrounding 
muscle, nerve, blood vessels, and connective tissues, they are also more likely to become 
fixed to the underlying tissues.22  
 
The histological diversity of the malignant CMGTs included in the present study was high. 
In fact, out of the 23 malignant CMGT sub-types listed in the Goldschmidt classification, 18 
were reported in the present study. A recent prospective study conducted in Italy 
confirmed the prognostic significance of the Goldschmidt classification.21 Given the high 
histological diversity revealed by the present results, Sri Lankan pathologists should be able 
to accurately differentiate tumour sub-types in order to provide reliable prognostic 
information. In this paper we used α-SMA to help differentiate between complex and 
simple carcinomas. In addition, the same antibody was used to help differentiate the 
myoepithelial origin of a malignant myoepithelioma, and to exclude myoepithelial origin 
within a mammary gland fibrosarcoma. However, definitive differentiation of myoepithelial 
cells  not possible using α-SMA alone. Instead, it is currently recommended that p63 or a 
panel of antibodies be used to differentiate between these tumour types. In the present 
study, only α-SMA was used to reproduce the likely situation in developing countries in 
which p63 is not often available, and clients are unlikely to be able to afford a panel of 
immunostains. Interestingly, one of the simple mammary carcinomas reported in the 
present study co-existed with a cutaneous mast cell tumour. Therefore, apart from being 
classified as a mammary carcinoma, it was identified as a collision tumour referring to the 
mixed presentation. Collision tumours are a type of a mixed tumour with 2 foci of 
neoplasia which develop adjacent to one another yet remain separate.24 These tumours 
are rare, and there is minimal information regarding treatment recommendations and 





Previous studies have reported that dogs with mammary gland tumours are generally 
healthy at the initial presentation.21 However, most of the dogs included in our study were 
systemically ill at the time of presentation, which might be due to tumour metastasis or 
other concurrent diseases. Systemic illness due to tumour metastasis was confirmed only 
in a few cases in the present study, due to the unavailability of necessary diagnostic 
testing. In systemically ill dogs, pre-surgical patient stabilisation is important for successful 
surgical and post-surgical management.31 Therefore, these results suggest that Sri Lankan 
veterinary surgeons should be vigilant about the pre-surgical patient stabilisation 
procedures to minimise possible post-surgical complications. 
 
In summary, a main finding from this study was a high proportion of malignant CMGTs with 
a wide variety of histological sub-types. The typical presentation was intact, middle-aged 
mixed breed dogs. This is broadly similar to what has been reported in India and Brazil, 
however notable differences were a younger age at diagnosis and lower body condition 
score of the dogs with mammary tumours. The reasons for these differences are not 
known but may be due to differences in risk factors, differences in the age and breed of 
the dog population or different behaviours of owners regarding the frequency seek 
veterinary advice. Further investigation is needed to better understand the above 
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Outcome known canine mammary gland tumour (CMGT) cases from New Zealand (NZ) 
were used for the inflammation-related prognostic marker studies included in this thesis. 
The NZ cases were used instead of the Sri Lankan cases described in the previous chapter 
as the Sri Lankan cases lacked sufficient follow-up data. The New Zealand CMGT cases 
were identified by searching the surgical biopsy database of a commercial veterinary 
diagnostic laboratory: IDEXX Laboratories, NZ. In addition to identifying outcome known 
cases for prognostic marker studies, the IDEXX database search generated a large amount 
of information regarding mammary gland diseases in NZ dogs. As no previous studies have 
investigated mammary gland diseases in dogs in NZ, the information gathered from the 
IDEXX database search was used to identify clinicopathological features of mammary gland 
diseases in dogs in NZ. This chapter is a comprehensive description and analysis of the 
compiled data from the IDEXX database. Additionally, it was determined whether the age, 
breed or reproductive status of the dog or the size of the mammary mass was associated 
with the subsequent histological diagnosis made by the pathologist. 
 
Female dogs often develop mammary gland disease (MGD) including neoplastic and non-
neoplastic conditions. Histopathology is considered as the gold standard to diagnose MGDs 
in dogs12 and biopsies are frequently submitted to diagnostic laboratories for 
histopathological examination. Studies performed in other countries have indicated that, 
among the laboratory submissions of mammary gland biopsies, neoplastic disease is more 
common than non-neoplastic disease.20,7 Of the mammary gland neoplasms, the 
proportion of mammary gland neoplasms that are malignant ranges from 50 to 90%.20 
Currently, there are no studies evaluating submissions of MGDs to NZ diagnostic 
laboratories. Therefore, the primary aim of this study was to determine the proportion of 





disease and, of the mammary gland neoplasms, what proportion are classified 
histologically as malignant. 
 
Currently no clinical features were shown to predict whether a canine mammary gland 
mass is more likely to be non-neoplastic or neoplastic. Likewise, of the masses that are 
neoplastic, only size is recognised to predict the histological diagnosis with most studies 
reporting that larger masses are more likely to be histologically-malignant than smaller 
ones.10,19 The secondary aim of this study was to determine if the age, breed or 
reproductive status of the dog or the size of the mammary mass was associated with the 
subsequent histological diagnosis made by the pathologist. 
 
While multiple studies have evaluated MGDs in dogs elsewhere in the world, the age at 
ovariohysterectomy (OHE), level of veterinary care, and willingness of the veterinarians to 
submit diagnostic samples contribute to the significant differences in the MGDs seen 
between different countries.2,23,3 Therefore, while MGDs in dogs in NZ are expected to be 
similar to countries where similar de-sexing practices and socioeconomic conditions exist, 
it was considered possible that diagnoses in NZ could show differences from those 
reported in other countries. Although only approximately representative of the general 
population of female dogs in NZ, the present study provides some useful insights on the 
commonly diagnosed MGDs in a relatively large group of dogs. Further, it allows 
comparison of MGDs in dogs in NZ to similar laboratory-based, retrospective studies of 
MGDs conducted elsewhere in the world. 
 
 
3.2 Material and methods 
2.2.1. Data collection and categorisation 
This retrospective study included canine mammary gland samples submitted to IDEXX 
Laboratories, NZ, between 2012 and 2016. The cases included in the study were identified 
by a search carried out in the IDEXX surgical biopsy database using the following key word 
combinations: Dog + mammary gland, Dog + mammary mass, Dog + mammary tumour. 





originating from tissues adjacent to the mammary gland rather than the mammary gland 
itself. For each identified case, the age, reproductive status, and breed of the dog, along 
with the number of mammary lesions, were derived from the submission form that 
accompanied the lesion. Tumour size was identified from the pathology report; the 
greatest diameter of all tumours was measured using a ruler during trimming of the 
sample by the pathologist. The histological diagnosis was also recorded from the pathology 
report, including tumour histological sub-type and the presence of intra-vascular or intra-
lymphatic tumour emboli where appropriate. The criteria and classification system used to 
determine tumour diagnosis was at the discretion of the pathologist who read the case, as 
cases were not available for re-examination. 
 
 
3.2.2 Statistical analyses 
Independent sample t-test or Chi-squared test of independence were performed to 
investigate differences in age, breed, reproductive status, or size of the mammary mass 
between non-neoplastic and neoplastic lesions, and between neoplasms histologically 
classified as benign versus those classified as malignant. All statistical analyses were 
performed using SPSS Version 25 (IBM Corporation, Armonk, New York) and p values < 




3.3.1 Selected cases 
The present study included samples taken from 798 dogs with MGDs. Among them there 
were 459 (55.5%) intact dogs and 339 (45.5%) spayed dogs. The mean age of the dogs was 
8.1 years (SD 2.7). The dogs included 78 different breeds with 672 (84.2%) purebred and 
126 (15.8%) cross-bred dogs.  
 
Histological examination of the masses had been performed by one of the seven veterinary 





criteria that were used by each pathologist to differentiate between a benign and 
malignant neoplasm were not recorded and may have varied between individual 
pathologists. Around two-third of the neoplasms were sub-classified according to the 
criteria reported by Goldschmidt et al. (2011) while the classification system used for the 
other neoplasms was not recorded. 
 
 
3.3.2 Types of mammary gland lesions  
Neoplastic lesions  
Neoplasia was diagnosed in 674 (84.5%) dogs with MGD. These mammary gland tumours 
were present as solitary masses in 592 (87.8%) dogs while 82 (12.2%) dogs had multiple 
tumours (Table 3.1). Due to the submission of multiple tumours from some dogs, a total of 
772 individual mammary gland neoplasms were included in the study. Of these 772 
neoplasms, 340 (44.1%) were classified using histopathology as benign while 432 (55.9%) 
were classified as malignant.  
 
Of the 772 mammary neoplasms, 701 (90.8%) were derived from mammary gland 
epithelium while 71 (9.2%) were derived from mammary gland tissues other than 
mammary epithelium. A variety of histological sub-types were included among the 
neoplasms derived from the mammary epithelium with mixed mammary tumour and 
simple carcinoma being the most common sub-types in benign and malignant categories 
respectively (Table 3.2). All the 71 neoplasms which had originated from tissues in the 
mammary gland other than mammary epithelium were solitary neoplasms and the 
majority were histologically classified as malignant. The most common histological sub-
type was sarcoma although a variety of other types were diagnosed. 
 
Intra-lymphatic or intra-vascular tumour emboli were observed in 72 (16.7%) of the 432 
malignant mammary neoplasms including 65 (17.4%) of the 374 malignant mammary 
epithelial neoplasms.  Emboli were visible in 7 (12.1%) of the 58 malignant neoplasms that 
originated from other mammary gland tissues including four squamous cell carcinomas, 





submitted for histology from 47 (7%) of the dogs with neoplastic MGD cases and neoplastic 
cells were visible in 21 of them. These 21 cases included nine neoplasms in which lympho-
vascular invasion had been noted in the descriptions of the primary tumour. 
 
Non-neoplastic lesions  
Of the 798 dogs included in the study, a diagnosis of a non-neoplastic MGD was made in 
124 (15.5%) dogs. Multiple non-neoplastic mammary lesions were diagnosed in 35 dogs. Of 
the reported non-neoplastic conditions, the most common were dysplastic or hyperplastic 
conditions of the mammary gland epithelium (78 ,62.9%) including ductal hyperplasia, 
ductal ectasia, lobular hyperplasia or adenosis and fibroadenomatous changes. Other 
common conditions included fibrosclerosis (28, 22.6%), cysts (15,12.1%), and mastitis (16, 
12.9%). Cholesterol granulomas, mammary abscessation and foreign body granulomas 
were also rarely reported. 
 
 
3.3.3 Age, reproductive status, and breed of dogs with mammary gland diseases  
Dogs with non-neoplastic versus neoplastic lesions 
 The mean age of the dogs with neoplastic lesions was 8.7 years (SD 2.1) which was not 
significantly different from that of dogs with non-neoplastic lesions (8.6 years, SD 2.5, p = 
0.09, Independent sample t-test). Of the 339 dogs that were spayed, 285 (84%) had 
neoplastic lesions which was not significantly different from the proportion of intact dogs 
that had neoplastic MGDs (389, 84.7%, p = 0.79, Chi-squared test). Neoplastic MGD was 
diagnosed in 613 of 672 (90.9%) dogs classified as purebred which was significantly higher 
than the 61 of 126 (48.4%) crossbred dogs that were diagnosed with neoplastic MGD (p < 
0.001, Chi-squared test). The most frequently reported dog breeds with mammary gland 
neoplasia were Labrador Retriever (50, 7.4%), Jack Russell Terrier (37, 5.5%), Border Collie 
(35, 5.1%), German Shorthaired Pointer (34, 5.1%) and Huntaway (34, 5.1%). 
 
 





The mean age of the dogs with malignant mammary neoplasms was 8.9 years (SD 2.4) 
which was not significantly different from the mean age of dogs with benign neoplasms 
(8.2 years, SD 2.7, p = 0.15, Independent sample t-test). The reproductive status of the 
dogs was also not significantly associated with whether the neoplasm was benign or 
malignant (p = 0.36, Chi-squared test). 
 
3.3.4 Size of the mammary gland lesions 
The mean diameter of the neoplastic mammary lesions was 3.0 cm (SD 2.3) which was not 
significantly different from mammary lesions histologically classified as non-neoplastic (2.8, 
SD 1.3 cm, p = 0.21, Independent sample t-test). However, for the neoplastic lesions, 
mammary neoplasms histologically classified as benign were significantly smaller (1.2 cm, 
























Table 3.1 Canine mammary gland biopsies submitted to IDEXX laboratories, NZ from 2012-2016.  




  N % 
Type of lesion (n* = 798)   
Neoplastic  674 84.5 
Non-neoplastic   124 15.5 
Number of tumours in an individual dog (n* = 674)   
Single 592 87.8 
Multiple 82 12.2 
           Two 67  
           Three 14  
           Four 1  
Histological malignancy status (n † = 772)   
Benign 340 44.1 
Malignant 432 55.9 
Histological type (n † = 772)   
Considered to be derived from mammary gland epithelium 701 90.8 
Derived from other tissues in the mammary gland 71 9.2 
Size of non-neoplastic lesions (n† = 124)   
< 3cm 75 60.4 
3-5 cm 39 31.5 
> 5cm 10 8.1 
Tumour size (n † = 772)   
< 3cm 370 47.9 
3-5 cm 210 27.2 
> 5cm 192 24.9 
Age (n* =798)   
< 5 years 67      8.4 
5-10 years 523 65.6 
> 10 years 186 23.3 
Unknown 22 2.7 
Breed (n* = 798)   
Pure-bred 672 84.2 
Cross-bred 126 15.8 
Sex (n* = 798)   
Intact 459 57.5 





Table 3.2 Histological sub-types of neoplastic mammary gland lesions   
 
  N % 
Tumours originated from mammary epithelium     
Benign 327   
Mixed mammary tumour 128 39.1 
Complex adenoma 105 32.1 
Intra-ductal adenoma 23 7.0 
Ductal adenoma 22 6.7 
Simple adenoma 33 10.1 
Cyst adenoma 13 4.0 
Papillary adenoma 1 0.3 
Myoepithelioma 1 0.3 
Fibropapilloma 1 0.3 
Malignant 374   
Simple carcinoma 160 42.8 
Complex carcinoma 54 14.4 
Ductal carcinoma 32 8.6 
Intra-ductal papillary carcinoma 30 8.0 
Anaplastic 25 6.7 
Solid carcinoma 20 5.3 
Mixed mammary carcinoma 16 4.3 
Carcinoma arising in a mixed mammary tumour 14 3.7 
Carcinosarcoma 11 2.9 
Malignant myoepithelioma 4 1.1 
Inflammatory carcinoma 3 0.8 
Carcinoma and malignant myoepithelioma 1 0.3 
malignant myoepithelioma arising in a mixed mammary tumour 1 0.3 
Mucinous carcinoma 1 0.3 
In situ carcinoma 2 0.5 
Tumours originated from tissues other than mammary epithelium 71   
Malignant 58   
Sarcoma 11 19.0 
Haemangiosarcoma 8 13.8 
Osteosarcoma 8 13.8 
Chondrosarcoma 2 3.4 
Liposarcoma 1 1.7 
Leiyomayosarcoma 1 1.7 
Pleomorphic sarcoma 1 1.7 
Squamous cell carcinoma 23 39.7 
Mast cell tumour 3 5.2 
Benign 13   
Lipoma 11 84.6 
Fibroma 1 7.7 






The main aim of the present study was to determine which MGDs are diagnosed most 
frequently in diagnostic laboratories in NZ. The results revealed that the majority of 
mammary gland biopsies submitted for histopathology were diagnosed as neoplastic 
disease with slightly more neoplasms being classified as malignant than benign. Most of 
the neoplastic lesions were solitary with multiple neoplasm reported infrequently. A 
variety of histological sub-types were included both in benign and malignant neoplasm 
categories. The secondary aim of the study was to determine if the signalment of the dog 
or the size of the neoplasm could be used to predict the subsequent histological diagnosis. 
The results suggested that a mammary gland mass from purebred dog was more likely to 
be neoplastic than one from a crossbred dog and that malignant neoplasms were larger 
than benign ones. However, the size of the non-neoplastic lesions was not significantly 
different from the size of neoplasms and neither the age nor the reproductive status of the 
dog predicted whether a mammary gland mass was more likely to be neoplastic. 
 
Most mammary gland biopsies submitted for histopathology to diagnostic laboratories in 
NZ were diagnosed as neoplastic disease. Furthermore, slightly over half of these 
neoplasms were classified histologically as malignant. The results of the present study are 
consistent with similar laboratory-based, retrospective studies conducted in Canada15, 
Japan28, and Mexico20 which reported that 40—50% of the submitted neoplasms were 
malignant. However, the proportion of malignant neoplasms in the present study is much 
lower than the 80—88% of canine mammary gland tumours classified as malignant in 
similar studies of dogs from India6, and Brazil25. The reasons for this difference are 
uncertain. It is possible that true differences in the rate of malignant neoplasms exist 
between the countries, potentially caused by a genetic predisposition for malignant 
neoplasms in dogs in some countries or exposure to a carcinogen that results in more 
frequent development of malignant neoplasms. Alternatively, the differences between 
countries may be artefactual, possibly because dogs in some countries only receive 






Only 12% of the dogs included in the present study had multiple neoplasms which was 
lower than the 60—70% reported by previous studies11,4,22. Multiple mammary neoplasms 
are suggested to develop due to simultaneous exposure of multiple mammary glands to 
reproductive hormones for a prolonged period.5,27 Therefore, it is possible that more dogs 
in NZ are spayed earlier in life and avoid the prolonged exposure to reproductive 
hormones. However, due to the absence of statistics on the ages that dogs are spayed in 
NZ and elsewhere, it is difficult to determine if the age of spaying influences the 
development of multiple mammary masses. Alternatively, it is possible that some 
veterinarians may have submitted a single neoplasm for histopathology even when 
multiple masses were present. It is also possible that dog owners have declined surgical 
tumour excision or sample submission for histopathology from multiple tumour cases as 
they may have felt that multiple tumours were associated with a worse prognosis or if they 
were from old dogs and so were less willing to spend the money on histopathology. 
 
A variety of histological sub-types were included in both in benign and malignant neoplasm 
categories. The mammary tumours  included in the present study had been submitted 
between 2012-2016 and while most neoplasms were classified using the classification 
proposed by Goldschmidt et al. (2011)12, some were likely to have been classified using 
older systems such as those by  Hampe and Misdorp (1974)13 or Misdrop et al. (1999).14 
The lack of consistent classification is a limitation of the study. Ideally, each diagnosis 
would have been confirmed and standardised by a single pathologist using the latest 
classification. However, older cases were not available for re-examination. While the lack 
of consistent classification may have introduced some error, it is interesting to note that 
the most common malignant and benign histological tumour sub-types identified in the 
present study were consistent with those reported in previous studies.20,19,16,17 This 
consistency with other studies suggests that the neoplasms that developed in dogs in NZ 
are similar to those that develop in dogs elsewhere in the world. 
 
A number of neoplasms of the mammary glands appeared to originate in tissues other 





studies11,4 and it is possible that these neoplasms originated from surrounding tissue and 
subsequently invaded the mammary glands. Whether the submitters considered these 
primary mammary gland neoplasms or whether they simply developed in the mammary 
gland region could not be definitively determined.  
 
A small number of inflammatory mammary carcinomas were diagnosed in the present 
study. As this particular subset of mammary neoplasm is a clinical diagnosis rather than a 
histological diagnosis24, it appears likely that the clinical appearance of the neoplasm was 
reported to the pathologist and this allowed a diagnosis of inflammatory carcinoma in 
these cases. 
 
Fibroadenomatous changes were reported in non-neoplastic lesions in the present study. 
Although these lesions were described in the Goldschmidt classification (2011)12, there are 
no published reports on them suggesting this lesion is rarely diagnosed in other studies.  It 
is uncertain why these were apparently common in the present study without the ability to 
re-examine the slides and confirm this diagnosis.  
 
Of the malignant mammary neoplasms reviewed in the present study, intra-lymphatic or 
intra-vascular tumour emboli were reported in around 17% of cases. Currently, while 
histological criteria are used to classify mammary gland neoplasms as benign or malignant, 
it is unknown how many tumours that are classified as malignant will metastasise if not 
removed.12 While the presence of tumour emboli does not guarantee that the neoplasm 
will metastasise, it strongly suggests the potential for a neoplasm to spread and eventually 
kill the host. Therefore, the findings of the present study emphasise the utility of histology 
in clinical decision making as it can highlight which mammary neoplasms need prompt 
attention. Additionally, the present results suggest the importance of submission of 
regional lymph nodes for histopathology as identification of neoplastic cells in the lymph 






In this series of mammary gland biopsies, the size of the mass was not predictive of 
whether the mass was neoplastic or non-neoplastic, but malignant neoplasms in the study 
were significantly larger than benign ones. Malignant neoplasms were also larger than 
benign neoplasms in several previous studies.18,21  Of the other clinical factors examined in 
the study, neither the age nor reproductive status of the dog was found to predict which 
masses were neoplastic or which neoplastic masses were malignant. A similar lack of 
association between age and benign or malignant status of a tumour was previously 
reported by Salas et al. (2015).20 However, these results contrast with two other previous 
studies which reported that the mean age at diagnosis was lower for dogs with benign 
mammary neoplasms than dogs with malignant neoplasms.22,26 Overall, the results of the 
present study confirm several previous studies that also reported that, for mammary 
masses, a presumptive diagnosis cannot be made from the clinical parameters and 
therefore histology is always recommended for diagnosis.20,21  
 
In the present study, purebred dogs were significantly more likely to be diagnosed with 
neoplastic MGD than crossbred dogs. This is similar to previous studies1,9,26 and could 
suggest a genetic predilection of purebred dogs for mammary neoplasms.8 Alternatively, it 
is possible that purebred dogs are more likely to be used for breeding and so have been 
spayed later in life predisposing them to mammary neoplasia. However, it is possible the 
association was artefactual due to purebred dogs receiving more frequent veterinary care 
that resulted in the higher number of mammary gland lesions submitted to the diagnostic 
laboratories. The high number of mammary gland lesions observed in Labrador Retriever 
and Border Collie dogs in the present study may simply be due to the popularity of these 
breeds in NZ during the period that lesions were collected for the study. 
 
A major limitation of this study is that it only included mammary masses submitted for 
histopathology and not all the mammary masses developed on dogs. Therefore, the results 
were confounded by the decisions made by veterinarian and owner whether or not to 





was the unavailability of some important clinical information regarding the mammary 
masses which was unable to be retrieved due to the retrospective nature of the study. 
 
In conclusion, the present study included a large number of mammary gland lesions from 
dogs that were submitted for diagnostic evaluation. The majority of the masses were 
neoplastic with slightly more neoplasms classified as malignant than classified as benign. 
There were no clinical parameters that allowed a presumptive diagnosis suggesting that all 
mammary gland lesions in dogs should be considered potentially malignant and histology is 
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Chapter 4 : Prognostic significance of stromal mast cells in 






An adequate number of canine mammary gland tumour (CMGT) cases with known disease 
outcome were identified from the surgical biopsy data base of IDEXX Laboratories, New 
Zealand, described in Chapter 3. The identified mammary tumour cases were then used to 
investigate the prognostic significance of tumour-associated inflammation related markers 
in CMGTs. These prognostic markers were adopted from previous human breast cancer 
studies and represented three categories: tumour infiltrating immune cells, chemokines 
and chemokine receptors and immune checkpoint molecules. This chapter describes the 
prognostic significance of tumour infiltrating immune cells in CMGTs. Of the different types 
of tumour infiltrating immune cells shown to influence the behaviour of human breast 
cancers, mast cells were selected for this study considering the abundance of them in 
CMGTs and simplicity of the techniques required to identify them. 
 
Mast cells are frequently present in different types of human and animal cancers and many 
human cancer studies have investigated the prognostic potential of tumour associated 
mast cells.3,9,37  These studies have shown that the presence of mast cells within a tumour 
influences tumour behaviour differently in different cancer types.  For example, in gastric, 
pancreatic and colorectal cancers in people, a high intra-tumoural mast cell density 
correlates with a poor prognosis.37  Conversely, oral squamous cell carcinomas  and ovarian 
carcinomas  with a high mast cell density have a more favourable prognosis.4,37  
Furthermore, mast cells in renal carcinoma and pulmonary small cell carcinoma in humans 
do not appear to influence the behaviour of the neoplasms.37  Considering this seemingly 
variable role of mast cells in different types of human cancers, the ability of mast cell 
density to predict prognosis cannot be generalised and appears to be specific for each 





suggested to be due to the high variety of chemical mediators produced by these cells, 
which have both pro- and anti-tumourigenic properties.9,20 
 
The prognostic significance of mast cells in human breast cancer is currently not fully 
resolved8,37, although most studies have revealed that high density of mast cells within a 
breast cancer is associated with a more favourable prognosis.37 In dogs, four studies have 
investigated the presence of mast cells in CMGTs. One study showed significant differences 
in mast cell density between non-neoplastic mammary glands and neoplastic or dysplastic 
mammary glands.34 In the other three studies, a positive correlation was observed 
between the mast cell density and tumour micro vessel density.38,21,15  While these 
previous studies suggest that mast cells could have a role in CMGT development and 
progression, the prognostic potential of the presence of mast cells in CMGTs has not been 
previously evaluated. Therefore, the aim of the study described in this chapter was to 
investigate the density of mast cells in peripheral and stromal compartments of benign and 
malignant CMGTs. As the clinical outcome of each case was known, the mast cell densities 
of the tumours could be correlated with clinical outcome and survival times of the dogs to 
determine whether mast cell density is prognostic. 
  
  
4.2 Material and methods 
4.2.1 Case selection and assessment of survival times 
This study included a subset of CMGT cases submitted for histopathology to IDEXX 
diagnostic laboratory, New Zealand, between 2012 and 2015, of which the contact details 
of submitting veterinarians were complete and current. In all cases, tumour surgical 
excision had been performed with a curative intent. Details regarding the patient 
signalment including age and reproductive status were identified from the surgical biopsy 
archive database. A questionnaire was sent to the submitting veterinarians to obtain other 
information. The information requested in the questionnaire included previous history of 





neoplasms present, abscessation or ulceration on the tumour surface, pre-surgical clinical 
exam findings, type of surgical procedure performed, additional treatments that had been 
used, evidence of mammary tumour metastasis, diagnostics used to detect tumour 
metastasis, and the cause of death for dogs that died. In addition, the submitting 
veterinarians were asked to provide the post-surgical clinical records of the dogs for at 
least three years from the date of surgery or until the date of the dog’s death or 
euthanasia. Cases were excluded if adjunct therapies including anti-inflammatory drugs, 
steroids, cytotoxic chemotherapy or tyrosine kinase inhibitors were used to alter the 
neoplasm behaviour. Dogs which received antibiotics or vitamin supplements were not 
excluded. If the tumour surface was reported to be ulcerated or contained abscesses, 
those cases were excluded to avoid inclusion of inflammatory carcinomas. Using the post-
surgical clinical records provided by the submitting veterinarians, the disease-specific 
survival time for each case was calculated retrospectively from the date of tumour excision 




4.2.2 Histology and mast cell quantification 
Three micrometre sections were prepared from formalin-fixed, paraffin embedded (FFPE) 
mammary tumour tissue and stained with haematoxylin and eosin (HE) or toluidine blue 
(0.1% toluidine blue solution in 30% ethanol). The HE-stained sections were examined to 
determine the histological sub-types and grades of the tumours, following the guidelines of 
Goldschmidt et al. (2011) and Peña et al. (2013) respectively.13,24 Briefly, simple carcinomas 
were graded according to three criteria: percentage tubule formation, nuclear 
pleomorphism, and mitoses/ 10 high power fields. In heterogeneous carcinomas, tubular 
scoring was assessed in the most representative malignant area. In addition, in complex 
and mixed tumours, the percentage of tubular formation was scored considering only 






Tumours were classified into three groups: malignant-metastatic, malignant non-
metastatic, and benign tumours. A tumour was classified as malignant-metastatic if the 
neoplasm was classified as malignant using histological criteria and had a clinical diagnosis 
of mammary tumour metastasis based on the development of radiographic lesions of 
pulmonary metastasis with other suggestive clinical signs of tumour metastasis during the 
follow-up period. Tumours were classified as malignant non-metastatic if the neoplasm 
was classified as malignant using histological criteria but had no clinical or radiographic 
evidence of metastases developed during the follow-up period. A tumour was classified as 
benign when the histology was consistent with a benign neoplasm. In addition to these 
three groups, a separate group of non-neoplastic mammary tissues was also included in 
the analysis. This group was comprised of non-neoplastic mammary gland tissue that had 
been submitted together with mammary gland neoplasms of some dogs. 
 
Mast cell quantification was carried out using toluidine blue-stained sections, using a 
modification of a previously described method to evaluate mast cell density in human 
tissues.31  Briefly, tumour peripheral and stromal areas with the highest mast cell density 
were identified by scanning the sections at low power (×100 magnification).  Tumour 
periphery was defined as the area at the periphery of the tumour capsule in encapsulated 
tumours or the area immediately adjacent to the tumour margins in non-encapsulated 
tumours. Tumour stroma was defined as the inter- and intra-lobular and inter-ductal 
regions within the tumour. Individual mast cells were then counted in 10 non-overlapping 
high-power fields at ×400 magnification, where each microscopical field corresponded to 
an area of 0.785 mm.2 This procedure was repeated twice for each tumour and then the 
average of the two counts was taken as the mast cell density of a mammary tumour.  
When non-neoplastic mammary gland tissues were available in addition to the neoplastic 
mammary gland, peripheral and stromal mast cell densities were also assessed in the non-
neoplastic mammary gland tissue following the same method described above.  When 
multiple wax blocks were available for a single large neoplasm, mast cells were counted in 
all sections and the average was taken. For the cases with multiple mammary neoplasms, 






4.2.3 Statistical analysis 
Peripheral and stromal mast cell densities of the malignant–metastatic, malignant non-
metastatic, benign tumours and non-neoplastic mammary tissues were compared using 
the Kruskal–Wallis H test to identify whether there were any significant differences 
between groups. The same test was used to identify the differences in stromal or 
peripheral mast cell densities in different mammary tumour histological sub-types and 
tumour grades. When significant differences were identified, post hoc analysis was 
performed by mean rank test to identify which group or groups were significantly different 
from the others. The association between stromal or peripheral mast cell density and 
survival time were analysed using Spearman’s rank-order correlation.  Other group 
comparisons were performed using Chi-squared or Fisher’s exact tests.  Survival times 
were investigated by Kaplan–Meier curves, and significant differences were determined by 
Log-rank test. These statistical analyses were performed using SPSS software Version 25 
(IBM Corporation, Armonk, New York) and p values < 0.05 were considered to indicate 
significant differences.  X-tile software 
(https://medicine.yale.edu/lab/rimm/research/software.aspx) was used to identify the 
optimal cut-off point for the stromal mast cell density that would best predict prognosis in 
dogs with malignant CMGTs.5 A hierarchal multivariate analysis was performed to identify 
whether any tumour-related variables or stromal mast cell density were independently 
prognostic of the survival times of dogs with malignant mammary gland tumours. The 
tumour-related variables: tumour size, tumour histological grade, and the presence of 
intra-vascular or intra-lymphatic tumour emboli were included in the multivariate analysis 
because of their significant association with the survival times of the dogs with malignant 








4.3.1. Selected cases 
From the 674 CMGT cases sourced from the surgical biopsy archive of IDEXX Laboratories, 
New Zealand, contact details of the submitting veterinarians were complete and current in 
521 cases.  Of them, the submitting veterinarians responded to the questionnaire in 201 
cases while additional information regarding pre-surgical clinical exams and post-surgical 
follow-ups were available only in 63 cases. Ten of these 63 cases were excluded; the cause 
of death was not known in five dogs, there was insufficient follow-up time in three dogs, 
and two dogs had received anti-inflammatory drugs. Therefore, a total of 53 cases were 
available for prognostic analyses. The 53 CMGTs included 7 cases from 2012, 13 from 
2013, 21 from 2014, and 12 cases from 2015. Of the selected 53 dogs, 36 (67.9%) were 5 – 
10 years old, 14 (26.4%) were older than 10 years and age was unknown in three (5.5%) 
dogs. Forty-three (81.1%) dogs were intact female dogs while 10 (18.9%) dogs were spayed 
females. Of the selected 53 dogs, 51 (96.2%) dogs had solitary mammary neoplasms and 
two dogs had multiple neoplasms. Ten dogs had been diagnosed with other concurrent 
disease conditions at the time of diagnosis of mammary neoplasia including lipoma in two 
dogs and single cases of  alopecia, hindlimb weakness, heart failure, dental diseases, ocular 
cyst, intervertebral disc disease, ceruminal cyst and debility due to old age. None of the 
dogs had any history of previous mammary gland disease, except one dog which was 
reported to have had a benign neoplasm that had been previously surgically removed. 
Simple mastectomies had been performed in 51 (96.2%) dogs while regional mastectomies 
had been performed in two dogs (3.8%). 
  
  
4.3.2 Tumour size, histological sub-type, and grade 
There were 10 (18.9%) small tumours (< 3 cm), 31 (58.5%) medium-sized tumours (3—5 
cm) and 12 (22.6%) large tumours (> 10 cm). Forty one (77.3%) CMGTs were histologically 
classified as malignant while 12(22.7%) were benign tumours. The two dogs which had 





one histologically-malignant neoplasm. The malignant mammary tumours were classified 
into eight different histological sub-types with simple carcinomas further sub-classified into 
tubular, tubulopapillary, cribriform, and cystic papillary carcinomas (Table 4.1). Grading of 
the malignant tumours revealed that 13 were Grade I, 23 were Grade II and 5 were Grade 
III. Of the 53 neoplasms, 21 subsequently metastasised (therefore were classified as 
malignant-metastatic), 20 were malignant with no clinical evidence of metastasis 
(malignant non-metastatic), and 12 were benign. Intra-vascular or intra-lymphatic tumour 
emboli were observed in the HE-stained histological sections of five malignant mammary 
gland tumours all of which were in the malignant-metastatic group. An inflammatory cell 
infiltrate, predominantly present in the stromal compartment, was observed in all except 






Table 4.1 Histological classification of canine mammary gland tumours.  
Histological sub-type   
Malignant tumours  
Simple carcinoma 10 
     Tubular  5 
     Tubulopapillary 3 
     Cribriform 1 
     Cystic papillary 1 
Intra-ductal papillary carcinoma 7 
Adenosquamous carcinoma 6 
Ductal carcinoma 6 
Carcinoma-mixed 4 
Carcinoma-complex 3 
Solid carcinoma 2 
Anaplastic carcinoma 2 
Comedo carcinoma 1 
Benign tumours  
Complex adenoma 5 
Simple adenoma 3 
Intra-ductal papillary adenoma 2 
Ductal adenoma 1 




4.3.3 Mast cell distribution 
In most tumours mast cells were scattered along the pericapsular area and throughout the 
tumour stroma.  Focal aggregates of mast cells were observed rarely in the neoplastic or 
non-neoplastic mammary tissues. In malignant CMGTs, mast cells were frequently found in 
the stromal and peripheral compartments of malignant non-metastatic tumours, while 
they were scarce in malignant–metastatic tumours (Figs. 4.1). There were no significant 
differences between stromal (p = 0.2) or peripheral (p = 0.47) mast cell densities between 
different mammary tumour histological sub-types (Kruskal-Wallis H test).  Similarly, 
peripheral (p = 0.39) or stromal (p = 0.37) mast cell density did not differ between different 







The lowest median stromal mast cell density (MCs/10HPFs) was observed in malignant–
metastatic tumours (3 ± 37.4 (Quartile 3 – Quartile 1) followed by malignant non-
metastatic tumours (69.6 ± 124.6 Q3-Q1), benign tumours (95 ± 71.5Q3-Q1) and non-
neoplastic mammary tissues (107 ± 50 Q3-Q1; Table 4.2 and Fig. 4.1), with significant 
differences between groups (Z = 38.2, p < 0.001, Kruskal–Wallis H test). Post-hoc analysis 
revealed that mean rank of the stromal mast cell density in the malignant–metastatic 
CMGTs was significantly lower than the mean ranks of mast cell density in other groups 
(17.8 versus 51.8, 57.4 and 55.2, mean rank test).  In contrast, there was no difference in 










Figure 4.1 Grade II simple mammary carcinomas. 
 A: Note the abundant mast cells visible within the stroma (arrows) in this tumour, which did not develop 
subsequent metastases during the follow-up period. B: A grade II simple carcinoma which metastasised during 






Figure 4.2 Clustered Boxplot of stromal and peripheral mast cell densities in different canine mammary gland 
tumour categories. 
The box represents the first to third quartiles with the median indicated by the horizontal line.  The vertical lines 
indicate the minimum and maximum values. Outliers are indicated by a circle, or an asterisk for extreme outliers 
greater than three times the interquartile range from first or third quartile. 
 
 
Table 4.2 Peripheral and stromal MC densities in various categories of mammary gland tumours and non-
neoplastic mammary tissue.  
*Q3 – Q1 = Quartile 3 – Quartile 1 
  Number Median ± (Q3-Q1*) Z p value 
Peripheral mast cell density 
    
Malignant metastatic  21 126 ± 88.2 
  
Malignant non-metastatic 20 142 ± 72.2 2.7 0.45 
Benign  12 95 ± 71.5 
  
Non-neoplastic mammary tissue 44 113.4. ± 51.6 
  
Stromal mast cell density 
    
Malignant metastatic  21 3 ± 22 
  
Malignant non-metastatic  20 69.6 ± 124.6 38.2 < .001 
Benign  12 95 ± 71.5 
  







4.3.4 Cut-off Analysis 
By X-tile analysis, a strong, direct, and continuous association between stromal mast cell 
density and survival times of dogs with malignant CMGTs was identified.  Furthermore, an 
optimal cut-off was identified as 10 MCs/10 HPFs (χ2 = 20.13), which best predicted the 
disease outcome. Therefore, a low stromal mast cell density was defined as ≤ 10 MCs/10 
HPFs while a high stromal mast cell density was defined as > 10 MCs/10 HPFs. 
 
 
4.3.5 Risk of tumour metastasis  
In this study, 21/53 (39.6%) of dogs with malignant mammary tumours died after 
developing evidence of CMGT metastasis. In two of the 21 dogs, tumour metastasis was 
confirmed by post-mortem examination. Histology from one of these dogs revealed 
variably sized clusters of anaplastic epithelial cells arranged in glands within sections of 
lung, spleen, heart, and regional lymph nodes. Similar neoplastic cells were visible within 
sections of lung in the other dog in which necropsy examination was performed. In a 
further two of the 21 dogs in which metastases was diagnosed, the diagnosis was 
confirmed by cytology of fine needle aspirates of pulmonary masses identified in thoracic 
radiographs. Cytology from these cases revealed a population of anaplastic epithelial cells 
consistent with a malignant epithelial neoplasm. In the other 17 dogs in which metastasis 
was diagnosed, this diagnosis was made based on thoracic radiographical findings that 
revealed the presence of multiple solid masses in the pulmonary parenchyma 
accompanying an interstitial lung pattern. While these were not confirmed to be 
metastases microscopically, the radiographical findings in these cases were consistent with 
metastases and these neoplasms were classified as malignant–metastatic in this study. 
Moderate to severe regional lymphadenopathy was observed in clinical exams in 20 of the 
21 dogs that had radiographic evidence of neoplasm metastasis including six dogs with 
enlarged lymph nodes that were reported to be fixed to the underlying tissues. However, 
lymphadenopathy was not further investigated using other diagnostics including 





deaths due to tumour metastasis 2- and 3-years after surgical excision of a malignant 
CMGTs were 41.6% (15/36) and 58% (21/36), respectively. 
 
In 20 dogs which had histologically-malignant mammary neoplasms, radiographic evidence 
of tumour metastasis was not observed in pre- or post-surgical follow-ups. Except one dog 
which had mild popliteal lymph node enlargement which resolved in the next follow-up, 
post-surgical lymph node assessments were normal in all 19 dogs. Of these 20 dogs, four 
dogs died or were euthanised before the end of the three-year follow-up period due to 
unrelated causes. These four dogs died after 172, 423, 519 and 788 days of surgical 
excision of tumours. The causes included intervertebral disc disease in two dogs, age-
related general debility in a single dog and one dog died following a road traffic accident. 
Another five dogs were lost for follow-up after three-years due to change in veterinary 
care provider while five dogs died or were euthanised due to unrelated causes after 4-6 
years. The causes of death or euthanasia in these dogs included age-related general 
debility in three dogs, heart failure and degenerative joint disease in one dog each. The 
remaining six dogs were alive without any clinical records suggestive of tumour metastasis 
at the time of the retrospective survey was conducted for the present study. 
 
The twelve dogs which had mammary neoplasms classified as histologically-benign were 
alive until the end of the three-year follow-up period. Three of them died after the three-
year follow-up due to unrelated causes. Post-surgical lymph node assessments of all these 
12 dogs were normal. Therefore, 21 dogs had mammary neoplasms which were classified 
as “malignant-metastatic”, 20 dogs had “malignant non-metastatic” neoplasms while 12 
dogs had “benign” neoplasms. The median survival times of dogs classified to have 
malignant-metastatic neoplasms was 494 days while the median survival times of dogs 
with malignant non-metastatic and benign neoplasms were 1497 and 1717 days, 
respectively.  
 
Rates of tumour metastasis were not significantly different between different histological 





Chi-squared test).  According to the cut-off identified from X-tile analysis, 16 (43%) 
malignant mammary tumours had a low stromal mast cell density while 21 (57%) had a 
high stromal mast cell density. Thirteen of 16 (81%) dogs with malignant CMGTs with a low 
stromal mast cell density died of tumour metastasis during the follow-up period, while just 
2 (9.5%) of the 21 dogs which had malignant CMGTs with high stromal mast cell density 
died due to tumour metastasis.  Therefore, in this study, dogs with malignant CMGTs with 
low stromal mast cell density were approximately eight times more likely to die due to 




4.3.6 Survival time analysis 
The overall mean survival time (MST) of the 41 dogs with malignant CMGTs was 721 days 
(95% CI 609–833). There was a significant, moderate positive correlation between the 
stromal mast cell density and survival time (rs = 0.50, p <0.001, Spearman’s rank-order 
correlation), but no correlation between peripheral mast cell density and survival time (rs = 
0.13, p =0.41), Spearman’s rank-order correlation).  As part of the cut-off analysis 
performed using X-tile software, the survival times between dogs with malignant 
mammary tumours with low and high mast cell densities were compared.  Dogs that had 
malignant mammary tumours with a low stromal mast cell density had a significantly 
shorter survival time (497 days 95% CI 342–651) than dogs with CMGTs that had a high 
stromal mast cell density (973 days, 95% CI 879–1,068, p < 0.001, X-tile analysis). 
    
There were no significant differences between the MSTs of dogs with CMGTs of different 
histological sub-types (p = 0.08, Log-rank test, Table 4.3).  However, there were significant 
differences in the MSTs of dogs with CMGTs of different grades (p = 0.001, Log-rank test).  
Post-hoc analysis showed that MST of dogs with grade I tumours (971 days, 95% CI 812–
1,130) was significantly longer than the MSTs of dogs with grade II (729 days, 95% CI 585–





the MST of dogs with grade II tumours was significantly longer than that of dogs with grade 
III tumours (p = 0.04). 
 
The hierarchical multivariate analysis showed that stromal mast cell density is prognostic of 
survival times of the dogs with malignant mammary neoplasms independent of tumour 
size, tumour grade and presence of intra-vascular or intra-lymphatic tumour emboli (ΔF = 
8.4, p = 0.006). Tumour grade (ΔF = 6.3, p = 0.016) was also independently prognostic of 
survival times while neither tumour size ((ΔF = 1.2, p = 0.28) nor the presence of intra-
lymphatic or intra-vascular tumour emboli (ΔF = 0.24, p = 0.68) were  independently 












Estimated Mean Survival Time 
(95% CI) Days 
p value 
Histological sub-type       
Total 29   
Simple carcinoma 10 809 (565-1053)  
Intra-ductal papillary carcinoma 7 1040 (943-1138) 0.08 (Log-rank test) 
Adenosquamous carcinoma 6 610 (427-794)  
Ductal carcinoma 6 764 (457-1071)  
Histological grade       
Total 41   
Grade I 13 971 (812-1130)  
Grade II 23 729(585-872) 0.001 (Log-rank test) 
Grade III 5 429(201-656)  
Mast cell density-Malignant tumours       
Stromal MCD    
     ≤ 10/10 HPFs 16 497 (342-651) < 0.001 (X-tile analysis) 











In the present study, the behaviour of the CMGTs could be predicted by the density of the 
mast cells in the tumour stroma.  Stromal mast cell density was significantly lower in 
malignant tumours where the patient later developed metastasis, compared with 
malignant tumours that did not subsequently metastasise during the follow-up period.  
Furthermore, there was a significant correlation between stromal mast cell density and the 
survival time of dogs with malignant mammary gland tumours while stromal mast cell 
density was independently prognostic of survival times of dogs with malignant neoplasms. 
In addition, dogs with malignant CMGTs classified as having low stromal mast cell density 
were eight times more likely to die due to tumour metastasis than dogs with malignant 
CMGTs with a high stromal mast cell density.  These results therefore suggest that stromal 
mast cell density is an important prognostic indicator for CMGTs. 
 
Similar to the results in the present study of CMGTs, mast cell density has been found to be 
prognostic in the majority of human breast cancer studies.1,2,28,12,16  Interestingly, while 
most studies of human breast cancer have reported that a high stromal mast cell density 
was indicative of a favourable prognosis, a small number of studies have associated high 
stromal mast cell density with an unfavourable prognosis.17,29,19  These apparently 
contradictory results suggest that stromal mast cells may influence tumour behaviour 
differently in some circumstances.  Three studies have investigated whether stromal mast 
cell density in breast cancer is associated with other molecular prognostic factors including 
the presence of oestrogen or progesterone hormone receptors or human epidermal 
growth factor receptor–2.2,12,31  These studies produced conflicting results and it is 
currently unclear whether or not stromal mast cell density is a prognostic factor that is 
independent of the other molecular factors currently recognised as prognostic for human 
breast cancer. There are currently no studies investigating an association of hormone or 







The mean overall survival time of the dogs with malignant CMGTs included in this study 
was 721 days. This is consistent with the MSTs reported by previous studies on these 
neoplasms which ranged between 359–720 days.6,30,32  Previous studies conducted in 
countries including Sweden, Greece, Spain and Italy have reported that 41–80% of dogs 
with malignant CMGTs survive for at least 2 years after neoplasm excision.14,18,24,33  
Similarly, the 2-year survival rate in the present study was 59%. The similarities in survival 
times and survival rates between the present and previous studies of CMGTs suggest that 
the 41 malignant neoplasms included in the present study were representative of 
malignant CMGTs in the wider population of dogs.  Therefore, although the present study 
contained comparatively small numbers of CMGTs, it is expected that stromal mast cell 
density will be also associated with CMGT behaviour in larger samples of these tumours. 
 
In the present study, tumour histological grade was identified to be independently 
predictive of survival times of the dogs with malignant canine mammary neoplasms. In this 
study and in several previous studies, tumour grade was shown to be prognostic of disease 
outcome or survival times of dogs with malignant CMGTs in multivariate analyses.18,24 
Unlike tumour histological grade, tumour size or presence of tumour emboli were not 
independently predictive of the survival times of the dogs in the present study. Tumour 
size has been identified to be prognostic of CMGTs in previous studies by multivariate 
analysis.30 The lack of significance in the present study could be due to small number of 
large-sized neoplasms. Although the presence of intra-lymphatic or intra-vascular tumour 
emboli is generally suggestive of more aggressive disease, detection of tumour emboli in 
histological sections is dependent on several factors such as number of histological 
sections prepared from a neoplasm. Therefore, the lack of significance identified in the 
present study could be a result of that. Alternatively, it is possible that presence of tumour 
emboli is prognostic of disease outcome of malignant CMGTs but not independent of other 
prognostic factors.    
   
Survival times were not significantly different between different histological sub-types of 





less common sub-types included in this study. Therefore, histological sub-type was not 
included in the multivariate analysis. Further studies with sufficiently large numbers of 
tumours in each histological subtype are necessary to investigate the impact of histological 
sub-type on prognosis. 
 
Currently, tumour grade and histological classification are recommended for prognostic 
determination in CMGTs.23,35 However, the subjectivity of tumour classification and grading 
has been identified as a disadvantage due to high interobserver variability.7,22 Therefore, 
histological classification and grading need to be complemented with other reliable 
histochemical or molecular methods to improve the prognostic accuracy for CMGTs.  
Advantages of assessing stromal mast cell density include the low cost of toluidine blue-
staining compared to other immunohistochemical or molecular methods used to 
determine prognostic markers for CMGTs25,27,32, the ease of recognising mast cells within 
the toluidine blue-stained sections, and the ability to objectively count the numbers of cells 
in histological fields. Due to the ease of identification of mast cells, using these cells to 
predict prognosis would appear to be readily adaptable to automated counting of the cells 
within a histological field. Additionally, the simplicity and low cost of toluidine blue staining 
method would facilitate the incorporation of measuring stromal mast cell density into the 
routine assessment of prognosis for CMGTs. 
 
The present study revealed a continuous positive correlation between stromal MC density 
and survival times of dogs with malignant CMGTs. Despite the continuous nature of the 
association, it is practical to have cut-offs that can be communicated to clients in a 
commercial setting. In this study, ≤ 10/10 HPFs was identified as the optimal cut-off for 
stromal mast cell density with 81% of the dogs with malignant CMGTs with a stromal mast 
cell density ≤ 10/10 HPFs developing tumour metastasis, while metastasis developed in 
only 9.5% of the dogs with malignant CMGTs that had a mast cell density of > 10/10HPFs.  
Therefore, determining whether a malignant CMGT has more or less than 10 stromal 





predictor of prognosis and therefore which dogs are most likely to benefit from post-
surgical adjuvant therapy to prevent subsequent tumour metastasis. 
 
The results of the present study revealed that stromal mast cell density predicted the 
biological behaviour of CMGTs. However, it is unknown whether the stromal MC density 
directly influences tumour metastasis or whether both the mast cell density and the 
behaviour of the neoplasm are determined by the properties of the neoplastic cells.  If 
mast cells influence tumour behaviour, they could do it by producing anti-tumour 
compounds that prevent tumour metastasis.36,37,10,3  For example, chondroitin sulphate 
secreted by MCs may increase adhesion between tumour cells and the extracellular matrix 
and therefore inhibit tumour metastasis.10  In addition, heparan sulphate proteoglycans 
secreted by MCs inhibit neovascularisation in tumours, minimising the possibility of 
tumour metastasis.36 
 
In the present study, peripheral MC density was not associated with disease outcome. It is 
not certain what mechanisms operate differently between the tumour stromal and 
peripheral compartments to produce this discrepancy.  However, stromal mast cells are 
located within the tumour and therefore more closely associated with the tumour cells and 
tumour microenvironment than the MCs scattered along the tumour periphery.  Typically, 
the disease outcome of a tumour is determined by the properties of the tumour cells and 
tumour microenvironment.26,11 Therefore, stromal mast cells which are in close association 
with tumour cells and the tumour microenvironment are more likely to influence tumour 
behaviour and be prognostic of the disease outcome than peripheral mast cells. 
 
Only two previous studies have investigated the mast cell density within normal or 
neoplastic canine mammary glands. In contrast to the present study, mast cell density of 
non-neoplastic mammary tissues in both previous studies was lower than that of 
neoplastic mammary gland.34,15  The reasons for this difference is unclear, although both 





mast cell density, rather than distinguishing between peripheral and stromal 
compartments. 
 
In conclusion, these findings suggest that measuring stromal mast cell density using 
toluidine blue staining may represent an easy-to-perform and cost-effective 
histopathological parameter that, in conjunction with classification and grading, could 
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Chapter 5 : Prognostic significance of chemokines and 






In the previous chapter, the potential of using stromal mast cell density for prognostic 
determination in canine mammary gland tumours (CMGTs) was investigated. Like tumour 
stromal mast cell density, many studies have investigated the potential of using 
chemokines and chemokine receptor expression in tumour cells for prognostic 
determination in human breast cancers.7,30 Chemokines are small molecular weight 
signalling proteins secreted by immune cells that control migration and positioning of 
immune and inflammatory cells within the body.10 Although the primary function of 
chemokines is leukocyte trafficking, recent research suggests they also influence growth, 
progression and metastasis of many human cancers.30 Some human cancer cells have been 
shown to produce chemokines while other studies have identified abnormal expression of 
chemokine receptors by neoplastic cells.20  Breast cancer cells have been shown to express 
chemokine receptors and increased expression of some chemokine receptors has been 
associated with a worse disease outcome.20 Additionally, some breast cancer cells have 
also been reported to produce chemokines with increased expression of some chemokines 
associated with a more aggressive clinical course and a worse disease outcome.33  
 
Many similarities have been identified between human breast cancers and canine 
mammary gland tumours including a hormonal influence on development, histopathologic 
features, expression patterns of some molecular markers, and an unpredictable clinical 
course.14,27  As in humans, gene expression of chemokines and chemokine receptors has 
been evaluated in CMGTs with two studies finding higher expression of some chemokines 
and chemokine receptors in CMGTs that were histologically classified as malignant 
compared to CMGTs that were histologically classified as benign or normal mammary 





expression of chemokine or chemokine receptors influence the biological behaviour of 
CMGTs has not been previously investigated. Therefore, the aim of this chapter was to 
evaluate gene expression of five chemokine receptors, CXCR3, CXCR4, CXCR7, CCR4, CCR9 
and three chemokines CXCL10, CXCL12, CCL5 in a series of 41 malignant and 12 benign 
CMGTs identified from the retrospective survey described in Chapter 3. These chemokines 
and chemokine receptors were selected because they have been extensively studied in 
humans and have been shown to influence the biological behaviour of human breast 
cancers.31,17,15,18,23,13,21,36 As the disease outcome of the CMGTs included was known, 
chemokines and chemokine receptor gene expression could be compared in neoplasms 
that subsequently metastasised with those that did not. Additionally, it could be 
determined if chemokine and chemokine receptor expression was associated with survival 
times of these dogs. The identification of an association between chemokine and 
chemokine receptor gene expression and disease outcome would suggest that chemokine 




5.2 Material and methods 
5.2.1 Case selection and assessment of survival times 
The same set of canine mammary tumour cases described in Chapter 4 was used for this 
study. Briefly, mammary gland tumour cases submitted to IDEXX diagnostic laboratory, 
New Zealand, for histopathology between 2012 and 2015 were sourced from the 
laboratory surgical biopsy archive. Details regarding the patient signalment were identified 
from the IDEXX surgical biopsy archive while the clinical records of the patients and 
information regarding the post-surgical follow-ups were obtained by contacting the 
submitting veterinarians. Cases were excluded if adjunct therapies including anti-
inflammatory drugs or steroids were used to alter the neoplasm behaviour or if the tumour 
surface was reported to be ulcerated or contained abscesses. The disease-specific survival 
time for each case was calculated retrospectively from the date of tumour excision to the 







5.2.2 Histological classification and grading 
The histological classification and grading of the canine mammary neoplasms was 
performed as described in section 4.2.2 in Chapter 4. Tumours were classified into three 
groups; malignant-metastatic, malignant non-metastatic and benign following the criteria 
described in the same section.  
 
 
5.2.2 RNA extraction 
For RNA extraction, three 10 µm tissue sections were cut from each formalin-fixed 
paraffin-embedded (FFPE) mammary tumour tissue and placed on glass slides. In the tissue 
sections which contained moderate amounts of intervening stroma, the sections were 
placed on glass slides but left unstained and unfixed. They were then viewed under a 
dissecting microscope and neoplastic cells were carefully scraped off using a clean scalpel 
blade into 1.5 mL microtubes for RNA extraction, using the HE stained section of the same 
specimen as a guide. This step was used to ensure that all tissue sections used for RNA 
extraction contained at least 80% tumour tissue. When neoplastic cells of various origins 
were present on a single section, all neoplastic cells were included for RNA extraction 
without discrimination. Before RNA extraction, all the equipment used, as well as the 
surface of the laboratory bench, was cleaned with RNAse decontamination solution 
(RNAseZap, Sigma-Aldrich, MO, USA). Total RNA was extracted from the samples using the 
Nucleospin totalRNA FFPE XS kit (Macherey-Nagel, Düren, Germany) following the 
manufacturer’s instructions and nucleic acid concentrations were quantified using a Qubit 
2.0 fluorometer and assay kit (Life Technologies, Carlsbad, CA, USA). For the cases which 
had more than one FFPE block for a single tumour, RNA extraction was performed from 
each block separately and the extracts were mixed prior to further assessments. For cases 
that had more than one mammary neoplasm, tissue block from the malignant tumour was 
used for RNA extraction. To remove any residual DNA, post-extraction DNAse digestion 
was performed using Ambion Turbo DNA-free DNAse following the manufacturer’s 





Transcriptor first strand cDNA synthesis kit (Roche Applied Science, Mannheim, Germany) 
using 0.5 µg total RNA, and both random hexamer and oligo-dT primers. 
5.2.3 RT-PCR 
Five chemokine receptors including CXCR3, CXCR4, CXCR7, CCR4, CCR9 and three 
chemokines CXCL10, CXCL12, and CCL5 were selected for gene expression analysis. To 
normalize the gene expression between CMGT samples of varying quantity and quality, 
HPRT and RPL32 reference genes were used.  For all the selected genes except CXCR7, 
previously published primer sequences were used (Table 5.1).4,16,22,11  
 
For CXCR7, new primers were designed using Primer-BLAST 
(https://www.ncbi.nlm.nih.gov/tools/primer-blast/) and mfold 
(http://unafold.rna.albany.edu/?q=mfold) and the newly developed assay was validated. 
To validate the specificity of the primers, positive control cDNA samples were prepared 
using RNA extracted from a lymph node of a dog that had died of an unrelated cause. The 
product amplified with the new CXCR7 primers was purified and sequenced. The sensitivity 
of the new CXCR7 assay was determined using three ten-fold serial dilution assays of the 
amplicon while the linearity of the assays was determined from the efficiency and r2 values 
calculated using the curves generated from the dilution assays. Precision was evaluated by 
calculating intra-assay variability based on the distribution of linearised Ct values for five 
replicates of each standard in a single PCR run. Reproducibility was evaluated by 
calculating inter-assay variability comparing the linearised Ct values obtained for the same 
standards in the three separate dilution assays. The intra- and inter-assay variability was 
expressed as a coefficient of variance (CV), which was the ratio of the standard deviation to 
the mean of the linearised Ct values for a particular standard, expressed as a percentage. 
 
All real-time PCR assays (RT-PCR) were performed using a Mic qPCR Cycler (Bio Molecular 
System, Upper Coomera, Australia). The RT- PCR reactions were performed using AccuMelt 
HRM SuperMix (Quanta Biosciences, Gaithersburg, MD), using 10 ng of cDNA with 0.5 µM 
forward and reverse primer concentration in a total volume of 10 µL reaction mix.  All 





template control. Residual genomic DNA was excluded on the basis of the melting 




















Gene Gene bank 
Accession No: 
Primers (5' - 3')  bps Tm (°C) Reference 
CCL5 NM_001003010.2  F: AAGGGCTGACTGATAAATGTGA 52 51 Nascimento et al., 
2013 
  
    R: AGCGAGAATTTTAATGGAAAGC     
CXCL10 AB183191.1 F: CACATGTTGAGATCATTGCCA 62 54 Nascimento et al., 
2013 
  
    R: TTCAGACATCTTTTCTCCCCA     
CXCR4 NM_001048026.1 F: GAGCGGTTACCATGGAAGAG 108 54 Im et al., 2017 
      R: CGGTTGAAGTGAGCATTTTCC     
CXCR7 NM_001003281.2 F: TTGGAGCAAAACGCCAAGTG 92 56 Designed primers 
      R: TCTTGGAGACGATGCAACCC     
CXCL12 NM_001128097.1 F: TCTTCGAGAGCCACAT TGC 82 57 Im et al., 2017 
      R: TTCAGTCTTGCCACGAT CTG     
CCR9 XM_541909 F:  CACTTCCTCCCACCCTTGTA 100 56 Maeda et al., 2011 
      R:  TGGTCTTGACTCTGGTGCAG     
CXCR3 AB185149.1 F: TTCTTTGCCATCCCAGATTTC 67 53 Nascimento et al., 
2013 
  
    R: ATGCATGGCATTTAGGCG     
CCR4 NM_001003020.1  F:  TTTGGACTAGGTCTCTGCAAGA 52 55 Nascimento et al., 
2013 
  
    R: AAAAGCCCACCAGGTACATC     
RPL32 XM_848016.1  F: TGGTTACAGGAGCAACAAGAA  100 54 Maeda et al., 2011 
      R: GCACATCAGCAGCACTTCA      









5.2.4 Relative quantification of the chemokine and chemokine receptor gene 
expression in mammary tumour samples 
 
For each gene, the melting temperatures and the shapes of the melting curves of the 
samples were compared with the corresponding positive controls. The samples which had 
melting temperatures within the range of ± 1.5 °C of the melting temperature of the 
positive controls were selected for the analyses. When multiple runs were included for a 
single gene, the CV of the cycle threshold (Cts) of the positive controls were calculated and 
only considered appropriate for analysis if the CVs were < 20%. 
 
Relative expression of genes of interest in each CMGT was analysed using ∆∆Ct method. 
Briefly, for each sample, the difference (∆Ct) between the Ct value of the gene of interest 
and the average Ct value of the two reference genes were calculated. Then a ∆∆Ct value 
was calculated by taking the difference between the calculated ∆Ct value of each sample 
and the average ∆Ct value of the control group, considering the non-metastatic malignant 
mammary gland tumours as the control group. 
 
 
5.2.5 Statistical analysis 
The correlation between the relative expression of genes of interest and the survival times 
of the dogs was analysed by Spearman rank-order correlation test. Kruskal-Wallis H test 
was used to compare the gene expression between malignant-metastatic and malignant 
non-metastatic CMGTs, and different histological grades of CMGTs. Samples with 
detectable reference gene expression but without detectable expression of the gene of 
interest were considered as negative for the particular gene. When a gene had a high 
number of negative samples, gene expression data was converted to a binary positive or 
negative result. Pearson Chi-Squared test was used for the group comparisons in these 
genes instead of Kruskal-Wallis H test as the former allowed inclusion of negative samples 
into the statistical analysis. The differences in survival times between gene expression 





curves and Log-rank test. A hierarchal multivariate analysis was performed to identify 
which tumour-related variables and chemokine, or chemokine receptor genes 
independently predicted the survival times of dogs with malignant mammary gland 
tumours. The tumour-related variables tested in multivariate analysis included tumour size, 
tumour histological grade, and the presence of intra-vascular or intra-lymphatic tumour 
emboli. The chemokines or chemokine receptors included in the multivariate analysis were 
selected considering the significant correlation between their expression and survival times 
of dogs identified in the present study. All statistical analyses were performed using the 
SPSS version 25 program (IBM Corporation, Armonk, NY, USA). P values less than < 0.05 




5.3.1 Selected cases  
The clinicopathological characteristics of patients are described in section 4.3.1 of Chapter 
4. 
 
5.3.2 Tumour size, histological sub-types and grades 
The characteristics of the tumours are described in 4.3.2 of Chapter 4. 
 
 
5.3.3 Risk of tumour metastasis 
The details of mammary tumour metastasis in the dogs included in the study are described 
in section 4.3.5 of Chapter 4. Briefly, 21/41 (51.2 %) dogs with malignant mammary 
tumours died after developing evidence of tumour metastasis within three years of 
surgical excision of the neoplasms. The other dogs 20 (48.8%) with malignant neoplasms 
were not diagnosed to have clinically evident mammary tumour metastasis during the 3-














Table 5.2 Clinical characteristics of the patients and gross and histological characteristics of the neoplasms 



































Number of cases 21 20 12 
Age       
5 - 10 yrs 15 10 11 
> 10 yrs 6 7 1 
Unknown 0 3 0 
Reproductive status     
Intact 16 16 11 
Spayed 5 4 1 
Number of tumours     
Single 19 20 12 
Multiple 2 0 0 
Tumour size       
Small (<3cm) 0 0 10 
Medium (3-5cm) 11 18 2 
Large (>5cm) 10 2 0 
Histological type       
 Simple carcinoma (5) 
Intra-ductal papillary 
carcinoma (6) Complex adenoma (7) 
 
Adenosquamous 
carcinoma (5) Simple carcinoma (6) Simple adenoma (3) 
 Ductal carcinoma (3) Complex carcinoma (3) Papillary adenoma (2) 
 
Carcinoma - Mixed 
type (3) Ductal carcinoma (3)  
 Carcinoma - solid (2) 
Adenosquamous 
carcinoma (1)  
 
Comedo carcinoma 
(1) Carcinoma - Anaplastic (1)  
 
Carcinoma - 
Anaplastic (1)   
 Intra-ductal papillary carcinoma (1)  
Histological grade       
Grade I 3 10 N/A 
Grade II 14 9 N/A 
Grade III 4 1 N/A 
Presence of tumour 
emboli 5 0 0 





5.3.4 Assay validation of CXCR7 and reference gene stability 
The newly developed CXCR7 gene expression assay was linear within the tested range from 
102 to 107 target copies with an efficiency of 1.035 and r2 value of 99.85%. The CV of the 
mean linearized Ct values obtained with five replicates of different dilutions of the 
standard in a single test run ranged from 10.1—17.9%. The CV of the mean linearized Ct 
values obtained in three separate runs of the test ranged from 7.4—19.5%. This indicates 
adequate precision and reproducibility of the assay. The average geNorm M value was ≤ 
0.2 indicating a high reference gene stability. The geNorm V value was < 0.15 suggesting 
that the pair-wise variation between the two reference genes HPRT and RPL32 is minimal 




5.3.5 Relative gene expression of chemokines CCL5, CXCL12 and CXCL10 in CMGTs  
In the 41 malignant CMGTs included in the study, reference gene expression was positive 
in 40 tumours and undetectable in one. This mammary tumour was excluded from further 
analyses. Analysis of the relative quantities of gene expression was only performed for 
genes in which a high proportion of the tumours had detectable expression of the gene of 
interest. This included three chemokines: CCL5, CXCL10 and CXCL12. For CXCL12 target 
gene expression was observed in 39 (97%) CMGTs. One sample was excluded due to 
absence of CXCL12 expression. CCL5 expression was observed in 38 (97.5%) mammary 
tumours. One tumour did not have detectable expression and the other was excluded due 
to inappropriate melting peak which suggests non-target amplification. Detectable CXCL10 
expression was observed in 26 (66.7%) mammary tumours and undetectable in six. Eight 
tumours were excluded from CXCL10 gene expression analysis due to other reasons; the 
melting temperatures were not appropriate in six tumours, and in two tumours only one 






For CCL5, the ∆∆Ct values in malignant CMGTs ranged from -3.97 to 7.08. The mean ranks 
of ∆∆Ct of CCL5 in malignant-metastatic tumours was significantly different from that of 
malignant non-metastatic tumours (Kruskal-wallis H test, Z = 4.3, p = 0.038). For CXCL12, 
the ∆∆Cts in malignant CMGTs ranged from -3.61 to 1.13 and the mean ranks of ∆∆Ct 
values between metastatic and non-metastatic mammary tumour groups was significantly 
different (Kruskal-wallis H test, Z = 12.4, p < 0.005). In contrast, expression of CXCL10 was 
not different between the two groups (p = 0.76). There were no significant differences in 
relative gene expression of CCL5, CXCL12 and CXCL10 genes between different histological 
grades of CMGTs. Gene expression between different histological sub-types was not 
evaluated due to small number of samples included in some categories. 
 
 
5.3.6 Gene expression of chemokine receptors: CXCR3, CXCR4, CXCR7, CCR4 and 
CCR9 in CMGTs 
 
Gene expression data for chemokine receptors was considered positive when target gene 
expression was detected in the tumour, or negative when target gene expression was not 
detected in the tumour despite adequate expression of the reference genes. Although 
CXCR3, CXCR4, CXCR7 and CCR4 genes had an adequate number of mammary tumours 
with detectable target gene expression, the data could not be reliably quantified as the Ct 
values of some of the samples were not within the linear range of the assay. For CCR9 
gene, the number of positive tumours was low. Therefore, relative gene quantification was 
not performed for these genes and tumours were considered on positive or negative basis 
for statistical analysis. 
 
Chemokine receptor CXC 3 (CXCR3) gene expression was detected in 23/39 malignant 
CMGTs, with no CXCR3 expression detected in 16 tumours. One tumour was excluded due 
to an inappropriate melting peak. Of the 20 CMGTs that subsequently metastasised, 15 
(75%) were positive for CXCR3 expression while CXCR3 expression was detected only in 





with positive CXCR3 expression metastasised significantly more frequently in this study 
than CMGTs without CXCR3 expression (Chi-squared test, p = 0.037). Positive CXCR4 
expression was identified in 20/38 malignant CMGTs samples and 18 samples were 
negative for CXCR4. Two samples were excluded due to inappropriate melting peaks. 
Fourteen (70%) metastatic tumours had positive expression of CXCR4 while only 6/18 
(33%) non-metastatic samples showed positive expression of CXCR4. Therefore, a 
significantly higher proportion of metastatic malignant CMGTs were positive for CXCR4 
expression compared to the non-metastatic malignant CMGTs (Chi-squared test, p = 
0.026). Positive CXCR7 expression was observed in 19/38 mammary tumours while it was 
negative in 19 tumours. Two samples were excluded due to inappropriate melting peaks. 
The proportion of metastatic malignant CMGTs which had positive CXCR7 expression 
(13/19, 68%) was significantly higher than the proportion of CXCR7 positive malignant 
tumours which did not subsequently metastasise (6/19, 32%) (Chi-squared test, p = 0.025). 
Only 33 CMGTs could be included in the CCR9 assay. Six samples had insufficient 
amplifiable RNA and therefore could not be assayed. One sample was excluded due to an 
inappropriate melting peak. Of the 14 metastatic mammary tumours included, 8 (57%) 
tumours had positive CCR9 expression while only 4/19 (21%) non-metastatic CMGTs had 
positive CCR9 expression. Therefore, a significantly higher proportion of CMGTs which had 
developed tumour metastases had positive CCR9 expression (p = 0.039) compared to those 
that did not develop metastasis during the follow-up period. Twenty samples were positive 
for CCR4 expression while 17 samples were negative. Four samples were excluded due to 
inappropriate melting temperatures. In contrast to the other chemokines and chemokine 
receptors, there was no significant difference between the proportions of CCR4 positive 
tumours in the metastatic (7/16, 45%) and non-metastatic (13/20, 65%) CMGT groups (Chi-










Table 5.3 Gene expression analysis for chemokine receptors. 
*For each gene, 1‒5 samples were excluded for inappropriate melting peaks. Six mammary tumours could not 
be included in CCR9 assay due to insufficient sample volumes. 
 
 Proportion of malignant CMGTs with positive target gene expression 
Chemokine 
receptor 
Total*  Metastatic Non-metastatic Chi-sq p value 
CXCR3 23/39 (56%) 15/20 (75%) 8/19 (42%) 0.037 
CXCR4 20/38 (55%) 14/20 (70%) 6/18 (33%) 0.026 
CXCR7 19/38 (50%) 13/19 (68%) 6/19 (32%) 0.025 
CCR9 12/33 (36%) 8/14 (57%) 4/19 (21%) 0.039 
CCR4 20/36 (55%) 7/16 (45%) 13/20 (65%) 0.17 
 
 
5.3.7 Gene expression and survival times of dogs 
Analysis of the correlation between chemokine gene expression (relative quantity) and 
survival time in the dogs with malignant CMGTs found a statistically significant, moderate 
negative correlation between CXCL12 gene expression and survival times (Spearman’s 
rank-order correlation rs = -0.40, p = 0.03). There was also a moderate, negative correlation 
between CCL5 expression and survival times of dogs (Spearman’s rank-order correlation, rs 
= -0.40, p = 0.02). However, there was no significant correlation between CXCL10 
expression in CMGTs and survival time (Spearman’s rank-order correlation, rs = 0.27, p 
=0.38).  
 
The overall mean survival time (MST) of the 41 dogs with malignant CMGTs was 721 days: 
(95% CI 609 – 833). When dogs were grouped according to chemokine receptor gene 
expression, the mean survival time differed significantly between groups of some 
chemokine receptors but not others. The mean survival time (MST) of the dogs with CXCR4 
positive tumours was significantly lower (623 days, 95% CI 455—793) than that of the dogs 
with CXCR4 negative mammary gland tumours (Log-rank test, 845 days, 95% CI 688-1002, 
p = 0.045, Figure 5.1). Similarly, the MST of the dogs with CCR9 positive tumours was 686 
days (95% CI 488-885) which was significantly lower than the MST of CCR9 negative dogs 





MSTs between the chemokine receptor positive and negative groups were not significant 
for CXCR3, CXCR7 and CCR4 chemokine receptors.  
 
A hierarchal multivariate analysis was performed which included the following chemokines 
and chemokine receptors: CCL5, CXCL12, CXCR4 and CCR9. These chemokines and 
chemokine receptors were selected for analysis because their expression was significantly 
associated with survival times of the dogs, through either relative quantification (CCL5 and 
CXCL12) or simply the presence or absence of gene expression (CXCR4 and CCR9). In 
addition to the chemokines and chemokine receptors, tumour size, tumour grade and 
presence of tumour emboli in histological section were also included as independent 
variables. Of these variables, histological grade (ΔF= 4.3, p = 0.048) and CCL5 gene 
expression (ΔF= 5.7, p = 0.026) were identified as independently predicting the survival 
times of the dogs with malignant mammary neoplasms (Table 5.4). 
 
 
Table 5.4 Hierarchical multivariate analysis.  
The variability of the survival times predicted by each variable is denoted by ΔF and p values indicate the 
significance of ΔF. **p < 0.05 
Independent variables Δ F p 
Tumour size 0.365 0.551 
Tumour histological grade 4.301 0.048** 
Presence of tumour emboli 2.528 0.124 
CCL5  5.665 0.026** 
CXCL12  0.522 0.477 
CXCR4  1.293 0.168 
CCR9  0.251 0.89 









Figure 5.1 Kaplan-Meier survival curves of the dogs.  
A: Dogs with mammary gland tumours positive and negative for CXCR4. The mean survival times 
between dogs which had malignant mammary tumours which were positive for CXCR4 was 
significantly different from that of tumours which were negative for CXCR4 (p = 0.039) B: Dogs with 
mammary gland tumours positive and negative for CCR9. The mean survival times between dogs 
which had malignant mammary tumours which were positive for CCR9 was significantly different 
from that of tumours which were negative for CCR9 (p = 0.018). Dogs with mammary gland tumours 
positive and negative for CXCR3 (C), CXCR7 (D) and CCR4 (E). For C, D and E the mean survival times 






5.3.8 Gene expression in benign CMGTs 
In regard to chemokine gene expression in the 12 benign CMGTs, expression of CCL5 was 
identified in 6/12 (50%) mammary tumours, CXCL10 expression in 7 (64%), and CXCL12 
expression in only one benign neoplasm (10%). However, even when chemokine gene 
expression was detected in benign tumours, this expression was very low and outside of 
the linear ranges of the assays. This is in contrast with the malignant CMGTs where 
chemokine gene expression was present in the majority of samples and was higher, being 
within the linear range of the assays. Regarding chemokine receptor gene expression 
(CXCR3, CXCR4, CXCR7, CCR4 and CCR9) only two benign tumours from each gene had 
detectable gene expression. Further, for all the chemokine receptor genes Chi-squared 
analysis showed that the proportion of benign CMGTs with positive gene expression was 
significantly lower than the proportion of malignant mammary tumours which had positive 




All the chemokines and chemokine receptors analysed in the present study, except CXCL10 
and CCR4, had higher gene expression in malignant CMGTs that subsequently metastasised 
than in malignant CMGTs that did not metastasise. In addition, higher expression of CXCR4, 
CCR9, CCL5 and CXCL12 was associated with shorter survival times of the dogs. Of the 
tested chemokines and chemokine receptors, CCL5 was identified to predict the survival 
times of the dogs with malignant mammary neoplasms independent of tumour size, 
histological grade, presence of tumour emboli in histological sections and gene expression 
of other included chemokines and chemokine receptors. Therefore, the present findings 
suggest that the expression of chemokines and chemokine receptors influences tumour 
behaviour. To the author’s knowledge, this is the first time that chemokine and chemokine 
receptor gene expression in CMGTs has been associated with disease outcome in dogs.  
 
The present results are consistent with many human breast cancer studies which have also 





influence tumour behaviour and patient survival.15,17,18,21,13,23,36 These human studies have 
identified several mechanisms to explain how the expression of chemokines or chemokine 
receptors may influence tumour behaviour.3 Firstly, the chemokine network in a tumour 
has been shown to influence the extent and phenotypic composition of the inflammatory 
cell infiltrate within the tumour. Some inflammatory cells are pro-tumourigenic while 
others have anti-tumourigenic properties.3,5 Therefore, altered chemokine gene expression 
may indirectly influence the tumour behaviour by changing the intra-tumoural 
inflammation in a way that promotes tumour growth and spread. Secondly, aberrant 
expression of chemokine receptors on the surface of neoplastic cells can promote 
migration of these cells towards distant organs that contain higher concentration of the 
corresponding chemokine.3 For example, human breast cancers with high CXCR4 
expression were shown to metastasise to lung, liver and bone more frequently than breast 
cancers with low CXCR4 expression. This is hypothesised to be because lung, liver and bone 
tend to contain a high concentration of CXCL12 which binds to the CXCR4 receptors.3 
 
The use of chemokine expression to predict prognosis has been investigated for many 
different human cancer types.12,1,25 For example, chemokine panels consisting of 7 to 12 
chemokines were shown to accurately predict the behaviour of breast cancers.28,34 In dogs, 
it is difficult to accurately predict the behaviour of malignant mammary neoplasms using 
existing conventional prognostic tools.32 The inability to predict which neoplasms are likely 
to metastasise can delay the therapeutic interventions aimed at preventing mammary 
tumour metastasis. In the present study, relative expression of chemokines CCL5 and 
CXCL12 was significantly higher in mammary tumours which subsequently developed 
metastasis compared to the tumours which did not develop metastasis. Chemokine CCL5 
was also identified to predict the survival times of the malignant canine mammary 
neoplasms independent of conventional prognostic indicators. In addition, chemokine 
receptors CXCR3, CXCR4, CXCR7 and CCR9 were detected more frequently in the tumours 
that subsequently metastasised compared to those which did not develop clinical evidence 
of metastasis. Therefore, the present findings suggest these chemokines and chemokine 
receptors may be useful to predict which CMGTs are more likely to metastasise. However, 
while measuring the expression of chemokines and chemokine receptors may help to 





development would be required before adopting measuring gene expression as a routine 
diagnostic tool.  
  
As well as their potential use as prognostic markers, chemokines and chemokine receptors 
represent potential targets for cancer immunotherapy.35,19 For example, if increased 
chemokine receptor activity leads to a more aggressive clinical behaviour of a neoplasm, 
blocking this receptor using a chemokine antagonist or a monoclonal antibody could 
reduce the likelihood of tumour metastasis and metastasis related death.3,19 Recently, a 
monoclonal antibody and several synthetic and natural chemokine receptor antagonists 
have been approved by the United States Food and Drug Administration to treat several 
human cancers including some types of breast cancers.19 However, considering the extent 
of research being carried out in the field of chemokine-targeted cancer immunotherapy, 
only a limited number of chemokine-targeted novel therapeutics have been introduced for 
clinical use. The lack of an appropriate animal model which mimics the characteristics and 
behaviour of human breast cancers contributes to the difficulties in developing novel 
chemokine related target therapies.19 Recently, dogs have been proposed as a better 
animal model than mouse or rat models for pre-clinical testing of cancer therapeutics.27,24 
The findings of the present study show that chemokine and chemokine receptor gene 
expression patterns in CMGTs resemble those of human breast cancers. Additionally, these 
results show that expression of chemokines and their receptors influence the behaviour of 
mammary gland neoplasms in dogs. Therefore, mammary gland neoplasms in dogs may 
provide an appropriate animal model of human breast cancers for testing chemokine-
targeted cancer therapeutics. Furthermore, the similarity of chemokine expression 
between CMGTs and human breast cancers may suggest the possibility of using already 
available chemokine receptor-targeted cancer therapeutics intended for human use to 
treat CMGTs.  
 
In the present study, gene expression of CXCR3, CXCR4, CXCR7, CCR9, CCL5 and CXCL12 
was associated with tumour behaviour similar to studies of human breast cancers. In 
contrast, expression of CXCL10 and CCR4 has been shown to predict tumour behaviour in 
humans but was not significantly associated with metastasis or survival time in the present 





small number of samples were able to be analysed for CXCL10 due to inappropriate 
melting temperatures observed in some samples. The smaller than anticipated sample size 
may have contributed to the lack of significant findings observed for this chemokine. It is 
also possible that the mechanism by which CXCL10 and CCR4 influence the behaviour of 
human cancers does not apply to CMGTs due to differences in tumour biology between 
dogs and humans.  
 
The present study did not identify any significant differences in chemokine gene expression 
between different histological types and histological grades of malignant CMGTs. Although 
it is possible that chemokine expression in CMGTs is not affected by histological type and 
grade, it is necessary to further investigate this matter with a larger sample size including 
sufficiently high number of samples in different histological types and tumour grades.  
 
Similar to the prognostic study described in chapter 4, in this study also tumour histological 
grade was identified to be independently prognostic of survival times of the dogs with 
malignant CMGTs while tumour size or presence of intra-vascular or intra-lymphatic 
tumour emboli were not independently predictive of metastatic behaviour of malignant 
CMGTs. As described in the discussion of chapter 3 of this thesis, these findings were 
consistent with previous studies.29, 14, 26,32,9 
 
A significantly lower proportions of benign CMGTs had positive gene expression for 
chemokine and chemokine receptor genes in this study.  This is consistent with previous 
canine studies and indicated that expression of chemokine and chemokine receptor genes 
increases as differentiation of a neoplasm decreases.2,6 However, the ideal comparison of 
chemokine and chemokine receptor expression should be performed between neoplastic 
mammary gland and the non-neoplastic mammary gland adjacent to the neoplastic 
mammary gland. This could not be fulfilled in the present study due to insufficient non-
neoplastic mammary gland available in the tissue sections and therefore benign mammary 
tumours were used as an alternative to non-neoplastic mammary gland. Although the 
benign mammary neoplasms are closely representative of the chemokine expression of the 





One limitation of the present study was the lack of tumour staging at diagnosis. This 
suggests it is possible that some CMGTs could have metastasised prior to the neoplasm 
being excised. Additionally, due to the retrospective nature of the study, it was impossible 
to definitively rule out the possibility that some of the CMGTs that were classified as non-
metastatic had developed clinically silent metastatic disease in the 3-year period of the 
study.  
 
Except for three benign mammary gland tumours, all of the mammary neoplasms 
contained an inflammatory cell infiltrate which was predominantly present in the tumour 
stroma. Most of these inflammatory cells were not included for RNA extraction as the 
stromal tissues were removed prior to RNA extraction. However, absolute exclusion of 
inflammatory cells or tumour stromal tissues from RNA extraction was not possible and 
this is recognised as a limitation of the present study. Further studies using 
immunohistochemistry are needed to confirm that chemokines and chemokine receptor 
proteins are expressed in neoplastic cells and to identify which neoplastic cells produce 
them in tumours where more than one cell type exists such as mixed mammary tumours.  
 
In summary, the present study is the first reported investigation of chemokine and 
chemokine receptor gene expression in CMGTs with known clinical outcome. The results 
showed that expression of some of the chemokine and chemokine receptor genes was 
significantly associated with the development of metastases and survival times in these 
dogs. As well as providing insight into the factors that influence behaviours of CMGTs, 
these results suggest that chemokines and chemokine receptors may have future uses as 
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Chapter 6 : Prognostic significance of immune checkpoints PD-






The two previous chapters described the prognostic significance of cancer-associated 
inflammation related prognostic markers including stromal mast cell density, and 
chemokines and chemokine receptors. In addition to these cancer-associated inflammation 
related markers, many studies have shown that expression of immune checkpoint 
molecules by cancer cells influence the behaviour of human breast cancers and thereby 
are useful as prognostic markers. This chapter presents the outcome of the investigations 
carried out to determine whether the two immune checkpoint molecules: programmed 
death ligand-1 (PD-L1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4) which were shown 
to be prognostic of human breast cancer behaviour are similarly prognostic for canine 
mammary gland tumours (CMGTs) . 
 
Immunosurveillance to detect and subsequently destroy infected or abnormal cells is a 
major function of the immune system. The activation of T-cells is an important event in 
immunosurveillance. This activation occurs following interactions between T-cell receptors 
and major histocompatibility complex proteins that are present on the surface of antigen 
presenting cells.14 However, T-cell activation is also controlled by a group of signalling 
molecules collectively referred to as immune checkpoints, which are typically comprised of 
receptors located on T-cells that interact with a corresponding ligand present on antigen 
presenting cells.14,21 Immune checkpoints can either be activating whereby activation 
allows T-cells to proliferate or inhibitory whereby receptor activation suppresses T-cell 
activation.21,14,10 
 
Recent research has shown that many human cancers aberrantly express inhibitory 





cell activity may allow neoplasms that express inhibitory immune checkpoint molecules to 
evade host immune surveillance resulting in a more aggressive clinical behaviour and less 
responsiveness to treatments. Two inhibitory immune checkpoints that are often 
expressed in human cancers are PD-L1 and CTLA-4.21,47 Studies have demonstrated that 
neoplasms with increased PD-L1 and CTLA-4 have a more aggressive behaviour and a 
worse disease outcome, therefore measuring these immune checkpoint molecules could 
be a useful way to predict prognosis.30,45 Further, using monoclonal antibodies (mAbs) to 
block these immune checkpoints has been shown to enhance cytotoxic T-cell mediated 
tumour cell destruction as well as increasing the activation of other immune responses 
such as antigen presentation and cytokine release.6,45 Currently, several such anti-PD-L1 
and anti-CTLA-4 mAbs are available to treat a variety of human cancer types.45 
 
In veterinary medicine, several previous studies have shown that a variety of canine 
cancers express PD-L1 and CTLA-4.2,22,26,41 The expression of PD-L1 and CTLA-4 on 
neoplastic lymphoid cells was previously shown to predict the prognosis of canine high-
grade B cell lymphomas.2  Further, in vitro studies have shown that PD-L1 blockade 
increases cytokine release by cultured cancer cells25 and anti-PD-L1 mAbs have been 
administered to a small number of dogs with cancer.27 Additionally it was shown that PD-L1 
protein is more frequently detectable in histologically-malignant CMGTs than 
histologically-benign ones.26,41 However, whether evaluation of this protein can predict the 
biological behaviour of CMGTs has not been previously evaluated. To the author’s 
knowledge, there have been no studies of CTLA-4 in CMGTs. Therefore, the present study 
investigated the immunostaining and gene expression of PD-L1 and CTLA-4 in 41 malignant 
and 12 benign CMGTs. As the clinical outcome of these tumours was known, it could be 
determined whether PD-L1 and CTLA-4 protein and gene expression were correlated to 







6.2 Material and methods 
6.2.1 Case selection and assessment of survival times 
The same set of canine mammary tumour cases described in detail in Chapter 4 was used 
for this study. Therefore, the case selection procedure and the inclusion criteria were the 
same as in sections 4.2.1 in Chapter 4. Briefly, mammary gland tumour cases submitted to 
IDEXX diagnostic laboratory, New Zealand, for histopathology between 2012 and 2015 
were sourced from the laboratory surgical biopsy archive. Details regarding the patient 
signalment were identified from the surgical biopsy archive data base while the clinical 
records of the patients and information regarding the post-surgical follow-ups were 
obtained by contacting the submitting veterinarians. Cases were excluded if adjunct 
therapies including anti-inflammatory drugs, steroids or anti-cancer drugs were used to 
alter the neoplasm behaviour or if the tumour surface was reported to be ulcerated or 
contained abscesses. The disease-specific survival time for each case was calculated 
retrospectively from the date of tumour excision to the date of the dog’s death or 
euthanasia due to clinically-diagnosed mammary tumour metastasis. 
 
 
6.2.2 Histological classification and grading 
The histological classification and grading of the canine mammary neoplasms was 
performed as described in section 4.2.2 in Chapter 4 following Goldschmidt et al. (2011) 
and Pena et al. (2013) classifications.11,34 Tumours were classified into three groups; 
malignant-metastatic, malignant non-metastatic and benign following the criteria 




6.2.3.1 Anti-PD-L1 and anti-CTLA-4 antibody validation 
The two primary antibodies used for PD-L1 and CTLA-4 immunostaining in CMGTs were 
prepared against the corresponding human proteins. The anti-PD-L1 antibody (ab233482, 





has an 83% sequence similarity with canine PD-L1 protein. Similarly, anti-CTLA-4 antibody 
(Santa Cruz Biotechnology, Dallas, TX, USA) was raised against a peptide sequence included 
in the C-terminus of the human CTLA-4 protein which has an 84% sequence identity with 
the canine CTLA-4 protein. Therefore, before using them for immunostaining in CMGTs, 
the cross reactivity of these antibodies with the corresponding canine proteins were 
assessed by immunoblotting. 
 
 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
Mammary tumour tissues of a dog that died due to tumour metastasis were collected 
during a post-mortem examination and used for protein extraction. To extract protein 
from tissues, the mammary tumour tissues from the dog was minced into fine pieces and 
homogenised on ice. A protease inhibitor cocktail was then added to the tissue 
homogenate and proteins were extracted using ReadyPrep™ kit following the 
manufacturer’s instructions (Bio-Rad, Hercules, CA, USA). The protein concentration of the 
extract was estimated using a commercial kit following manufacturer’s instructions 
(Qubit™ Protein Assay Kit, Invitrogen, Carlsbad, CA, USA) and adjusted to 2 µg/µl. The 
protein extract was then mixed with an equal volume of 2X Laemmli sample buffer (Bio-
Rad), and denatured by mixing with 2- mercaptoethanol (Bio-Rad) to have a 5% final 
concentration and then heat treated at 100°C for 10 minutes. Purified recombinant Fc Tag 
canine PD-L1 protein (Sino Biological, Wayne, PA, USA) was used as the positive control 
and prepared similarly to the protein extracted from mammary tumour tissues except 
adjusting the final protein concentration to 0.1 µg/µl. The processed samples were cooled 
to room temperature and 40 µl of each sample and the positive control were loaded into 
separate wells in a 4-20% SDS-PAGE gel (Criterion™ TGX™ Precast Midi Protein Gel, 12+2 
well, 45 µl, Bio-Rad) along with a protein molecular weight marker (Precision Plus Protein™ 
Kaleidoscope™ Pre stained Protein Standards, Bio-Rad). The loaded gel was placed inside a 
protein electrophoresis apparatus (Criterion™ Vertical Electrophoresis Cell, Bio-Rad), filled 
with 1X running buffer (10x Tris/Glycine/SDS, Bio-Rad), and proteins were separated by 
running the apparatus at 100V for 1 hr. Once complete, the gel was separated, stained 
with Coomassie blue staining solution (Bio-Rad) and imaged to visualise the size of the 






The proteins were separated by electrophoresis as described previously. A working 
solution of transfer buffer was prepared by mixing 100 ml of 10X transfer buffer (10x 
Tris/Glycine Buffer for Western Blots and Native Gels, Bio-Rad) with 200 ml methanol and 
700 ml distilled water. Polyvinylidene difluoride (PVDF) membrane (Immun-Blot® PVDF 
Membrane, Precut, 10 x 15 cm, Bio-Rad) was soaked in methanol for 1 minute and rinsed 
in 1X transfer buffer. A transfer sandwich was prepared by arranging following items in the 
given order ensuring no air bubbles between layers: plastic plate, sponge, filter paper, SDS-
PAGE gel, PVDF membrane, filter paper, sponge and plastic plate. The prepared transfer 
sandwich was placed in a protein transfer apparatus (Criterion™ Blotter with wire 
electrodes, Bio-Rad) and transfer buffer was added to the to the apparatus until the 
sandwich was covered with buffer. An ice pack was placed in the front compartment of the 
apparatus to maintain 4°C during the transfer. The electrodes were placed over the 
transfer sandwich and run at 100V for 1 hour to transfer the proteins from the gel to the 
PVDF membrane. At the end of the transfer, the PVDF membrane was carefully retrieved 
from the sandwich, stained with Ponceau-S (Sigma-Aldrich, New South Wales, Australia) to 
visualise the successful protein transfer, rinsed with TBS with 0.1% Tween 20 (TBST) (Bio-
Rad) and put in TBST with 5% non-fat dry milk (NFDM) for 1 hour to block non-specific 
binding. Next the PVDF membrane was rinsed with TBST three times and incubated with 
primary antibody (anti-human PD-L1 antibody, Rabbit polyclonal, ab233482, Abcam) 
diluted 1:100 in TBST with 5% NFDM and incubated overnight at 4°C. At the end of 
incubation, the membrane was rinsed four times with TBST and then incubated with the 
secondary antibody (Goat Anti-Rabbit IgG, HRP conjugated, ab233482, Abcam) diluted 
1:8000 in TBST with 5% NFDM, for 1 hr at room temperature. The membrane was then 
rinsed three times with TBST, and molecular weight ladder was marked using a 
chemiluminescent marker pen (WesternSure® Pen, LI-COR Biosciences, Lincoln, NE, USA). 
The HRP substrate was prepared by mixing equal volumes of Luminol buffer and enhancer 
buffer from a commercial kit (Immun-Star HRP Chemiluminescent Substrate Kit, Bio-Rad). 
The prepared substrate was added over the surface of the PVDF membraned, incubated 
for five minutes and imaged using C-DiGit ® Blot Scanner (LI-COR Biosciences, Lincoln, NE, 






To determine the binding specificity of the anti-CTLA-4 antibodies, immunoblotting was 
performed the same as for the anti-PD-L1 antibodies except that purified recombinant His-
Tag canine CTLA-4 protein (Sino Biological, Wayne, PA, USA) was included as the positive 
control and mouse anti-human CTLA-4 monoclonal antibody (Santa Cruz Biotechnology, 
Dallas, TX, USA) diluted 1:50 and HRP conjugated Goat Anti-mouse IgG antibody, 





Three micrometre thick sections of paraffin-embedded formalin-fixed (FFPE) canine 
mammary tumour tissues were pre-treated by a heat-induced antigen retrieval method 
using citrate buffer (0.01 M, pH 6.0). The primary antibody was a rabbit anti-PD-L1 
polyclonal antibody (ab233482, Abcam) which was used at 1:100 dilution. Tissue sections 
were incubated with the primary antibody for 2 hours at room temperature. Antigen 
detection was performed using VECTASTAIN® Elite® ABC HRP kit (Vector Laboratories, 
Burlingame, CA, USA) following the manufacturer’s instructions and the immunoreactivity 
was visualised using 3, 3’ diaminobenzidine chromogen (Biocare Medical, Pacheco, CA, 
USA) with a haematoxylin counterstain. A cutaneous granuloma from a dog was used as 
the positive control while the primary antibody was omitted from the negative controls. 
Additionally, sections of adrenal gland and pancreas obtained from a dog that died of an 
unrelated cause were also used as negative controls as these tissues have been previously 
shown not to contain PD-L1 protein.41 
 
The primary antibody used for CTLA-4 immunohistochemistry was a mouse anti-CTLA-4 
monoclonal antibody (Santa Cruz Biotechnology, Dallas, TX, USA) used in 1:50 dilution. The 
rest of the method used for immunostaining of CTLA-4 was the same as for 
immunostaining of PD-L1. A section of mandibular lymph node obtained from a dog that 
had died due to an unrelated cause was used as the positive control while the primary 






6.2.3.3. Quantification of immunostaining 
Immunostaining was quantified using a method which considered both the staining 
intensity and the proportion of positive cells present in a high-power (400x) microscopic 
field. Briefly, the immunostaining intensity of tumour cells in a 400x microscopic field was 
assessed using a scale that ranged from 0-3. For PD-L1, both the membrane and 
cytoplasmic immunostaining were considered together when determining the 
immunostaining of a cell while only cytoplasmic immunostaining was considered for CTLA-
4, consistent with  previous reports on immunostaining patterns of these two proteins in 
canine and human tissues.33,37,41 The  0-3 scale for PD-L1 was define as : 0 = membrane and 
cytoplasmic immunostaining is absent, 1 = incomplete membrane immunostaining with or 
without mild or moderate cytoplasmic staining, 2 = moderately intense complete 
membrane immunostaining, with or without moderate cytoplasmic immunostaining, 3 = 
intense complete membrane immunostaining with or with or without moderate or intense 
cytoplasmic immunostaining. The scale for CTLA-4 was defined considering cytoplasmic 
immunostaining: 0 = cytoplasmic immunostaining is absent, 1 = mild cytoplasmic staining, 
2 = moderate cytoplasmic immunostaining, 3 = intense cytoplasmic immunostaining To 
generate an immunostaining score, the percentage of immunostaining positive cells 
identified in each level of the scale were applied to the following formula:  immunostaining 
score = 0 x % of level 0 cells + 1 x %  of level 1 cells + 2 x %  of level 2 cells + 3 x % of level 3 
cells. The lowest possible immunostaining score was 0 while the highest was 300. From 
each tissue section, five representative high-power fields were individually scored, and the 
average was considered as the final immunostaining score for that mammary tumour. In 
instances where more than one tissue block was available for a single tumour, the average 
of the immunostaining scores calculated for different sections was taken as the final 
immunostaining score for the tumour. For the dogs which had multiple mammary 
neoplasms, the malignant neoplasm was used for immunostaining. Additionally, nuclear 
immunostaining of PD-L1 and CTLA-4 immunostaining status of the tumour infiltrating 







6.2.4 Real time PCR (RT-PCR) for PD-L1 and CTLA-4 genes 
RNA extraction, cDNA synthesis and RT-PCR 
Total RNA was extracted from FFPE canine mammary tumour samples using Nucleospin 
totalRNA FFPE XS kit (Macherey-Nagel, Düren, Germany) following manufacturer’s 
instructions and nucleic acid concentrations were quantified. Three, 10 µm sections from 
each block were used for RNA extraction. When multiple FFPE blocks were available for a 
single tumour, RNA extraction was performed from each block separately and the extracts 
were mixed prior to further assessments. To remove any residual DNA, post-extraction 
DNAse digestion was performed using Ambion Turbo DNA-free DNAse following the 
manufacturer’s instructions (Life Technologies, Carlsbad, CA, USA). When a single dog had 
multiple tumours, the malignant tumour was used for RNA extraction. RNA was extracted 
from a mandibular lymph node collected from a dog that had died of an unrelated cause to 
be used as positive controls in PD-L1 and CTLA-4 RT-PCR assays. 
 
Complementary DNA (cDNA) was synthesised from the total RNA extracted from canine 
mammary tumour samples using Transcriptor first-strand cDNA synthesis kit (Roche 
Applied Science, Mannheim, Germany).  Primers for PD-L1 and CTLA-4 were developed 
using the reference sequences of the target canine genes available in NCBI GenBank and 
Primer-BLAST (https://www.ncbi.nlm.nih.gov/tools/primer-blast/) and mfold 
(http://unafold.rna.albany.edu/?q=mfold) algorithms. All RT-PCR assays were performed in 
a Mic qPCR Cycler (Bio Molecular System, Upper Coomera, Australia). A 10 μL reaction mix 
included, 10 ng of cDNA, forward and reverse primers in 0.7 μM concentration for PD-L1 
and 0.5 μM for CTLA-4 and AccuMelt HRM SuperMix (Quanta Biosciences, Gaithersburg, 
MD, USA). The following running conditions were used for RT-PCR assays for PD-L1: 
:denaturation at 95 °C for 5 minutes, followed by 40 cycles at 95 °C for 30 seconds, 55 °C 
for 15 seconds and 70 °C for 20 seconds. For CTLA-4 running conditions included 
denaturation at 95 °C for 5 minutes, followed by 40 cycles at 95 °C for 30 seconds, 57 °C 
for 15 seconds and 70 °C for 20 seconds. All RT-PCR assays for mammary tumour samples 
were performed in duplicate and each plate included a positive control and a no template 
control. The residual genomic DNA was excluded based on the melting temperature and/or 





qbase+ software (qbase+, Biogazzele, Gent, Belgium). The fold change in the mRNA 
expression in malignant mammary tumours was calculated by 2^-ΔΔCT method using the 
data obtained from PD-L1 and CTLA-4 RT-PCR assays. Hypoxanthine-guanine 
phosphoribosyltransferase (HPRT) and ribosomal protein L32 (RPL-32) were used as the 
reference genes and the primers for these genes were obtained from previous 
publications.5,24 All the primers used in this study are included in Table 6.1. 
 
Validation of PD-L1 and CTLA-4 RT-PCR assays 
The newly developed PD-L1 and CTLA-4 assays were validated by determining the 
sensitivity, precision, reproducibility, and specificity of the assays. Sensitivity of the assays 
was determined using three ten-fold serial dilution assays of the amplicon while the 
linearity of the assays was determined from the efficiency and r2 values calculated using 
the curves generated from the dilution assays. Precision was evaluated by calculating the 
intra-assay variability based on the distribution of linearized Ct values for five replicates of 
each standard in a single PCR run. Reproducibility was evaluated by calculating inter-assay 
variability comparing the linearized Ct values obtained for the same standards in the three 
separate dilution assays. The intra- and inter-assay variability was expressed as a 
coefficient of variance (CV), which was the ratio of the standard deviation to the mean of 
the linearized Ct values. To assess the specificity of the assays the products amplified with 
the PD-L1 and CTLA-4 primers were purified and sequenced. Briefly, the PCR products 
were digested with Shrimp Exonuclease I and Alkaline phosphatase enzymes (illustra 
ExoProStar, Life Sciences, St. Petersburg, FL, USA), mixed with 4 nmoles of forward or 
reverse primers and sent to the DNA sequencing facility of Massey University, NZ. 
 
 
Table 6.1 Primers used for PD-L1 and CTLA-4 RT-PCR assays. 
Gene NCBI Accession No: Forward primer sequence (5’-3’) Reverse primer sequence (5’-3’) Product length (bp) 
PD-L1 XM_005615937.2 CCAGCAGGTCACTTCAGAAC CCATTGTCACATTGCCACCA 136 
CTLA-4 NM_001003106.1 CCCCGTCTTCTCCAAAGGGAT TATGTCGCGGCACAGACTTC 174 
HPRT AY283372 AGCTTGCTGGTGAAAAGGAC TTATAGTCAAGGGCATATCC 114 







6.2.5 Statistical analysis 
Kruskal-Wallis H test was used to compare the PD-L1 and CTLA-4 immunostaining scores 
and gene expression between malignant-metastatic and malignant non-metastatic CMGTs. 
The correlation between PD-L1 or CTLA-4 immunostaining scores and corresponding gene 
expression was tested using Spearman rank-order correlation test. The same test was used 
to evaluate the correlations between PD-L1 or CTLA-4 immunostaining scores and survival 
times of the dogs with malignant mammary gland tumours. X-tile software 
(https://medicine.yale.edu/lab/rimm/research/software/)7 was used to identify 
appropriate cut-off points to classify malignant mammary neoplasms into PD-L1 or CTLA-4 
immunostaining “high” and “low” categories based on the disease outcome of the 
patients. A hierarchal multivariate analysis was performed to identify whether “high” 
immunostaining scores of PD-L1 or CTLA-4 were predictive of shorter disease specific 
survival time in dogs with malignant mammary neoplasms independent of conventional 
prognostic factors including tumour size, tumour grade and presence of intra-vascular or 
intra-lymphatic tumour emboli in histological sections. Pearson Chi-Squared test was used 
for group comparisons regarding nuclear immunostaining of PD-L1 and immunostaining 
positivity of tumour infiltrating immune cells for PD-L1 or CTLA-4. All statistical analyses, 
except cut-off analysis were performed using the SPSS version 25 program (IBM 
Corporation, Armonk, New York).  
 
A final hieracheal multivariate analysis was also performed to identify which of the 
inflammation related prognostic markers investigated in this thesis were independently 
prognostic of survival times of dogs with malignant mammary neoplasms. This analysis 
included conventional prognostic factors of tumour size, tumour grade and presence of 
tumour emboli, along with the inflammation related prognostic markers of stromal mast 








6.3.1 Selected cases  
The clinicopathological characteristics of the selected patients are described in section 
4.3.1 of Chapter 4.  
 
 
6.3.2 Tumour size and histological classification 
The characteristics of the tumours are described in section 4.3.2 of Chapter 4. 
 
 
6.3.3 Disease outcome of the selected cases 
The details of mammary tumour metastasis of the dogs included in the study are described 
in section 4.3.5 of Chapter 4. Briefly, 21/41 (51.2 %) dogs with malignant mammary 
tumours died after developing evidence of tumour metastasis within three years of 
surgical excision of the neoplasms (malignant-metastatic group). The other 20 dogs with 
malignant neoplasms were not diagnosed to have clinically evident mammary tumour 
metastasis during the 3-year follow-up period (malignant non-metastatic group).  
 
 
6.3.4 SDS-PAGE and immunoblotting 
The immunoblot developed using the anti-PDL1 antibody contained three distinct bands of 
approximately 34 kDa, 60 kDa and 150 kDa in the lane loaded with protein extracted from 
CMGT tissues (Figure 6. 1: B). There was a single band of approximately 150 kDa in the lane 
loaded with purified recombinant canine PD-L1 protein. Canine PD-L1 protein has 289 
amino acids (https://www.uniprot.org/uniprot/?query=canine+PD-L1&sort=score) and the 
predicted molecular weight from the sequence is 33.1 kDa. The molecular weight of the 
canine PD-L1 was reported to be 35 kDa in a previous study and the band approximately of 





report.22Another study has reported canine PD-L1 molecular weight to be approximately 
60 kDa and it was suggested that this might be due to the post transitional glycosylation.31 
The 60 kDa band observed in the immunoblot of the present study may represent a 
similarly modified PD-L1 protein. The higher molecular band around 150 kDa may 
correspond to a PD-L1 polymer. While multiple bands were observed, the results of the 
immunoblotting are consistent with satisfactory specificity for canine PD-L1 protein of the 
antibody used. This is supported by the lack of immunostaining visible in negative control 
tissues and the significant positive correlation detected between PD-L1 gene expression 
and PD-L1 immunostaining. 
 
The immunoblot developed using the anti-CTLA-4 antibodies showed a single low 
molecular weight band of approximately 22 kDa and two higher molecular weight bands of 
approximately 200 kDa and 125 kDa  in the lane which contained protein extracted from 
canine mammary tumour tissues (Figure 6.2: B ). This band pattern was observed when 
proteins were denatured using mild reducing conditions which included heat treatment at 
100 °C for 5 minutes and separating in gels containing SDS. However, when the proteins 
were denatured with severe reducing conditions, by addition of 2-mercaptoethanol, the 
intensity of these higher molecular weight bands decreased and the intensity of the lower 
molecular weight band increased, which may suggest the higher bands were comprised of 
polymerized proteins (Figure 6. 2: C). Only a single band of approximately 22 kDa was 
observed with the purified recombinant CTLA-4 protein (Figure 6.2: C). 
 
The sequence of canine CTLA-4 protein contains 223 amino acids 
(https://www.uniprot.org/uniprot/Q9XSI1) and has an estimated molecular weight of 24.2 
kDa. However, a soluble isoform of canine CTLA-4 (s-CTLA-4) which was shown to result 
from alternative splicing of CTLA-4 mRNA has been described previously.43 The molecular 
weight of this s-CTLA-4 isoform is 23 kDa. The lower molecular weight bands observed in 
the CTLA-4 immunoblots of the present study were approximately 23 kDa and it was 
difficult to differentiate whether it corresponded to the splice variant or the full-length 
protein. The intensity of the two high molecular weight bands observed in the immunoblot 
decreased with a concurrent increase in the intensity of the lower molecular weight band, 





is not uncommon with human CTLA-4 and dimers and tetramers are frequently present in 
human immunoblots of this protein.23,32 In addition, CTLA-4 has several glycosylation sites 
and so is prone to post translational glycosylation.3 Therefore, the higher molecular weight 
bands are likely to be polymers of canine CTLA-4 which got denatured when more intense 
denaturing conditions were applied, although glycosylation is also a possibility. Overall, the 
immunoblotting suggests adequate specificity of the antibody used for canine CTLA-4 
protein. As with PD-L1 this was supported by the correlation between CLTA expression and 








Figure 6.1 SDS-PAGE gel and corresponding immunoblot with anti-PD-L1 antibodies. 
A: SDS-PAGE Gel, B: Immunoblot. M: Molecular weight marker (kDa), Lane 1: Purified recombinant 
canine PD-L1 protein-Fc tag (2 µg), Lane 2: Protein extracted from frozen mammary tumour tissues 
(40 µg). Primary antibody: rabbit anti PD-L1 polyclonal, 1:100 (ab233482), Secondary antibody:  goat 




















Figure 6.2. SDS-PAGE gel and corresponding immunoblot with anti-CTLA-4 antibody. 
A: SDS-PAGE Gel. B: Immunoblot with proteins processed under mild denaturing conditions. C: 
Immunoblot with proteins processed with severe denaturing conditions. M: Molecular weight marker 
(kDa), Lane 1: Protein extracted from fresh mammary tumour tissues (40 µg), Lane 2: Purified 
recombinant canine CTLA-4 protein-Fc tag (2 µg). Primary antibody: mouse anti CTLA-4 monoclonal, 
1:50 (Santa-cruz (F8) sc-376016). Secondary antibody: goat anti-mouse IgG (HRP), 1:8000 




Positive control samples immunostained as expected, with membrane and cytoplasmic 
immunostaining of PD-L1 observed in macrophages in the cutaneous foreign body 
granuloma that was used as the positive control (Figure 6.3). Immunostaining was absent 
in sections of adrenal gland and pancreas that were included as negative controls as well as 
the no-primary antibody control. The lymphocytes of the mandibular lymph node showed 
cytoplasmic immunostaining for CTLA- 4 while no immunostaining was present in the 
lymph node section prepared without the anti-CTLA-4 primary antibody (Figure 6.4). The 
0–3 scale used for PD-L1 immunostaining quantification is depicted in Figure 6.5, and the 






One malignant CMGT was excluded from PD-L1 immunostaining analysis as inadequate 
tumour tissue was present on the section for accurate quantification. The PD-L1 
immunostaining scores of the 40-remaining malignant CMGTs ranged from 6.1–286.5/HPF 
with a median of 82.5/HPF ± 124.4 (Q3-Q1). The median PD-L1 immunostaining scores of 
malignant tumours which subsequently metastasised (180.2/HPF ± 152.4 Q3-Q1) was 
significantly higher than those of malignant CMGTs that did not metastasise during the 
follow-up period (62.6/HPF ± 62.4 Q3-Q1, p = 0.005, Kruskal-Wallis H test). Two malignant 
mammary gland tumours were excluded from CTLA-4 immunostaining analysis due to 
inadequate tumour tissues to enable accurate quantification within the sections. In the 
remaining 39 malignant CMGTs, CTLA-4 immunostaining scores ranged from 40.8 – 
281.8/HPF with a median of 170.4/HPF ± 122.9 (Q3-Q1). The CTLA-4 immunostaining score 
of the malignant mammary tumours which subsequently developed metastases (211/HPF 
± 87.5 Q3-Q1) was significantly higher than the immunostaining scores of mammary 
tumours which did not develop tumour metastasis (144.3/HPF ± 100.9 Q3-Q1, p = 0.003, 
Kruskal-Wallis H test). Immunostaining for PD-L1 was observed in the nuclei of neoplastic 














Figure 6.2 PD-L1 Immunostaining (primary antibody dilution 1:100). 
A: Positive control – canine cutaneous foreign body granuloma. Note the positive staining in 
macrophages. B: Negative control –. cutaneous foreign body granuloma processed without primary 










Figure 6.3 CTLA-4 immunostaining (primary antibody dilution 1:50). 
A: Positive control – canine lymph node. Note the positive staining in lymphocytes. B: Negative 



















Figure 6.4 Canine mammary gland tumours with PD-L1 immunostaining (primary antibody dilution 1:100). 
A:  0 = Absence of membrane or cytoplasmic immunostaining. B: 1 = Incomplete membrane 
immunostaining with or without mild or moderate cytoplasmic staining. C: 2 = Moderately intense 
complete membrane immunostaining, with or without moderate cytoplasmic immunostaining. D: 3: 
Intense complete membrane immunostaining with or without moderate or intense cytoplasmic 











Figure 6.5 Canine mammary gland tumours with CTLA-4 immunostaining (primary antibody dilution 1:50). 
A: 0 = Absence of cytoplasmic immunostaining. B: 1 = Mild cytoplasmic immunostaining. C: 2 = 






6.3.6 PD-L1 and CTLA-4 RT-PCR assay validation 
The sequences of the PD-L1 and CTLA-4 amplicons produced using the newly developed 
primers showed 97.8% and 98.4% identity with the published cDNA sequences of canine 
PD-L1 and CTLA-4 (NCBI Blast search). The newly developed PD-L1 and CTLA-4 RT-PCR 
assays were linear within the tested range from 102 to 107 target copies and demonstrated 
adequate efficiency, r2, and inter- and intra-assay precision and accuracy within the 
specified range (Table 6.2). The reference genes, HPRT and RPL32, showed adequate 
stability with a GeNorm M value ≤ 0.2 and a GeNorm V value < 0.15. 
 
There was a significant positive association between PD-L1 immunostaining scores and 
relative gene expression in malignant CMGTs (rs = 0.75, Spearman rank-order correlation 
test). A similar association was observed between CTLA-4 immunostaining scores and 
relative gene expression (rs = 0.69, Spearman rank-order correlation test). 
 
 
Table 6.2 Efficiency, r2 and inter- and intra-assay CVs of PD-L1 and CTLA-4 RT-PCR says. 
Gene Assay 
efficiency 
r2 CV Copies/ul 
1 x 107 1 x 106 1 x 105 1 x 104 1 x 103 1 x 102 
PD-L1 0.90 0.99 Inter-assay 16.3 6.6 7.3 7 12.6 20.4 
Intra-assay 14.7 22.6 8.5 5.9 13.7 20.1 
CTLA-4 0.93 0.99 Inter-assay 8.3 1.2 4.4 8.1 2.6 19.3 
Intra-assay 8.5 9.8 6 7.5 7.8 19.9 
 
 
6.3.6 Relative quantification of PD-L1 and CTLA-4 gene expression in canine 
mammary gland tumours 
 
Of the 41 malignant CMGTs included in the RT-PCR assays, reference gene expression was 
absent in one mammary tumour and therefore this tumour was excluded from further 
analyses. Of the 40 malignant tumours which had detectable reference gene expression, 






malignant CMGTs which had subsequently metastasised was significantly higher than in 
the non-metastatic malignant mammary tumours (p = 0.023, Kruskal-Wallis H test). 
 
Of the 40 malignant CMGTs with detectable reference gene expression, CTLA-4 expression 
could not be evaluated in six mammary tumours because the available sample volume was 
insufficient in one tumour, another had an inappropriate melting temperature, and four 
samples had only one replicate in which expression was detected. In three samples, no 
target gene expression was detected but there was positive reference gene expression, 
suggesting a true absence of CTLA-4 gene expression. These latter three samples were 
included in the statistical analysis following a modified method. Briefly, the Ct value of 
these samples were presumed to be higher than the Ct value of the standard which 
provided the lowest limit of detection in the validation assay. Therefore, the Ct values of 
these samples were calculated by adding three cycles to the corresponding Ct value of the 
lowest limit of detection of the assay. Then for each sample, the ΔΔCt was calculated by 
taking the difference between newly calculated Ct value and average reference gene 
Ct.The relative gene expression of CTLA-4 was significantly higher in canine MGTs that 
developed metastases than the relative gene expression in MGTs that did not metastasise 
during the follow-up period (p = 0.022, Kruskal-Wallis H test). 
 
 
6.3.7 Cut-off analysis for PD-L1 and CTLA-4 immunostaining scores. 
By X-tile analysis, a strong, inverse and continuous association between PD-L1 
immunostaining scores and survival times of the dogs with malignant mammary tumours 
was identified. Furthermore, the software identified a PD-L1 immunostaining score of 
180/HPF (χ2 = 17.88, p < 0.001) as the optimal cut-off which best predicted the disease 
outcome. Therefore, a malignant CMGT with a PD-L1 immunostaining score >180/HPF is 
more likely to develop metastasis while a tumour with immunostaining score ≤180/HPF is 
less likely to metastasise. An inverse continuous association was identified between CTLA-4 





177/HPF (χ2 = 7.6, p = 0.07). This suggests that a malignant CMGT with a CTLA-4 
immunostaining score >177/HPF is more likely to develop tumour metastasis while a 
tumour with an immunostaining score ≤177/HPF is less likely to metastasise. 
 
 
6.3.8 Correlation between PD-L1 or CTLA-4 immunostaining scores and the survival 
times of the dogs with malignant mammary gland tumours and prognostic ability of 
PD-L1 and CTLA-4 immunostaining scores on survival times. 
 
The overall mean survival time of the 41 dogs with malignant CMGTs was 721 days (95% CI 
609–833). There was a significant negative correlation between PD-L1 immunostaining 
scores and the disease specific survival times of dogs with malignant mammary neoplasms 
(rs = - 0.42, p = 0.008) suggesting that the higher the PD-L1 immunostaining score, the 
shorter the survival time. The correlation between CTLA-4 immunostaining scores and the 
survival times of dogs with malignant mammary neoplasms also was significant and 
negative ((rs = - 0.4, p = 0.01).  
 
The hierarchal multivariate analysis showed that PD-L1 immunostaining scores (Δ F = 4.9, p 
= 0.035) and tumour grade (Δ F = 5.1, p = 0.03) were independently prognostic of survival 
times of dogs with malignant mammary neoplasms. In contrast, CTLA-4 immunostaining (Δ 
F = 1,7, p = 0.2), tumour size (Δ F = 1,8, p = 0.18), and the presence of tumour emboli in 
histological tumour sections (Δ F = 1.1, p = 0.3) were not independently prognostic of 
survival time. Mammary tumour histological sub-type was not included in multivariate 








6.3.9 PD-L1 and CTLA-4 immunostaining scores and gene expression in benign 
mammary gland tumours. 
 
The PD-L1 immunostaining scores of the 12 benign tumours included in the study ranged 
from 0–110/HPF with a median immunostaining score of 10.8/HPF. The immunostaining 
scores of the benign tumours was significantly lower than those of the malignant CMGTs (p 
= 0.001, Kruskal-Wallis H test). The CTLA-4 immunostaining scores of the benign mammary 
tumours ranged from 0-119.5/HPF with a median score of 95/HPF. The immunostaining 
scores of the benign tumours was significantly lower than the immunostaining scores 
observed for malignant CMGTs (p = 0.006, Kruskal-Wallis H test). The PD-L1 and CTLA-4 
immunostaining scores of CMGTs classified as benign, malignant non-metastatic and 
malignant-metastatic are shown in Figure 6.7 and Figure 6.8. Immunostaining for PD-L1 
was observed in the nuclei of neoplastic mammary tumour cells in a single benign 
mammary gland tumour. Of the 12 benign mammary neoplasms, detectable PD-L1 gene 
expression was observed in a single neoplasm while CTLA-4 expression was observed in 
















Figure 6.6 Boxplots of PD-L1 immunostaining in “malignant-metastatic”, “malignant non-metastatic” and 




Figure 6.7 Boxplots of CTLA-4 immunostaining in “malignant-metastatic”, “malignant non-metastatic” and 






6.3.10 Immunostaining of tumour infiltrating immune cells for PD-L1 and CTLA-4 in 
malignant canine mammary gland tumours. 
 
All 41 malignant CMGTs included in the study had a population of tumour infiltrating 
immune cells which predominantly comprised of lymphocytes. Tumour infiltrating immune 
cells had PD-L1 immunostaining in 11 CMGTs. This included seven tumours which 
subsequently developed tumour metastasis which was not significantly higher than four 
tumours which did not metastasise (p = 0.22, Pearson Chi-squared test). The infiltrating 
immune cells present in all malignant mammary tumours included in the study showed 
CTLA-4 immunostaining. 
 
Results of the final hieracheal multivariate analysis, including the tumour-associated 
inflammation related prognostic markers investigated in this thesis, revealed that tumour 
grade (Δ F = 4.9, p = 0.028), PD-L1 immunostaining (Δ F = 4.9, p = 0.042) and stromal mast 
cell density (Δ F = 4.9, p = 0.02) are independently prognostic of the survival times of dogs 
with malignant mammary neoplasms. None of the other prognostic markers were 
independently prognostic of survival times of dogs with malignant mammary neoplasms (p 




In the present study, the PD-L1 and CTLA-4 immunostaining scores of malignant CMGTs 
which subsequently developed tumour metastasis were significantly higher than the scores 
of malignant CMGTs that did not develop clinically evident tumour metastasis. In addition, 
higher PD-L1 and CTLA-4 immunostaining scores showed a significant association with 
shorter survival times of the dogs with malignant mammary neoplasms. These findings 
indicate that production of PD-L1 or CTLA-4 proteins by neoplastic canine mammary gland 
cells influences whether the cells from that neoplasm are likely to metastasise. To the 
author’s knowledge, this is the first time that either PD-L1 or CTLA-4 have been associated 





immune checkpoint proteins influence tumour metastasis in CMGTs is not known. 
However, previous human studies have suggested that increased PD-L1 or CTLA-4 
influences tumour metastasis by modulating the immune system. Generally, the immune 
system is protective against metastases and therefore suppression of the immune system 
through checkpoint molecules may promote tumour metastasis.4,46 This is supported by 
the observation that immunosuppression facilitates some steps of the metastatic cascade 
including cancer cell exfoliation, survival in circulation, and establishment at distant 
sites.13,39 Therefore, it appears likely that increased PD-L1 or CTLA-4 expression within a 
neoplasm may facilitate tumour metastasis by inhibiting the immune reaction against the 
neoplastic cells. 
 
Consistent with the findings of the present study, studies of human cancers have also 
associated increased PD-L1 production by cancer cells with increased lymph node 
metastasis, shorter disease free times, and shorter overall survival times.15,16,18,28 Due to 
this association between the presence of PD-L1 and poor disease outcome, PD-L1 has been 
proposed as a potential prognostic marker for these neoplasms. The findings of the 
present study suggest that PD-L1 immunostaining could be similarly useful to predict the 
prognosis of malignant CMGTs. 
 
As with PD-L1, there were significant differences in immunostaining and gene expression 
of CTLA-4 between metastatic and non-metastatic CMGTs. This suggests that evaluation of 
CMGTs for this protein could also be useful to predict prognosis. In human medicine, 
despite the well-known immunosuppressive role of CTLA-4, the association between the 
expression  of CTLA-4 protein by cancer cells and disease outcome is unclear, possibly due 
to the limited numbers of studies investigating this association.40,48 While one study 
reported CTLA-4 immunostaining predicted prognosis independently of other conventional 
prognostic factors40, it was not identified as an independent prognostic factor in another 
similar study.48 In the present study, unlike PD-L1, CTLA-4 immunostaining was not 







As with PD-L1, there were significant differences in immunostaining and gene expression 
of CTLA-4 between metastatic and non-metastatic CMGTs. This suggests that evaluation of 
CMGTs for this protein could also be useful to predict prognosis. In human medicine, 
despite the well-known immunosuppressive role of CTLA-4, the association between the 
expression  of CTLA-4 protein by cancer cells and disease outcome is unclear, possibly due 
to the limited numbers of studies investigating this association.40,48 While one study 
reported CTLA-4 immunostaining predicted prognosis independently of other conventional 
prognostic factors40, it was not identified as an independent prognostic factor in another 
similar study.48 In the present study, unlike PD-L1, CTLA-4 immunostaining was not 
identified to be independently prognostic of survival times of the dogs with malignant 
mammary neoplasms. 
 
In the present study, immunostaining scores for PD-L1 and CTLA-4 ranged from 0–300/HPF 
with neoplasms that metastasised having higher immunostaining scores than those that 
did not. For pathologists to be able to predict which tumours are likely to metastasise, it 
would be helpful to have a cut-off score which divides tumours into immunostaining “high” 
and immunostaining “low” categories. The cut-offs derived in the present study were an 
immunostaining score of 180/HPF for PD-L1 and 177/HPF for CTLA-4. However, as these 
values were determined by only 41 CMGTs, further prospective studies containing larger 
numbers of dogs are needed to assess the reliability of these identified cut-offs. 
 
Blockade of immune checkpoint pathways using anti-PD-L1 and anti-CTLA-4 monoclonal 
antibodies (mAbs) is currently used to treat a variety of different human cancer types 
including non-small cell lung cancer, urothelial cancer, Merkel cell carcinoma, renal cell 
carcinoma, and triple-negative breast cancer.12,40 In dogs, a rat–dog chimeric anti-PD-L1 
mAb was found to be safe and well tolerated by dogs with oral malignant melanomas and 
undifferentiated sarcomas with a reported response rate of 14.3% (1/7) and 50% (1/2) 
respectively.27 At present, surgical tumour excision is the most common treatment 





be successfully treated with surgery alone, and these patients are considered as candidates 
for adjuvant therapy.9,42 While additional studies are required, the results of the present 
study suggest that blockade of PD-L1 or CTLA-4 could potentially have some therapeutic 
benefits in dogs with CMGTs. 
 
Immunostaining of PD-L1 was present on both neoplastic cells and immune cells that were 
infiltrating the tumour. The presence of PD-L1 on infiltrating immune cells has also been 
reported in human cancers. However, whether the presence of PD-L1 on tumour 
infiltrating cells helps predict subsequent tumour behaviour or response to PD-L1 blockade 
therapy is uncertain.1,19,44 In the present study, neither the presence of PD-L1 nor CTLA-4 
immunostaining in tumour-infiltrating cells was associated with the subsequent 
development of metastases, suggesting this feature is not prognostic for CMGTs. 
 
Immunostaining for PD-L1 was observed in the nuclei of neoplastic mammary tumour cells 
in 11 of the 40 malignant mammary tumours included in the present study. Nuclear PD-L1 
immunostaining was reported to be associated with more aggressive neoplasm behaviour 
in one study of human cancers33, although other studies have reported nuclear PD-L1 
immunostaining as an artefact.29,35 The present study did not identify any association 
between nuclear PD-L1 immunostaining and disease outcome of CMGTs and it is uncertain 
whether the PD-L1 immunostaining observed was real or artefactual. 
 
In the present study, both PD-L1 and CTLA-4 immunostaining was higher in malignant 
CMGTs than in benign neoplasms. This is in agreement with a previous study that also 
reported higher PD-L1 immunostaining in malignant CMGTs compared to benign CMGTs.41 
The higher PD-L1 and CTLA-4 immunostaining in malignant neoplasms supports the 
hypothesis that inhibition of an immune reaction due to these proteins results in a more 






Tumour histological grade was independently prognostic of survival times of the dogs with 
malignant CMGTs in the present study. This was consistently observed in the prognostic 
studies included in Chapter 4 and Chapter 5 of this thesis. Similar prognostic significance of 
tumour histological grade for CMGTs has been previously reported by univariate36 and 
multivariate analyses.20,34 However, tumour size or presence of tumour emboli were not 
prognostic of survival times of dogs with malignant CMGTs in the present study. In 
contrast, several previous studies have shown that tumour size and presence of tumour 
emboli are prognostic of survival times of dogs with malignant CMGTs. 17,38,36 The possible 
causes for the discrepancy of results between studies are similar to what is described in 
section 4.4 of Chapter 4 of this thesis. 
 
One limitation of the present study was the lack of tumour staging at diagnosis. This 
suggests it is possible that some CMGTs could have metastasised prior to the neoplasm 
being excised. Additionally, due to the nature of the study, it was impossible to definitively 
exclude the possibility that some of the dogs with non-metastatic CMGTs had developed 
clinically silent metastatic disease during the study. However, even if some of the non-
metastatic CMGTs had developed clinically silent metastases, the fact that these 
neoplasms remained clinically silent suggests that metastasis either happened late in the 
study or these metastases that developed were less clinically aggressive. The clinical 
relevance of the findings of this study are supported by the significant differences in 
survival times between dogs with CMGTs with a high expression of the immune checkpoint 
proteins and dogs with low expression of these proteins. 
 
Another limitation of the present study is the relatively small number of cases. However, 
significant differences in PD-L1 and CTLA-4 protein and gene expression were detected 
between metastatic and non-metastatic CMGTs suggesting the numbers included were 
adequate. Nevertheless, studies with larger numbers of cases are required to identify how 
PD-L1 and CTLA-4 protein and gene expression relate with other existing prognostic 






A final hierarchal multivariate analysis was conducted to see which of the cancer 
associated inflammation-related prognostic markers investigated in this thesis were 
independently prognostic of survival times of dogs with malignant mammary neoplasms. 
PD-L1 immunostaining and stromal mast cell density were independently prognostic, 
suggesting that these markers are capable of being used alone for prognostic 
determination of CMGTs. In contrast, other promising markers including CTLA-4 
immunostaining, CXCL12 and CCL5 were not independently prognostic of survival times. In 
the case of CTLA-4, the findings in this chapter suggest that CTLA-4 immunostaining is 
prognostic; for example, the significant negative correlation between CTLA-4 
immunostaining and survival times of dogs. However, CTLA-4 immunostaining lost its 
prognostic ability when tested with several conventional prognostic factors using the 
hieracheal multivariate analysis. This suggests that malignant mammary neoplasms which 
had higher CTLA-4 immunostaining scores developed metastasis not only because they had 
increased number of CTLA-4 molecules on tumour cells but also because those tumours 
were either large, high grade tumours or had histological evidence of lympho-vascular 
invasion. The same would also be true for the chemokines CXCL12 and CCL5. Therefore, 
more studies with large numbers of cases are necessary to investigate CTLA-4 
immunostaining and chemokine expression in relation to conventional prognostic factors. 
This suggested that these two markers are capable to use alone for prognostic 
determination of CMGTs while other markers may be useful to complement the diagnosis 
provided by other conventional prognostic markers available for canine mammary 
neoplasms. 
 
In conclusion, the study presented in this chapter is the first time that immune checkpoint 
proteins have been investigated in a series of malignant CMGTs of which the clinical 
outcome was known. The results revealed that increased production of these proteins was 
significantly associated with the development of metastatic disease and reduced survival 
times of affected dogs. As these two proteins influence the biological behaviour of CMGTs, 
they may be important as prognostic markers and as therapeutic targets for these 
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Tumour-associated inflammation has recently gained widespread attention due to the 
interesting association observed between inflammation and biological behaviour of 
cancers.1,14 Numerous studies have demonstrated that certain components of tumour-
associated inflammation (TAI) are useful prognostic markers and therapeutic targets for 
many types of cancer in humans.14,1 Breast cancer is one of the most common neoplasms 
among women worldwide. Current research on breast cancer is mainly focused on 
identifying novel prognostic markers to accurately predict the disease outcome of patients 
and developing new therapeutics to treat the disease more effectively. During the past two 
decades, the utility of TAI related components as prognostic markers and therapeutic 
targets in breast cancers has been extensively researched. This thesis was inspired by the 
novel and interesting findings of TAI in human breast cancers and the clinical and 
molecular similarities between mammary neoplasms in humans and dogs.13 
 
The main aim of this thesis was to identify whether a group of TAI related prognostic 
markers adopted from human breast cancer studies are similarly prognostic in canine 
mammary gland tumours (CMGTs). As hypothesised, most of the tested prognostic 
markers were prognostic in CMGTs as they are in human breast cancers. Stromal mast cell 
density was the most promising prognostic marker due to both its prognostic value and the 
relative ease of implementing the technique in a diagnostic laboratory. The other markers, 
including chemokines and immune checkpoint molecules, carry the potential to be 
adopted for routine diagnostics but need further research to make them more user-
friendly and cost-effective prognostic markers. This chapter will discuss the feasibility of 
these prognostic markers for routine prognostic determination in a diagnostic laboratory. 
Further, this discussion will include possible ways to further improve the prognosis 





challenges associated with retrospective prognostic studies and a few other interesting 
findings from two surveys carried out for data collection.  
  
Of the prognostic markers identified by this thesis, stromal mast cell density appeared to 
be the most appropriate marker for routine prognostic determination in a diagnostic 
laboratory due to several reasons.  Firstly, veterinary pathologists rarely use additional 
laboratory diagnostics other than HE staining for prognostic determination in CMGTs 
mostly due to cost. For instance, many potential molecular prognostic marker assays for 
CMGTs use immunohistochemistry (IHC) or PCR techniques which require expensive 
reagents. Conversely, the reagents used for toluidine blue staining are relatively 
inexpensive and therefore it is more economical than IHC or PCR. Secondly, sample 
processing protocols and preferred brands of antibodies or primers used for IHC or PCR 
may vary between diagnostic laboratories. Currently there is no consensus over how to 
manage inter-laboratory variability of many IHC or PCR-based prognostic marker assays 
developed for dogs. In contrast, toluidine blue staining is already routinely performed by 
veterinary diagnostic laboratories and therefore many laboratories follow a standard 
protocol.11,6 Considering these advantages, it is likely that veterinary pathologists would be 
more likely to use stromal mast cell density assessed by toluidine blue staining to 
complement the prognosis provided by HE staining for CMGTs.  
 
One potential disadvantage of measuring stromal mast cell density is the requirement to 
manually count mast cells, which is a time-consuming process, and cell counts may vary 
between observers. Only a single observer performed the mast cell counting for the 
CMGTs included in this thesis and therefore the inter-observer variability of mast cell 
counting could not be evaluated. Recently, there is growing interest in the scientific 
community to use computer-based software programs to automate cell counting in 
histological sections. These software programs have been shown to make cell counting in 
histological sections easy and rapid while minimising inter-observer and inter-laboratory 





cell counting in histological sections of CMGTs before adopting measuring stromal mast 
cell density as a routine diagnostic procedure. 
  
In addition to stromal mast cell density, this thesis identified that increased gene 
expression of chemokines CCL5, CXCL12 and chemokine receptors CXCR4 and CCR9 was 
associated with a poor disease outcome in dogs with malignant CMGTs. Similar human 
breast cancer studies have also reported alike associations and discussed the possibility of 
using these chemokines and chemokine receptors as prognostic markers or therapeutic 
targets for breast cancers. These previous studies have shown that prognostic significance 
and therapeutic effects occur consequent to downstream signalling pathways activated by 
chemokines and chemokine receptors.8 The activated downstream signalling pathways, 
including phosphoinositide 3-kinase and mitogen activated protein kinase pathways, are 
involved in cell proliferation, motility, and expression of matrix metalloproteinases.8 
Neoplasms with aggressive behaviours have higher cell proliferation rates while synthesis 
of matrix metalloproteinases has found to be altered in these neoplasms making neoplastic 
cells more prone to get dislodged from the primary sites. However, some of these human 
breast cancer studies have suggested that in vivo functions of these chemokines and 
chemokine receptors may be more complex than what is predicted by in vitro studies due 
to the complexity of chemokine signalling in the tumour microenvironment (TME). For 
example, the ability of multiple chemokines to bind with the same receptor and the ability 
of a single chemokine to bind with multiple receptors may create redundant signalling and 
thereby interfere with prognostic efficacy or therapeutic potential of a particular 
chemokine or chemokine receptor. 8 Therefore, it may be useful to investigate the 
downstream signalling pathways activated by the chemokines and chemokine receptors 
shown to be prognostic in CMGTs in this thesis using in vivo models to better clarify their 
prognostic or therapeutic roles. 
 
Many chemokines have been reported in the tumour microenvironment and there are 
complex interactions between them. Considering these complexities, human breast cancer 





prognostic marker or therapeutic target may have limitations. To overcome these 
limitations, some recent human breast cancer studies have used combinations of 
chemokines to predict cancer recurrence and metastasis.17,9 Interestingly, these multi-
targeted approaches were more promising than single chemokine or chemokine receptor-
targeted approaches.17 There have been attempts to develop some of these chemokine 
combinations into commercial diagnostic kits for routine laboratory use. The initial 
development and production cost of such diagnostic kits is high. However, considering the 
number of breast cancer patients seeking precise prognostic determination and alternative 
therapies, the unit price of a kit would become affordable over time. Further research is 
necessary to integrate the canine chemokines and chemokine receptors identified in this 
thesis into a clinically applicable diagnostic algorithm in dogs. However, compared to 
human breast cancer patients, relatively lower numbers of canine patients with mammary 
tumours seek sophisticated diagnostics or adjuvant therapies. Therefore, although it may 
be possible to develop similar types of diagnostic tools for canine patients with mammary 
tumours, the commercial success of such products in the veterinary field is currently 
uncertain.   
    
The findings in Chapter 6 of this thesis suggested that immune checkpoint molecules: PD-
L1 and CTLA-4, are potential prognostic markers for determining the biological behaviour 
of CMGTs. These two immune checkpoints have been identified as prognostic markers for 
many different types of human cancers.2 Consequent to the success of immune checkpoint 
inhibition as a novel cancer treatment modality, assaying for immune checkpoints has 
become not only a useful diagnostic tool for prognostic determination but, also a 
prerequisite for immune checkpoint inhibition therapy. For example, immunostaining for 
PD-L1 is an FDA-approved diagnostic test and a prerequisite for treatment with anti-PD-1 / 
PD-L1 antibodies.2 Therefore, human oncologists often request these immunoassays from 
diagnostic laboratories. Prognostic determination of canine cancers using immune 
checkpoint assays is still a novelty in the field of veterinary oncology. In addition, immune 
checkpoint molecules have been researched only in a limited number of canine cancers. 
Thus, although PD-L1 and CTLA-4 show considerable promise as both prognostic markers 





determination in a diagnostic laboratory or treating dogs with mammary neoplasms. 
Therefore, it is necessary to have further investigations to identify the availability and 
prognostic significance of PD-L1 and CTLA-4 immune checkpoint molecules in other canine 
neoplasms which may increase the awareness of the utility of these markers creating a 
demand for testing them.   
 
Commercially available antibodies produced against human immune checkpoint proteins 
(PD-L1 and CTLA-4) were used for immunostaining of canine tumour tissues in this thesis. 
Currently, no canine-specific anti-PD-L1 or anti-CTLA-4 antibodies are commercially 
available. Even though canine-specific antibodies may be available in future, they are 
unlikely to be cheaper than antibodies developed against the corresponding human 
proteins. Therefore, the ability to use antibodies developed against human immune 
checkpoint proteins to detect the corresponding canine proteins shown in this thesis may 
facilitate developing these immunoassays into diagnostic assays affordable to dog owners. 
Despite these promising attributes, developing PD-L1 or CTLA-4 immunostaining into 
routine diagnostic assays would have other obstacles. For example, the average cost of PD-
L1 immunostaining available for human patients is around US$500.10  Although the human 
diagnostic laboratories advertise the cost for a single test, samples are mostly processed in 
batches using commercial reagent kits.10 This is feasible for human laboratories as immune 
checkpoint assays are frequently requested.2 In contrast, it is less likely for veterinary 
diagnostic laboratories to receive canine cancer biopsies at a similar rate to allow batch 
processing. If a laboratory has to perform immunostaining for samples individually as they 
arrive this will result in a much higher cost. This suggests that veterinary diagnostic 
laboratories may be less likely to invest in developing an immune checkpoint assay for 
routine testing canine neoplasms. However, there are ongoing research projects which 
have shown promising preliminary findings on using immune checkpoint inhibition to treat 
canine neoplasms. If these investigations are able to prove that immune checkpoint 
inhibition is a successful method to treat canine neoplasms then dog owners may be more 
willing to pay the cost for immune checkpoint testing, making diagnostic laboratories more 






The samples used for the prognostic marker assays described in this thesis were surgically 
excised, formalin-fixed canine mammary tumour tissues. However, formalin fixation is time 
consuming and therefore does not facilitate rapid testing. In human medicine, diagnostic 
assays are available to determine chemokines or immune checkpoint molecules in blood or 
serum of cancer patients.10 These assays are useful as sample collection is relatively non-
invasive and quicker than using surgically excised, formalin-fixed neoplasms. Most 
importantly, these assays also provide sufficiently accurate prognostic information to be 
useful for decision making in patients with breast cancers. Currently, no such diagnostic 
applications are available to determine chemokines or immune checkpoint proteins in 
blood or serum of dogs with CMGTs. However, some past studies have shown that 
chemokines or soluble isoforms of immune checkpoint proteins are present in blood and 
serum of dogs similar to humans.16,5 Thus, it would be useful to investigate bioavailability 
of chemokines and immune checkpoint proteins in blood or serum of dogs with CMGTs to 
determine whether the concentrations of these proteins differ significantly between dogs 
with better or worse disease outcomes. 
   
While identifying prognostic significance of TAI related prognostic markers, this thesis 
highlights certain important aspects of choosing retrospective study models for canine 
prognostic marker studies. Retrospective studies are less time consuming and relatively 
inexpensive compared to prospective studies. However, a big disadvantage of using a 
retrospective study in this thesis was the inability to obtain necessary data for mammary 
tumour staging in most cases. Pre-surgical tumour staging is important to determine the 
extent of tumour metastasis at the time of surgical excision of a mammary tumour.  
Inability to obtain tumour staging has not been reported in similar types of human breast 
cancer studies. The discrepancy is likely due to the higher standard of care in human 
patients compared to canine patients with mammary neoplasms. Cancer staging is 
performed routinely for human breast cancer patients due to its importance in 
determining therapeutic options for individual patients. However, the online survey 
conducted for data collection in this thesis revealed that tumour staging is not routinely 
performed in most canine patients with mammary neoplasms. According to the 





mammary neoplasms was the high cost associated with the necessary diagnostic tests. The 
lack of staging data was a big disadvantage of the retrospective study in this thesis as it is 
not possible to go back and stage a neoplasm. Pre-surgical staging of a neoplasm requires 
thoracic and abdominal radiographs and fine needle aspirations or core biopsies of 
regional lymph nodes. However, in a retrospective study, as the surgical excision has 
already been performed it is impossible to repeat radiographs or obtain lymph node 
biopsies, making tumour staging not possible unless the radiographs and biopsies have 
been previously collected. In contrast, staging could be mandated in a prospective study of 
these neoplasms. Another difficulty encountered with retrospective studies is obtaining 
follow-up data of the patients. In this thesis, many mammary neoplasm cases which 
fulfilled basic inclusion criteria identified from the IDEXX database on primary search had 
to be excluded due to the unavailability of follow-up data. In the majority of cases, the 
patients had been lost for follow-up due to change in the veterinary care provider. 
Additionally, follow-up data of some dogs were incomplete as the clinical records of some 
dogs which had died by the time of the survey had been removed from veterinary clinic 
databases due to technical reasons. 
 
Many human breast cancer studies that correlated the expression of TAI related prognostic 
markers with tumour metastasis measured the expression of the particular markers not 
only in primary tumours but also in metastatic sites.12,15 This approach has been helpful to 
identify how some of these prognostic markers influence tumour metastasis to specific 
sites. However, due to the retrospective nature of the data collection process included in 
this thesis, it was not possible to obtain biopsies or post-mortem samples of metastases 
from most of the cases that were reported to have clinical evidence of tumour metastasis. 
In fact, post-mortem examinations had not been performed on most of the dogs, as per 
the wishes of the dog owners, while in the cases where post-mortem examinations were 
performed, not all metastatic sites were sampled and submitted for histopathology due to 
economic reasons. The inability to compare marker levels between primary tumours and 






The two surveys included in this thesis were carried out to collect samples for the 
prognostic marker studies. The New Zealand survey included 896 cases, of which 53 cases 
were used for prognostic marker studies as follow-up information was able to be retrieved 
successfully. The Sri Lankan survey included 72 cases, but unfortunately there was 
insufficient data on disease outcome to use these cases for prognostic marker evaluation. 
However, both surveys provided a large number of CMGT cases which were helpful to 
determine the clinicopathological features of mammary neoplasms in dogs in Sri Lanka and 
New Zealand. This was important as no previous studies have investigated mammary 
neoplasia in dogs in either country. Further, analysis and comparison of the 
clinicopathological data of mammary neoplasms in dogs in Sri Lanka and New Zealand 
provided some interesting insights which may pave the way for future studies to better 
understand mammary gland diseases in dogs in these two countries.  
 
The most noteworthy feature of the two surveys was the marked difference in proportions 
of histologically-malignant neoplasms in dogs between the two countries. In Sri Lanka 88% 
of dogs had malignant mammary neoplasms while malignant neoplasms were found only 
in 55% of dogs in New Zealand. The reason for the observed difference is unknown. It is 
possible that dogs in Sri Lanka are more frequently exposed to carcinogens which promote 
development of malignant neoplasms than dogs in New Zealand. Possible examples might 
include exposure to pesticides and the use of steroid contraceptives to prevent unwanted 
pregnancies in female dogs in Sri Lanka. Alternatively, the discrepancy could be due to 
differences in veterinary care received by dogs in these two countries. It is possible that 
dogs in New Zealand are more frequently seen by veterinarians than dogs in Sri Lanka, 
facilitating early detection of benign mammary neoplasms which are generally small and 
only identified on careful examination. Additionally, the two veterinary hospitals selected 
for the prospective survey in Sri Lanka were referral centres. Therefore, these practices 
may have received CMGT cases referred by the regional veterinarians which are more 
likely to be large malignant tumours than small benign tumours. Therefore, future studies 
designed to investigate the factors responsible for the differing rates of malignancy would 
be helpful to better understand the disease process in general as well as to identify 





The statistical analyses of surveys from both New Zealand and Sri Lanka identified that 
tumour size is useful to predict whether a mammary neoplasm on a dog is histologically 
malignant or benign, with larger neoplasms more likely to be malignant. However, there 
was no statistically significant difference in size between non-neoplastic mammary lesions 
and neoplastic mammary lesions. Therefore, a clinician would not be able to use size as a 
criterion to differentiate between neoplastic and non-neoplastic lesion, so the importance 
of size in differentiating between histologically-benign or malignant neoplasms is not 
useful in a clinic setting. Given these limitations, this thesis highlights the importance of 
using additional diagnostics such as cytology and histopathology to diagnose mammary 
gland diseases in dogs shown by previous studies.   
 
Mammary neoplasms were common in intact female dogs in both Sri Lanka and New 
Zealand although the percentage of intact dogs from Sri Lanka was higher than New 
Zealand. This was not unexpected as routine dog spaying is practiced more frequently in 
New Zealand compared to Sri Lanka. Interestingly, the Sri Lankan survey identified that 
nearly half of the intact dogs included in the survey were nulliparous. The parity of the 
intact New Zealand dogs was unknown as it was not recorded for the cases submitted to 
IDEXX Laboratories, New Zealand. The hormonal aetiology of canine mammary neoplasms 
is well known and the higher percentage of affected dogs being intact is therefore 
justifiable. Nulliparity may cause prolonged exposure of mammary neoplasms to 
reproductive hormones elevating the risk of developing mammary neoplasms compared to 
uniparous or multiparous dogs. However, this cannot be confirmed without the knowledge 
of proportion of nulliparous dogs in the Sri Lankan female dog population. Therefore, in a 
future study it would be interesting to identify whether being nulliparous is a risk factor for 
mammary gland neoplasia in dogs. 
 
Multiple mammary tumours were reported in 20% and 12% of dogs in Sri Lanka and New 
Zealand respectively. These proportions were markedly lower than the 60–70% of cases 
with multiple mammary neoplasms reported in previous studies.7 It is unknown why the 





relatively lower than some previous reports. It has been suggested that multiple mammary 
neoplasms develop subsequent to simultaneous exposure of multiple mammary glands to 
reproductive hormones.3,18 Therefore, the reason for the relatively low proportion of 
multiple neoplasm cases in New Zealand could be attributed to routine early spaying of 
female dogs which prevents the prolonged exposure of mammary gland tissues to 
reproductive hormones. Alternatively, being a laboratory-based survey, the NZ survey may 
not have included all the CMGT diagnosed, but the cases of which the samples had been 
submitted for histopathology, artificially reducing the multiple CMGT cases. However, this 
does not similarly apply to the Sri Lankan dogs as in Sri Lanka the majority of dogs are 
either intact or spayed late in their reproductive life. Therefore, it is likely that there are 
other factors which may contribute to lower percentage  of dogs with multiple mammary 
neoplasms in Sri Lanka and NZ and future studies are necessary to identify these factors.  
 
In conclusion, this thesis identified that several TAI related markers shown to be prognostic 
in human breast cancers are similarly prognostic in canine mammary neoplasms. Of these 
prognostic markers, stromal mast cell density was the most useful and could be easily 
adopted for prognostic determination of CMGTs in a veterinary diagnostic laboratory. The 
other prognostic markers, including chemokine and chemokine receptors and immune 
checkpoint molecules, were shown to be useful in prognostic determination in malignant 
canine mammary neoplasms. However, these assays would be more difficult and expensive 
to implement in a veterinary diagnostic laboratory compared to the method for measuring 
stromal mast cell density. Therefore, further studies are necessary to identify ways to make 
these chemokine and immune checkpoint molecule prognostic marker assays more user-
friendly and cost effective. Overall, the investigations carried out in this thesis are helpful 
to broaden our understanding of how cancer-associated inflammation influences the 
behaviour of canine cancers while paving the way for further studies to develop these 
markers for use in routine laboratory diagnostics. The two surveys carried out for data 
collection helped to identify the clinicopathological features of mammary neoplasms in Sri 
Lanka and New Zealand which have not been studied previously. The findings of these two 
surveys may serve as a platform for future studies on canine mammary neoplasms in these 





malignant mammary neoplasia in dogs. Additionally, the statistical analyses carried out in 
this thesis helped to confirm the limitations of some of the currently used patient and 
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